PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
24858827-6	2014	Importantly, in vivo studies demonstrated that 5-N-formylardeemin significantly improved the therapeutic effects of doxorubicin in nude mice bearing A549-R xenografts, which was associated with reduced expression of MDR-1 protein level and increased apoptosis in tumor tissues.	5-n-formylardeemin	47-65	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	216-221
24858827-6	2014	Importantly, in vivo studies demonstrated that 5-N-formylardeemin significantly improved the therapeutic effects of doxorubicin in nude mice bearing A549-R xenografts, which was associated with reduced expression of MDR-1 protein level and increased apoptosis in tumor tissues.	Doxorubicin	116-127	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	216-221
24948812-2	2014	We show here that Nrf2 activation with sulforaphane (SFN) in vivo or in vitro increases expression and transport activity of three ATP-driven drug efflux pumps at the blood-brain barrier [P-glycoprotein, ATP binding cassette b1 (Abcb1); multidrug resistance-associated protein-2 (Mrp2), Abcc2; and breast cancer resistance protein (Bcrp), Abcg2].	sulforaphane	39-51	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	229-234
24867782-0	2014	Irinotecan and temozolomide brain distribution: a focus on ABCB1.	Irinotecan	0-10	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	59-64
24867782-6	2014	Our results show that TMZ, CPT-11 and SN-38 are transported by ABCB1 at the BBB level with brain/plasma ratios of 1.1, 2.1 and 2.3, respectively.	Temozolomide	22-25	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	63-68
24867782-6	2014	Our results show that TMZ, CPT-11 and SN-38 are transported by ABCB1 at the BBB level with brain/plasma ratios of 1.1, 2.1 and 2.3, respectively.	Irinotecan	27-33	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	63-68
24867782-6	2014	Our results show that TMZ, CPT-11 and SN-38 are transported by ABCB1 at the BBB level with brain/plasma ratios of 1.1, 2.1 and 2.3, respectively.	Irinotecan	38-43	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	63-68
24948812-2	2014	We show here that Nrf2 activation with sulforaphane (SFN) in vivo or in vitro increases expression and transport activity of three ATP-driven drug efflux pumps at the blood-brain barrier [P-glycoprotein, ATP binding cassette b1 (Abcb1); multidrug resistance-associated protein-2 (Mrp2), Abcc2; and breast cancer resistance protein (Bcrp), Abcg2].	sulforaphane	53-56	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	229-234
24948812-2	2014	We show here that Nrf2 activation with sulforaphane (SFN) in vivo or in vitro increases expression and transport activity of three ATP-driven drug efflux pumps at the blood-brain barrier [P-glycoprotein, ATP binding cassette b1 (Abcb1); multidrug resistance-associated protein-2 (Mrp2), Abcc2; and breast cancer resistance protein (Bcrp), Abcg2].	Adenosine Triphosphate	131-134	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	229-234
24727322-1	2014	PURPOSE: To clarify the role of ABCB1, ABCG2, and CYP3A in blood and brain exposure of everolimus using knockout mouse models.	Everolimus	87-97	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	32-37
24727322-11	2014	CONCLUSIONS: Brain accumulation of everolimus was restricted by Abcb1, but not Abcg2, suggesting the use of coadministered ABCB1 inhibitors to improve brain tumor treatment.	Everolimus	35-45	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	64-69
24727322-11	2014	CONCLUSIONS: Brain accumulation of everolimus was restricted by Abcb1, but not Abcg2, suggesting the use of coadministered ABCB1 inhibitors to improve brain tumor treatment.	Everolimus	35-45	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	123-128
24692704-0	2014	Multidrug resistance reversing activity of newly developed phenothiazines on P-glycoprotein (ABCB1)-related resistance of mouse T-lymphoma cells.	Phenothiazines	59-73	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	93-98
24647572-9	2014	Importantly, ABT-888 does enhance TMZ efficacy in Pten deficient glioblastoma allografts and spontaneous tumors, even in Abcb1/Abcg2 proficient wild-type mice.	veliparib	13-20	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	121-126
24597976-0	2014	The central cavity of ABCB1 undergoes alternating access during ATP hydrolysis.	Adenosine Triphosphate	64-67	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	22-27
24692704-1	2014	BACKGROUND: Phenothiazines have anticancer properties and are able to reverse the multidrug resistance of neoplastic cells by inhibiting the ATP-binding cassette, sub-family B (MDR/TAP), member 1 protein (ABCB1 or P-glycoprotein) activity.	Phenothiazines	12-26	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	141-195
24692704-1	2014	BACKGROUND: Phenothiazines have anticancer properties and are able to reverse the multidrug resistance of neoplastic cells by inhibiting the ATP-binding cassette, sub-family B (MDR/TAP), member 1 protein (ABCB1 or P-glycoprotein) activity.	Phenothiazines	12-26	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	205-210
24692704-2	2014	MATERIALS AND METHODS: A series of new phenothiazine derivatives was investigated regarding their ABCB1-modulating effect on multidrug resistant mouse T-lymphoma cells by rhodamine 123 accumulation assay and real-time ethidium bromide accumulation assay.	phenothiazine	39-52	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	98-103
24692704-3	2014	RESULTS: The phenothiazine derivatives exhibited a potent anticancer effect on the parental cell line and on its multidrug-resistant mouse T-lymphoma subline overexpressing the ABCB1 transporter.	phenothiazine	13-26	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	177-182
24692704-4	2014	The inhibition of the ABCB1 transporter in the presence of the newly-developed phenothiazines was greater than that for the known ABCB1 inhibitors thioridazine and verapamil.	Phenothiazines	79-93	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	22-27
24692704-4	2014	The inhibition of the ABCB1 transporter in the presence of the newly-developed phenothiazines was greater than that for the known ABCB1 inhibitors thioridazine and verapamil.	Phenothiazines	79-93	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	130-135
24692704-4	2014	The inhibition of the ABCB1 transporter in the presence of the newly-developed phenothiazines was greater than that for the known ABCB1 inhibitors thioridazine and verapamil.	Thioridazine	147-159	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	22-27
24692704-4	2014	The inhibition of the ABCB1 transporter in the presence of the newly-developed phenothiazines was greater than that for the known ABCB1 inhibitors thioridazine and verapamil.	Thioridazine	147-159	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	130-135
24692704-4	2014	The inhibition of the ABCB1 transporter in the presence of the newly-developed phenothiazines was greater than that for the known ABCB1 inhibitors thioridazine and verapamil.	Verapamil	164-173	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	22-27
24692704-4	2014	The inhibition of the ABCB1 transporter in the presence of the newly-developed phenothiazines was greater than that for the known ABCB1 inhibitors thioridazine and verapamil.	Verapamil	164-173	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	130-135
24692704-5	2014	CONCLUSION: Based on the chemical structures and biological activity, compounds with bivalent sulfur atom in the phenothiazine ring demonstrated marked ABCB1-modulating effect, however, other derivatives with halogen or amide substitutions were ineffective.	Sulfur	94-100	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	152-157
24692704-5	2014	CONCLUSION: Based on the chemical structures and biological activity, compounds with bivalent sulfur atom in the phenothiazine ring demonstrated marked ABCB1-modulating effect, however, other derivatives with halogen or amide substitutions were ineffective.	phenothiazine	113-126	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	152-157
24692704-5	2014	CONCLUSION: Based on the chemical structures and biological activity, compounds with bivalent sulfur atom in the phenothiazine ring demonstrated marked ABCB1-modulating effect, however, other derivatives with halogen or amide substitutions were ineffective.	Halogens	209-216	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	152-157
24037730-9	2014	Our results indicate that crizotinib oral availability and brain accumulation were primarily restricted by Abcb1 at a non-saturating dose, and that coadministration of elacridar with crizotinib could substantially increase crizotinib oral availability and delivery to the brain.	Crizotinib	26-36	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	107-112
23701205-1	2014	The adenosine triphosphate-binding cassette transport protein P-glycoprotein (ABCB1) is involved in the export of beta-amyloid from the brain into the blood, and there is evidence that age-associated deficits in cerebral P-glycoprotein content may be involved in Alzheimer"s disease pathogenesis.	Adenosine	4-13	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	78-83
24549231-6	2014	Some of the investigated compounds inhibited the ABCB1 transporter and caused rhodamine-123 accumulation in murine lymphoma cells transfected by human MDR1 gene, expressing the efflux pump (L5178).	Rhodamine 123	78-91	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	49-54
24454901-8	2014	On the behavioral assessment, MDR mice displayed distinctive behaviors in the object exploration and elevated plus maze tests, which were not observed in the LS group.	leucylserine	158-160	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	30-33
24037730-0	2014	Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.	Crizotinib	72-82	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	126-131
24334255-2	2014	The food-derived carcinogen PhIP (2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine) is transported by BCRP, MDR1, and MRP2.	2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine	34-81	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	107-111
23907215-0	2013	Expression of aryl hydrocarbon receptor nuclear translocator enhances cisplatin resistance by upregulating MDR1 expression in cancer cells.	Cisplatin	70-79	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	107-111
23428338-6	2013	In brain, 3-fold higher concentrations of S- and R-citalopram, and its metabolites, were found in abcb1ab (-/-) mice than in abcb1ab (+/+) mice after both acute and chronic citalopram treatments.	s- and r-citalopram	42-61	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	98-103
23428338-6	2013	In brain, 3-fold higher concentrations of S- and R-citalopram, and its metabolites, were found in abcb1ab (-/-) mice than in abcb1ab (+/+) mice after both acute and chronic citalopram treatments.	Citalopram	51-61	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	98-103
24292587-3	2013	The modulation of ABCB1 transporter activity was studied by rhodamine123 accumulation, the apoptosis-inducing effect was investigated using fluorescein isothiocyanate (FITC)-labeled annexin V and propidium iodide.	Rhodamine 123	60-72	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	18-23
24292587-5	2013	Drug accumulation by MDR mouse T-lymphoma cells was moderately modified in the presence of thioridazine derivatives.	Thioridazine	91-103	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	21-24
24292587-6	2013	Thioridazine induced apoptosis of the MDR cancer cell line, but there was no significant apoptotic effect on the PC3 cell line.	Thioridazine	0-12	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	38-41
24011632-3	2013	MATERIALS AND METHODS: In vitro MDCK-MDR1 assay was used to determine permeability and efflux ratio (RE) of gefitinib.	Gefitinib	108-117	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	37-41
23315030-1	2013	We explored whether barasertib (AZD1152), a selective Aurora B kinase inhibitor, is a substrate for P-glycoprotein (Pgp, MDR1), breast cancer resistance protein (BCRP), and multidrug resistance protein 2 (MRP2) in vitro.	2-((3-((4-((5-(2-((3-fluorophenyl)amino)-2-oxoethyl)-1H-pyrazol-3-yl)amino)quinazolin-7-yl)oxy)propyl)(ethyl)amino)ethyl dihydrogen phosphate	20-30	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	121-125
23315030-1	2013	We explored whether barasertib (AZD1152), a selective Aurora B kinase inhibitor, is a substrate for P-glycoprotein (Pgp, MDR1), breast cancer resistance protein (BCRP), and multidrug resistance protein 2 (MRP2) in vitro.	2-((3-((4-((5-(2-((3-fluorophenyl)amino)-2-oxoethyl)-1H-pyrazol-3-yl)amino)quinazolin-7-yl)oxy)propyl)(ethyl)amino)ethyl dihydrogen phosphate	32-39	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	121-125
23845421-2	2013	There is some evidence in literature that verapamil inhibits two other ABC transporters expressed at the BBB, i.e. multidrug resistance protein 1 (MRP1) and breast cancer resistance protein (BCRP).	Verapamil	42-51	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	115-145
23845421-7	2013	RESULTS: In vitro transport experiments exclusively showed directed transport of [(3)H]verapamil in Mdr1a- and MDR1-overexpressing cells which could be inhibited by tariquidar (0.5muM).	[(3)h]verapamil	81-96	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	111-115
23845421-7	2013	RESULTS: In vitro transport experiments exclusively showed directed transport of [(3)H]verapamil in Mdr1a- and MDR1-overexpressing cells which could be inhibited by tariquidar (0.5muM).	tariquidar	165-175	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	111-115
23827160-4	2013	In vitro, CYT387 was efficiently transported by both human MDR1 and BCRP, and very efficiently by mouse Bcrp1 and its transport could be inhibited by specific MDR1 inhibitor, zosuquidar and/or specific BCRP inhibitor, Ko143.	N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide	10-16	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	159-163
23843632-0	2013	Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) gene dosage on plasma pharmacokinetics and brain accumulation of dasatinib, sorafenib, and sunitinib.	Dasatinib	143-152	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	26-31
23907215-7	2013	Furthermore, the downregulation of multidrug resistance 1 (MDR1) expression and retention of drugs in cells caused by suppression of ARNT, resulting in the resensitization of drug-resistant cells to cisplatin, was observed.	Cisplatin	199-208	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	35-57
23907215-7	2013	Furthermore, the downregulation of multidrug resistance 1 (MDR1) expression and retention of drugs in cells caused by suppression of ARNT, resulting in the resensitization of drug-resistant cells to cisplatin, was observed.	Cisplatin	199-208	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	59-63
23907215-8	2013	When overexpressed, ARNT interacted with Sp1 to enhance the expression of MDR1 through Sp1-binding sites on the MDR1 promoter, resulting in a reversal of the effect of cisplatin on cell death.	Cisplatin	168-177	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	74-78
23907215-8	2013	When overexpressed, ARNT interacted with Sp1 to enhance the expression of MDR1 through Sp1-binding sites on the MDR1 promoter, resulting in a reversal of the effect of cisplatin on cell death.	Cisplatin	168-177	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	112-116
23750858-1	2013	P-glycoprotein (Pgp, encoded by ABCB1, commonly known as MDR1), an ATP-dependent transporter with a broad range of hydrophobic drug substrates, has been associated with the in vitro intracellular transport of cholesterol; however, these findings have not been confirmed in vivo.	Adenosine Triphosphate	67-70	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	32-37
23750858-1	2013	P-glycoprotein (Pgp, encoded by ABCB1, commonly known as MDR1), an ATP-dependent transporter with a broad range of hydrophobic drug substrates, has been associated with the in vitro intracellular transport of cholesterol; however, these findings have not been confirmed in vivo.	Adenosine Triphosphate	67-70	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	57-61
23750858-1	2013	P-glycoprotein (Pgp, encoded by ABCB1, commonly known as MDR1), an ATP-dependent transporter with a broad range of hydrophobic drug substrates, has been associated with the in vitro intracellular transport of cholesterol; however, these findings have not been confirmed in vivo.	Cholesterol	209-220	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	32-37
23750858-1	2013	P-glycoprotein (Pgp, encoded by ABCB1, commonly known as MDR1), an ATP-dependent transporter with a broad range of hydrophobic drug substrates, has been associated with the in vitro intracellular transport of cholesterol; however, these findings have not been confirmed in vivo.	Cholesterol	209-220	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	57-61
23559630-0	2013	Transintestinal cholesterol excretion is an active metabolic process modulated by PCSK9 and statin involving ABCB1.	Cholesterol	16-27	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	109-114
23616082-0	2013	Incorporation of ABCB1-mediated transport into a physiologically-based pharmacokinetic model of docetaxel in mice.	Docetaxel	96-105	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	17-22
23616082-3	2013	Regarding the latter, the ATP-binding cassette transporter B1 (ABCB1, PGP, MDR1) is primarily responsible for docetaxel elimination.	Docetaxel	110-119	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	26-61
23616082-3	2013	Regarding the latter, the ATP-binding cassette transporter B1 (ABCB1, PGP, MDR1) is primarily responsible for docetaxel elimination.	Docetaxel	110-119	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	63-68
23616082-3	2013	Regarding the latter, the ATP-binding cassette transporter B1 (ABCB1, PGP, MDR1) is primarily responsible for docetaxel elimination.	Docetaxel	110-119	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	75-79
23616082-4	2013	To further understand the role of ABCB1 in the biodistribution of docetaxel in mice, we utilized physiologically-based pharmacokinetic (PBPK) modeling that included ABCB1-mediated transport in relevant tissues.	Docetaxel	66-75	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	34-39
23616082-8	2013	Overall, our PBPK model furthers the understanding of the role of ABCB1 in the biodistribution of docetaxel.	Docetaxel	98-107	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	66-71
23682680-1	2013	For efficient reversal of multidrug resistance (MDR) in chemotherapy for breast cancer, multifunctional self-assembled nanoparticles (MSN) based on a new amphiphilic copolymer consisting of bioreducible poly[bis(2-hydroxylethyl)-disulfide-diacrylate-beta-tetraethylenepentamine] and polycaprolactone (PBD-PCL) were constructed and characterized.	amphiphilic copolymer	154-175	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	48-51
23620484-4	2013	Using cell lines expressing the aforementioned transporters, we showed that the lipophilic AR-67 lactone form is a substrate for efflux transporters BCRP and MDR1.	Lactones	97-104	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	158-162
23620484-6	2013	Notably, both BCRP and MDR1 conferred resistance to AR-67 lactone.	7-tert-butyldimethylsilyl-10-hydroxycamptothecin	52-57	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	23-27
23620484-6	2013	Notably, both BCRP and MDR1 conferred resistance to AR-67 lactone.	Lactones	58-65	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	23-27
23620484-9	2013	In conclusion, BCRP- and MDR1-mediated efflux of AR-67 lactone confers resistance to AR-67, but OATP1B3-mediated uptake of the AR-67 carboxylate does not sensitize OATP1B3-expressing tumor cells.	Lactones	55-62	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	25-29
23620484-9	2013	In conclusion, BCRP- and MDR1-mediated efflux of AR-67 lactone confers resistance to AR-67, but OATP1B3-mediated uptake of the AR-67 carboxylate does not sensitize OATP1B3-expressing tumor cells.	Argon	49-51	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	25-29
23635651-5	2013	Similarly, the Abcc2;Abcb1(-/-) strain also had elevated renal elimination and reduced fecal excretion of topotecan lactone.	Topotecan	106-123	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	21-26
23432917-9	2013	In animals injected with Abeta1-40-Cy5.5, the deficiency in either Abcb1 or Abcg2 resulted in significant increases in fluorescence concentration in the head ROIs 2 hours after injection compared to wild-type animals.	cyanine dye 5	35-38	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	67-72
23090875-1	2013	Paclitaxel is avidly transported by P-glycoprotein (P-gp/MDR1/ABCB1).	Paclitaxel	0-10	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	57-61
23090875-1	2013	Paclitaxel is avidly transported by P-glycoprotein (P-gp/MDR1/ABCB1).	Paclitaxel	0-10	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	62-67
23778405-11	2013	The expression of the multidrug resistance protein 1 and survivin genes was significantly reduced in xenografts of curcumin-treated mice and mice treated with both curcumin and vincristine relative to control mice.	Curcumin	115-123	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	22-52
23778405-11	2013	The expression of the multidrug resistance protein 1 and survivin genes was significantly reduced in xenografts of curcumin-treated mice and mice treated with both curcumin and vincristine relative to control mice.	Curcumin	164-172	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	22-52
23778405-11	2013	The expression of the multidrug resistance protein 1 and survivin genes was significantly reduced in xenografts of curcumin-treated mice and mice treated with both curcumin and vincristine relative to control mice.	Vincristine	177-188	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	22-52
23422148-1	2013	AIM: Recently, sildenafil was reported to be an inhibitor of P-glycoprotein (P-gp/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) in vitro.	Sildenafil Citrate	15-25	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	82-87
23422148-6	2013	On the other hand, sildenafil increased the plasma levels of the cytotoxic drugs, but not by inhibition of Abcb1 or Abcg2, since this effect was also seen in Abcb1;Abcg2 knockout mice.	Sildenafil Citrate	19-29	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	158-163
23422148-7	2013	The brain penetration of sildenafil was more than 20-fold higher in Abcb1;Abcg2 mice versus wild-type mice, indicating that sildenafil is a good substrate of the two transporters.	Sildenafil Citrate	25-35	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	68-73
23422148-7	2013	The brain penetration of sildenafil was more than 20-fold higher in Abcb1;Abcg2 mice versus wild-type mice, indicating that sildenafil is a good substrate of the two transporters.	Sildenafil Citrate	124-134	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	68-73
23422148-10	2013	CONCLUSION: These results demonstrate that the potency and specificity of sildenafil as an inhibitor of ABCB1 and ABCG2 is not sufficient to warrant further clinical testing of this agent in combination with anticancer drugs.	Sildenafil Citrate	74-84	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	104-109
23461902-0	2013	Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues.	Camptothecin	115-127	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	20-25
22958812-8	2013	Interestingly, rivaroxaban brain-to-plasma ratio did not differ in mice lacking only Mdr1a or Bcrp, but more than two times higher in the Mdr1a/Mdr1b(-/-)/Bcrp(-/-) mice.	Rivaroxaban	15-26	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	144-149
22958812-9	2013	Rivaroxaban is a shared substrate of MDR1 and BCRP.	Rivaroxaban	0-11	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	37-41
22958812-11	2013	These data have important implications for safety and efficacy of anticoagulation therapy with rivaroxaban as many drugs in clinical use are known MDR1 inhibitors and loss-of-function polymorphisms in BCRP are common.	Rivaroxaban	95-106	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	147-151
22820863-2	2013	An adenovirus armed with Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24; abbreviated to "IL-24" here) was shown to reverse the MDR of colon cancer cells to oxaliplatin and doxorubicin.	Oxaliplatin	180-191	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	151-154
22958812-0	2013	Absence of both MDR1 (ABCB1) and breast cancer resistance protein (ABCG2) transporters significantly alters rivaroxaban disposition and central nervous system entry.	Rivaroxaban	108-119	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	16-20
22958812-0	2013	Absence of both MDR1 (ABCB1) and breast cancer resistance protein (ABCG2) transporters significantly alters rivaroxaban disposition and central nervous system entry.	Rivaroxaban	108-119	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	22-27
22958812-3	2013	As renal rivaroxaban clearance exceeds glomerular filtration rate, we suggested that active secretion by efflux transporters P-glycoprotein (MDR1) and breast cancer resistance protein (BCRP) contributes to rivaroxaban clearance.	Rivaroxaban	9-20	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	141-145
22958812-3	2013	As renal rivaroxaban clearance exceeds glomerular filtration rate, we suggested that active secretion by efflux transporters P-glycoprotein (MDR1) and breast cancer resistance protein (BCRP) contributes to rivaroxaban clearance.	Rivaroxaban	206-217	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	141-145
22958812-4	2013	The ability of MDR1 and BCRP efflux transporters to mediate rivaroxaban transport in vitro was assessed in polarized cell monolayers.	Rivaroxaban	60-71	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	15-19
22958812-7	2013	However, rivaroxaban clearance was significantly reduced in Mdr1a/Mdr1b(-/-)/Bcrp(-/-) mice.	Rivaroxaban	9-20	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	66-71
23085402-6	2013	Disruption of the actin cytoskeleton, upon treatment of the cells with latrunculin B or cytochalasin D, caused severe changes in cell and membrane morphology, and concomitant changes in the subcellular distribution of ABCB1, as revealed by confocal laser scanning and electron microscopy.	latrunculin B	71-84	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	218-223
23085402-6	2013	Disruption of the actin cytoskeleton, upon treatment of the cells with latrunculin B or cytochalasin D, caused severe changes in cell and membrane morphology, and concomitant changes in the subcellular distribution of ABCB1, as revealed by confocal laser scanning and electron microscopy.	Cytochalasin D	88-102	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	218-223
23085402-8	2013	In NIH 3T3 MDR1 G185 cells, ABCB1 is partly localized in detergent-free lipid rafts, which partitioned in two different density gradient regions, both enriched in cholesterol and sphingolipids.	Cholesterol	163-174	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	28-33
23085402-8	2013	In NIH 3T3 MDR1 G185 cells, ABCB1 is partly localized in detergent-free lipid rafts, which partitioned in two different density gradient regions, both enriched in cholesterol and sphingolipids.	Sphingolipids	179-192	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	28-33
22820863-2	2013	An adenovirus armed with Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24; abbreviated to "IL-24" here) was shown to reverse the MDR of colon cancer cells to oxaliplatin and doxorubicin.	Doxorubicin	196-207	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	151-154
23063650-0	2013	Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models.	nilotinib	0-9	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	60-65
23063650-1	2013	A panel of clinically used tyrosine kinase inhibitors were compared and nilotinib was found to most potently sensitize specific anticancer agents by blocking the functions of ABCB1/P-glycoprotein, ABCG2/BCRP and ABCC10/MRP7 transporters involved in multi-drug resistance.	nilotinib	72-81	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	175-180
23063650-2	2013	Nilotinib appreciably enhanced the antitumor response of (1) paclitaxel in the ABCB1- and novel ABCC10-xenograft models, and (2) doxorubicin in a novel ABCG2-xenograft model.	nilotinib	0-9	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	79-84
23063650-3	2013	With no apparent toxicity observed in the above models, nilotinib attenuated tumor growth synergistically and increased paclitaxel concentrations in ABCB1-overexpressing tumors.	nilotinib	56-65	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	149-154
23063650-3	2013	With no apparent toxicity observed in the above models, nilotinib attenuated tumor growth synergistically and increased paclitaxel concentrations in ABCB1-overexpressing tumors.	Paclitaxel	120-130	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	149-154
23251289-4	2013	Genes for fatty acid, peptide, amino acid and glucose and multidrug resistance/multidrug resistance-associated protein (MDR/MRP) transport were expressed at relatively higher levels than the other transporter types.	Fatty Acids	10-20	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	120-123
23063411-0	2013	Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo.	Dactinomycin	104-117	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	33-38
23063411-7	2013	Lower intracellular accumulation of actinomycin D was observed in MDCKII-ABCB1 cells as compared to MDCKII-WT (0.98 nM vs. 0.1 nM, p<0.0001), which was reversed upon ABCB1 inhibition.	Dactinomycin	36-49	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	73-78
23063411-7	2013	Lower intracellular accumulation of actinomycin D was observed in MDCKII-ABCB1 cells as compared to MDCKII-WT (0.98 nM vs. 0.1 nM, p<0.0001), which was reversed upon ABCB1 inhibition.	Dactinomycin	36-49	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	169-174
23063411-9	2013	Actinomycin D efflux over 2 h was most pronounced in MDCKII-ABCB1 cells, with 5.5-fold lower intracellular levels compared to WT.	Dactinomycin	0-13	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	60-65
23063411-12	2013	Results confirm actinomycin D as a substrate for ABCB1, ABCC1 and ABCC2, and indicate that Abcb1a/1b and Abcc2 can influence the in vivo disposition of actinomycin D.	Dactinomycin	16-29	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	49-54
24289639-2	2013	This study was conducted to establish paclitaxel-resistant breast cancer cell line and nude mice models to explore underlying mechanisms of MDR.	Paclitaxel	38-48	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	140-143
23251289-4	2013	Genes for fatty acid, peptide, amino acid and glucose and multidrug resistance/multidrug resistance-associated protein (MDR/MRP) transport were expressed at relatively higher levels than the other transporter types.	Peptides	22-29	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	120-123
22982598-9	2012	This occurred concomitantly with decreased mRNA expression levels and activity of the multidrug resistance protein 1 (Mrp1), a transport protein that mediates cellular export of glutathione disulfide and glutathione conjugates.	Glutathione Disulfide	178-199	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	86-116
23433151-0	2013	[The effects of benzene poisoning on expression of multidrug resistance 1 gene and P-glycoprotein in bone marrow mononuclear cells of C57BL/6 mice].	Benzene	16-23	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	51-73
23433151-1	2013	OBJECTIVE: To investigate the effects of benzene poisoning on the expression of multidrug resistance 1 (MDR1) gene and P-glycoprotein (P-gp) in the bone marrow mononuclear cells (BMMNCs) of C57BL/6 mice.	Benzene	41-48	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	80-102
23433151-1	2013	OBJECTIVE: To investigate the effects of benzene poisoning on the expression of multidrug resistance 1 (MDR1) gene and P-glycoprotein (P-gp) in the bone marrow mononuclear cells (BMMNCs) of C57BL/6 mice.	Benzene	41-48	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	104-108
23433151-10	2013	CONCLUSION: Benzene poisoning can affect the expression of MDR1 gene and P-gp, which may be one of the mechanisms of benzene hematotoxicity.	Benzene	12-19	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	59-63
23433151-10	2013	CONCLUSION: Benzene poisoning can affect the expression of MDR1 gene and P-gp, which may be one of the mechanisms of benzene hematotoxicity.	Benzene	117-124	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	59-63
23285492-0	2004	(11)C-Labeled rhodamine-123 The P-glycoprotein (P-gp; also known as MDR1 or ABCB1) is a member of the ATP-binding cassette transporter family of proteins (the multi-drug resistance (MDR) protein and the breast cancer resistance protein (BCRP) are the other two members of this group of proteins) that is responsible for the rapid transportation of drugs across the cell membrane (uptake and efflux) (1).	Rhodamine 123	14-27	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	68-72
23285492-0	2004	(11)C-Labeled rhodamine-123 The P-glycoprotein (P-gp; also known as MDR1 or ABCB1) is a member of the ATP-binding cassette transporter family of proteins (the multi-drug resistance (MDR) protein and the breast cancer resistance protein (BCRP) are the other two members of this group of proteins) that is responsible for the rapid transportation of drugs across the cell membrane (uptake and efflux) (1).	Rhodamine 123	14-27	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	76-81
23285492-8	2004	Rhodamine-123 is a fluorescent dye that is used to measure the expression of P-gp in drug-resistant cells, and the National Cancer Institute of the United States uses it to screen for drugs that serve as substrates for MDR1 (6).	Rhodamine 123	0-13	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	219-223
22982598-9	2012	This occurred concomitantly with decreased mRNA expression levels and activity of the multidrug resistance protein 1 (Mrp1), a transport protein that mediates cellular export of glutathione disulfide and glutathione conjugates.	Glutathione Disulfide	178-199	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	118-122
22982598-9	2012	This occurred concomitantly with decreased mRNA expression levels and activity of the multidrug resistance protein 1 (Mrp1), a transport protein that mediates cellular export of glutathione disulfide and glutathione conjugates.	Glutathione	178-189	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	86-116
22982598-9	2012	This occurred concomitantly with decreased mRNA expression levels and activity of the multidrug resistance protein 1 (Mrp1), a transport protein that mediates cellular export of glutathione disulfide and glutathione conjugates.	Glutathione	178-189	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	118-122
22982598-10	2012	Additionally, inhibition of Mrp1 enhanced intracellular GSH in wild-type cells only.	Glutathione	56-59	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	28-32
22982598-11	2012	These data suggest that FL-mHtt affects the export of glutathione by decreasing the expression of Mrp1.	fl-mhtt	24-31	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	98-102
22982598-11	2012	These data suggest that FL-mHtt affects the export of glutathione by decreasing the expression of Mrp1.	Glutathione	54-65	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	98-102
23020847-6	2012	Oral coadministration of the dual ABCB1 and ABCG2 inhibitor elacridar almost completely eliminated the roles of Abcb1 and Abcg2 in restricting oral availability and brain accumulation of vemurafenib.	Vemurafenib	187-198	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	34-39
23020847-6	2012	Oral coadministration of the dual ABCB1 and ABCG2 inhibitor elacridar almost completely eliminated the roles of Abcb1 and Abcg2 in restricting oral availability and brain accumulation of vemurafenib.	Vemurafenib	187-198	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	112-117
22633931-0	2012	Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors.	vandetanib	60-70	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	106-111
22688250-1	2012	Primary objective of this investigation was to delineate the differential impact of efflux transporters P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) on brain disposition and plasma pharmacokinetics of pazopanib.	pazopanib	235-244	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	125-130
22505225-9	2012	We found that the multidrug resistance gene 1 (MDR1) transporter was responsible for the efflux of Hoechst from SP cells in our MYC-driven model.	hoechst	99-106	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	18-45
22505225-9	2012	We found that the multidrug resistance gene 1 (MDR1) transporter was responsible for the efflux of Hoechst from SP cells in our MYC-driven model.	hoechst	99-106	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	47-51
22505225-10	2012	Accordingly, SP cells and their tumor-initiating subset were more resistant than non-SP cells to chemotherapeutics that are effluxed by MDR1.	sp	13-15	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	136-140
22505225-10	2012	Accordingly, SP cells and their tumor-initiating subset were more resistant than non-SP cells to chemotherapeutics that are effluxed by MDR1.	sp	85-87	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	136-140
22451472-3	2012	Multidrug resistance protein 1 blockade by the specific inhibitor reduced the percentage of rhodamine 123(low) cells in LDCs from aged mice (54.8% +- 2.6% to 13.2% +- 2.5%, p < .01).	Rhodamines	92-101	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	0-30
22739506-4	2012	Norbuprenorphine is an in vitro substrate of the efflux transporter P-glycoprotein (Mdr1), but the role of P-glycoprotein in norbuprenorphine transport in vivo is unknown.	norbuprenorphine	0-16	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	84-88
22704597-7	2012	PAEN lowered the IC(50) value of doxorubicin (DOX) in MDR tumor cells to a comparable level to that in the sensitive cell line through down-regulating the expression of P-gp and Survivin, and decreased the tumor volumes in mice xenograft model bearing DOX-resistant human breast cancer when combined with DOX.	Doxorubicin	33-44	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	54-57
22704597-7	2012	PAEN lowered the IC(50) value of doxorubicin (DOX) in MDR tumor cells to a comparable level to that in the sensitive cell line through down-regulating the expression of P-gp and Survivin, and decreased the tumor volumes in mice xenograft model bearing DOX-resistant human breast cancer when combined with DOX.	Doxorubicin	46-49	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	54-57
23020847-0	2012	Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.	Vemurafenib	68-79	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	119-124
23020847-2	2012	We aimed to establish whether oral availability and brain penetration of vemurafenib could be restricted by the multidrug efflux transporters P-glycoprotein (P-gp/ABCB1) and breast cancer resistance protein (BCRP/ABCG2), as these might limit therapeutic efficacy, especially against brain metastases.	Vemurafenib	73-84	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	163-168
22667338-10	2012	SP cells were detected at a frequency of 4.4% and expressed stem/progenitor markers, Abcb1b, Abcg2, Sca1, Notch1, Notch4, Hes1, and Jag1 in microarray analysis.	sp	0-2	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	85-91
22233293-5	2012	KEY RESULTS: Crizotinib significantly enhanced the cytotoxicity of chemotherapeutic agents which are also ABCB1 substrates, in MDR cells with no effect found on sensitive cells in vitro and in vivo.	Crizotinib	13-23	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	106-111
22454535-0	2012	Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032).	Vemurafenib	131-142	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	26-31
22264856-2	2012	We sought to evaluate the relationship between 2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG) and P-gp expression using breast carcinoma Bcap37/multidrug resistant (MDR1) and Bcap37 in vitro and in vivo.	Fluorodeoxyglucose F18	47-78	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	161-165
22264856-3	2012	METHODS: The function of P-gp expressed in Bcap37/MDR1 cells was evaluated using verapamil (VER), a classical inhibitor of P-gp.	Verapamil	81-90	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	50-54
22233293-6	2012	Additionally, crizotinib significantly increased intracellular accumulation of rhodamine 123 and doxorubicin and inhibited the drug efflux in ABCB1-overexpressing MDR cells.	Crizotinib	14-24	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	142-147
22233293-7	2012	Further studies showed that crizotinib enhanced the ATPase activity of ABCB1 in a concentration-dependent manner.	Crizotinib	28-38	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	71-76
22233293-10	2012	CONCLUSIONS AND IMPLICATIONS: Crizotinib reversed ABCB1-mediated MDR by inhibiting ABCB1 transport function without affecting ABCB1 expression or blocking the Akt or ERK1/2 pathways.	Crizotinib	30-40	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	50-55
22233293-10	2012	CONCLUSIONS AND IMPLICATIONS: Crizotinib reversed ABCB1-mediated MDR by inhibiting ABCB1 transport function without affecting ABCB1 expression or blocking the Akt or ERK1/2 pathways.	Crizotinib	30-40	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	83-88
22233293-10	2012	CONCLUSIONS AND IMPLICATIONS: Crizotinib reversed ABCB1-mediated MDR by inhibiting ABCB1 transport function without affecting ABCB1 expression or blocking the Akt or ERK1/2 pathways.	Crizotinib	30-40	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	83-88
22058426-3	2012	Property modeling around the D-threo-1-phenyl-2-decanoylamino-3-morpholino-propanol (PDMP) pharmacophore was employed in a search for compounds of comparable activity against the GCS but lacking P-glycoprotein (MDR1) recognition.	RV 538	85-89	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	211-215
22238213-0	2012	P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) restrict brain accumulation of the active sunitinib metabolite N-desethyl sunitinib.	Sunitinib	110-119	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	16-21
22238213-0	2012	P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) restrict brain accumulation of the active sunitinib metabolite N-desethyl sunitinib.	SU 12662	131-151	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	16-21
22238213-4	2012	At 5 muM, ABCB1 and ABCG2 contributed almost equally to N-desethyl sunitinib transport.	SU 12662	56-76	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	10-15
22238213-9	2012	In conclusion, brain accumulation of N-desethyl sunitinib is effectively restricted by both Abcb1 and Abcg2.	SU 12662	37-57	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	92-97
22335402-0	2012	Insight into the cooperation of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) at the blood-brain barrier: a case study examining sorafenib efflux clearance.	Sorafenib	151-160	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	48-53
22531820-6	2012	STZ treatment elevated Mrp1, 2, 4, and 5 and reduced Mrp3, 6, and Mdr1b mRNA and/or protein in non-pregnant mice.	Streptozocin	0-3	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	66-71
22577854-4	2012	To that effect, a monoclonal antibody, C219, directed against the intracellular ATP-binding site of the membrane-anchored MDR transporter ABCB1 [P-glycoprotein (P-gp), MDR1], was conjugated to human immunodeficiency virus [HIV(37-72)Tat] translocator peptide through a disulfide bridge.	Adenosine Triphosphate	80-83	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	138-143
22577854-4	2012	To that effect, a monoclonal antibody, C219, directed against the intracellular ATP-binding site of the membrane-anchored MDR transporter ABCB1 [P-glycoprotein (P-gp), MDR1], was conjugated to human immunodeficiency virus [HIV(37-72)Tat] translocator peptide through a disulfide bridge.	Disulfides	269-278	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	138-143
22258826-3	2012	In a cell-based assay system with human MDR1 cDNA overexpressed mouse fibroblast NIH MDR1-G185 cell line, we demonstrated that this metal complex can directly interact with this transporter.	Metals	132-137	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	85-89
22842366-6	2012	The MDR1-shRNA2 transfected cells showed that the sensitivities to chemotherapy drugs were higher than other shRNAs transfected A2780 cells, and that the formed tumor in mice grew slower than those of other mice after paclitaxel was injected into tumor-bearing nude mice.	Paclitaxel	218-228	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	4-8
21965738-2	2011	Previously, we demonstrated that eight hydantoin derivatives inhibited the P-glycoprotein (ABCB1) efflux pump of mouse T-lymphoma cells, as well as acting synergistically with the anticancer drug doxorubicin.	Hydantoins	39-48	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	91-96
22024132-10	2012	However, studies with actinomycin D revealed that the half-life of Mdr1a and Mdr1b mRNA were significantly prolonged by two-fold in ivermectin-treated cells suggesting a post-transcriptional mode of ivermectin regulation.	Dactinomycin	22-35	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	77-82
22037022-0	2012	Targeting the mitochondrial pathway to induce apoptosis/necrosis through ROS by a newly developed Schiff"s base to overcome MDR in cancer.	ros	73-76	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	124-127
22037022-0	2012	Targeting the mitochondrial pathway to induce apoptosis/necrosis through ROS by a newly developed Schiff"s base to overcome MDR in cancer.	schiff"s base	98-111	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	124-127
22037022-1	2012	Multidrug resistance (MDR) in cancer, a major obstacle to successful application of cancer chemotherapy, is often characterized by over-expression of multidrug resistance-related proteins such as MRP1, P-gp or elevated glutathione (GSH) level.	Glutathione	219-230	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	22-25
22037022-1	2012	Multidrug resistance (MDR) in cancer, a major obstacle to successful application of cancer chemotherapy, is often characterized by over-expression of multidrug resistance-related proteins such as MRP1, P-gp or elevated glutathione (GSH) level.	Glutathione	232-235	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	22-25
21351087-0	2012	Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.	Sunitinib	22-31	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	65-70
21351087-2	2012	We aimed to investigate the in vivo roles of the ATP-binding cassette drug efflux transporters ABCB1 and ABCG2 in plasma pharmacokinetics and brain accumulation of oral sunitinib, and the feasibility of improving sunitinib kinetics using oral coadministration of the dual ABCB1/ABCG2 inhibitor elacridar.	Adenosine Triphosphate	49-52	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	95-100
21351087-2	2012	We aimed to investigate the in vivo roles of the ATP-binding cassette drug efflux transporters ABCB1 and ABCG2 in plasma pharmacokinetics and brain accumulation of oral sunitinib, and the feasibility of improving sunitinib kinetics using oral coadministration of the dual ABCB1/ABCG2 inhibitor elacridar.	Adenosine Triphosphate	49-52	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	272-277
21351087-2	2012	We aimed to investigate the in vivo roles of the ATP-binding cassette drug efflux transporters ABCB1 and ABCG2 in plasma pharmacokinetics and brain accumulation of oral sunitinib, and the feasibility of improving sunitinib kinetics using oral coadministration of the dual ABCB1/ABCG2 inhibitor elacridar.	Sunitinib	169-178	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	95-100
21351087-2	2012	We aimed to investigate the in vivo roles of the ATP-binding cassette drug efflux transporters ABCB1 and ABCG2 in plasma pharmacokinetics and brain accumulation of oral sunitinib, and the feasibility of improving sunitinib kinetics using oral coadministration of the dual ABCB1/ABCG2 inhibitor elacridar.	Sunitinib	213-222	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	95-100
21351087-2	2012	We aimed to investigate the in vivo roles of the ATP-binding cassette drug efflux transporters ABCB1 and ABCG2 in plasma pharmacokinetics and brain accumulation of oral sunitinib, and the feasibility of improving sunitinib kinetics using oral coadministration of the dual ABCB1/ABCG2 inhibitor elacridar.	Sunitinib	213-222	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	272-277
22391220-9	2012	Perfusing the brains of Abcb1/Abcg2- and Abca1-deficient mice with [3H] Abeta1-40 plus probucol significantly increased the Clup of Abeta.	Tritium	68-70	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	24-29
22768295-5	2012	In the brains of P-gp-deficient Mdr1(0/0) mice, we found quinacrine reached concentrations of ~80 microM without any signs of acute toxicity.	Quinacrine	57-67	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	32-36
22768295-6	2012	Additionally, we examined the distribution and metabolism of quinacrine in the wild-type and Mdr1(0/0) brains.	Quinacrine	61-71	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	93-97
22536451-3	2012	Here we aim to show that mice devoid of Abcb1 and Abcg2 retain higher brain THC levels and are more sensitive to cannabinoid-induced hypothermia than wild-type (WT) mice.	Dronabinol	76-79	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	40-45
22536451-3	2012	Here we aim to show that mice devoid of Abcb1 and Abcg2 retain higher brain THC levels and are more sensitive to cannabinoid-induced hypothermia than wild-type (WT) mice.	Cannabinoids	113-124	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	40-45
21965738-2	2011	Previously, we demonstrated that eight hydantoin derivatives inhibited the P-glycoprotein (ABCB1) efflux pump of mouse T-lymphoma cells, as well as acting synergistically with the anticancer drug doxorubicin.	Doxorubicin	196-207	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	91-96
21350189-9	2011	Culture supernatant (CS; 1:10 or 1:50, 24 h) of Lactobacillus acidophilus or Lactobacillus rhamnosus treatment of differentiated Caco-2 monolayers (21 days postplating) increased (~3-fold) MDR1/P-gp mRNA and protein levels.	Cesium	21-23	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	189-193
21592089-5	2011	PTC (phenylthiocarbamide), an agonist for the T2R38 bitter receptor, increased ABCB1 expression in both intestinal cells and mouse intestine.	Phenylthiourea	0-3	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	79-84
21592089-5	2011	PTC (phenylthiocarbamide), an agonist for the T2R38 bitter receptor, increased ABCB1 expression in both intestinal cells and mouse intestine.	Phenylthiourea	5-24	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	79-84
21592089-7	2011	Thus gut ABCB1 is regulated through signalling by CCK/gastrin released in response to PTC stimulation of T2R38 on enteroendocrine cells.	Phenylthiourea	86-89	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	9-14
21393247-6	2011	IL-6 activates GSH release through a methionine-sensitive/organic anion transporter polypeptide 1- and multidrug resistance protein 1-independent channel located on the sinusoidal site of hepatocytes.	Glutathione	15-18	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	103-133
21711510-10	2011	Moreover, the markedly increased Abcb1a/Abcb1b expression was correlated to an efficient Rhodamine 123 efflux, which was completely inhibited by verapamil, a well-known Abcb1a/Abcb1b inhibitor.	Rhodamines	89-98	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	40-46
21711510-10	2011	Moreover, the markedly increased Abcb1a/Abcb1b expression was correlated to an efficient Rhodamine 123 efflux, which was completely inhibited by verapamil, a well-known Abcb1a/Abcb1b inhibitor.	Rhodamines	89-98	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	176-182
21711510-10	2011	Moreover, the markedly increased Abcb1a/Abcb1b expression was correlated to an efficient Rhodamine 123 efflux, which was completely inhibited by verapamil, a well-known Abcb1a/Abcb1b inhibitor.	Verapamil	145-154	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	40-46
21711510-10	2011	Moreover, the markedly increased Abcb1a/Abcb1b expression was correlated to an efficient Rhodamine 123 efflux, which was completely inhibited by verapamil, a well-known Abcb1a/Abcb1b inhibitor.	Verapamil	145-154	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	176-182
21711510-12	2011	In accordance to Rhodamine 123 efflux data, chemotherapeutic drug resistance of mBMDC/67NR-Hyg cells was impaired by verapamil mediated blockage of Abc1a/Abcb1b multidrug transporter function.	Verapamil	117-126	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	154-160
21378205-0	2011	P-glycoprotein (ABCB1) transports the primary active tamoxifen metabolites endoxifen and 4-hydroxytamoxifen and restricts their brain penetration.	Tamoxifen	53-62	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	16-21
21378205-0	2011	P-glycoprotein (ABCB1) transports the primary active tamoxifen metabolites endoxifen and 4-hydroxytamoxifen and restricts their brain penetration.	4-hydroxy-N-desmethyltamoxifen	75-84	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	16-21
21378205-0	2011	P-glycoprotein (ABCB1) transports the primary active tamoxifen metabolites endoxifen and 4-hydroxytamoxifen and restricts their brain penetration.	hydroxytamoxifen	89-107	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	16-21
21282407-4	2011	Axitinib was a good substrate of ABCB1 and Abcg2, whereas transport activity by ABCG2 was moderate.	Axitinib	0-8	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	33-38
21282407-10	2011	Thus, Abcb1 strongly restricts axitinib brain accumulation and completely compensates for the loss of Abcg2 at the blood-brain barrier, whereas Abcg2 can only partially take over Abcb1-mediated axitinib efflux.	Axitinib	31-39	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	6-11
21309545-1	2011	P-glycoprotein (P-gp/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) combination knockout mice display disproportionately increased brain penetration of shared substrates, including topotecan and several tyrosine kinase inhibitors, compared to mice deficient for only one transporter.	Topotecan	191-200	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	21-26
21309545-5	2011	ABCB1 and ABCG2 contributed to similar extents to topotecan transport, which was only partly saturable.	Topotecan	50-59	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	0-5
21309545-7	2011	However, saturation of ABCG2-mediated transport occurred at higher sorafenib concentrations, where ABCB1 was still fully active.	Sorafenib	67-76	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	99-104
21309545-8	2011	Furthermore, sunitinib was transported equally by ABCB1 and ABCG2 at low concentrations, but ABCG2-mediated transport became saturated at lower concentrations than ABCB1-mediated transport.	Sunitinib	13-22	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	50-55
21393174-7	2011	RESULTS: Elvitegravir and vicriviroc inhibited ABCB1 in P388/dx and L-MDR1 cells (f2 values 1.9+-0.2 micromol/L and 8.5+-3.6 micromol/L, respectively).	elvitegravir	9-21	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	47-52
21393174-7	2011	RESULTS: Elvitegravir and vicriviroc inhibited ABCB1 in P388/dx and L-MDR1 cells (f2 values 1.9+-0.2 micromol/L and 8.5+-3.6 micromol/L, respectively).	vicriviroc	26-36	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	47-52
21148080-0	2011	Endoxifen, the active metabolite of tamoxifen, is a substrate of the efflux transporter P-glycoprotein (multidrug resistance 1).	4-hydroxy-N-desmethyltamoxifen	0-9	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	104-126
21148080-0	2011	Endoxifen, the active metabolite of tamoxifen, is a substrate of the efflux transporter P-glycoprotein (multidrug resistance 1).	Tamoxifen	36-45	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	104-126
21148080-3	2011	However, little is known regarding the role of drug transporters such as P-glycoprotein [multidrug resistance 1 (MDR1), ATP-binding cassette B1 (ABCB1)] to endoxifen disposition and response.	4-hydroxy-N-desmethyltamoxifen	156-165	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	89-111
21148080-3	2011	However, little is known regarding the role of drug transporters such as P-glycoprotein [multidrug resistance 1 (MDR1), ATP-binding cassette B1 (ABCB1)] to endoxifen disposition and response.	4-hydroxy-N-desmethyltamoxifen	156-165	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	113-117
21148080-3	2011	However, little is known regarding the role of drug transporters such as P-glycoprotein [multidrug resistance 1 (MDR1), ATP-binding cassette B1 (ABCB1)] to endoxifen disposition and response.	4-hydroxy-N-desmethyltamoxifen	156-165	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	120-143
21148080-3	2011	However, little is known regarding the role of drug transporters such as P-glycoprotein [multidrug resistance 1 (MDR1), ATP-binding cassette B1 (ABCB1)] to endoxifen disposition and response.	4-hydroxy-N-desmethyltamoxifen	156-165	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	145-150
21204761-3	2010	Inhibition of P-gp function by MDR1 shRNA and functional activity of hNIS gene was assessed using a 99(m)Tc sestamibi uptake and 125I uptake, respectively.	Technetium	105-107	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	31-35
21351274-0	2010	Individual and combined roles of CYP3A, P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) in the pharmacokinetics of docetaxel.	Docetaxel	112-121	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	56-60
21351274-0	2010	Individual and combined roles of CYP3A, P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) in the pharmacokinetics of docetaxel.	Docetaxel	112-121	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	61-66
21351274-4	2010	The drug-metabolizing enzyme CYP3A and the drug transporter MDR1 (P-glycoprotein) are major determinants of docetaxel pharmacokinetics.	Docetaxel	108-117	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	60-64
21187464-0	2010	Biological activity of hydantoin derivatives on P-glycoprotein (ABCB1) of mouse lymphoma cells.	Hydantoins	23-32	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	64-69
21187464-8	2010	CONCLUSION: These results indicated the role of chemical modifications within the hydantoin ring for its potential inhibition of the ABCB1 transporter.	Hydantoins	82-91	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	133-138
21204761-3	2010	Inhibition of P-gp function by MDR1 shRNA and functional activity of hNIS gene was assessed using a 99(m)Tc sestamibi uptake and 125I uptake, respectively.	Technetium Tc 99m Sestamibi	108-117	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	31-35
20709040-9	2010	DEX treatment during mid-gestation modified Abcb1 mRNA expression and P-gp function in a dose-, gestational age-, and sex-specific manner.	Dexamethasone	0-3	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	44-49
20583968-1	2010	The ATP-binding cassette transporters P-glycoprotein (ABCB1, MDR1) and multidrug resistance protein 4 (MRP4) efflux irinotecan and its active metabolite SN-38 in vitro, and thus may contribute to system clearance of these compounds.	Irinotecan	116-126	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	54-59
20583968-1	2010	The ATP-binding cassette transporters P-glycoprotein (ABCB1, MDR1) and multidrug resistance protein 4 (MRP4) efflux irinotecan and its active metabolite SN-38 in vitro, and thus may contribute to system clearance of these compounds.	Irinotecan	116-126	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	61-65
20583968-1	2010	The ATP-binding cassette transporters P-glycoprotein (ABCB1, MDR1) and multidrug resistance protein 4 (MRP4) efflux irinotecan and its active metabolite SN-38 in vitro, and thus may contribute to system clearance of these compounds.	Irinotecan	153-158	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	54-59
20583968-1	2010	The ATP-binding cassette transporters P-glycoprotein (ABCB1, MDR1) and multidrug resistance protein 4 (MRP4) efflux irinotecan and its active metabolite SN-38 in vitro, and thus may contribute to system clearance of these compounds.	Irinotecan	153-158	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	61-65
20735798-8	2010	Furthermore, we could exclude surgical damage of the BBB because peripherally-injected dexamethasone, which is a high affinity substrate for the Mdr1 Pgp and therefore restricted from entering the brain, could only be detected in the plasma and was virtually absent in the brain.	Dexamethasone	87-100	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	145-149
20642825-11	2010	The drug resistance index to Adriamycin (ADM), vincristine (VCR), paclitaxel (Taxol) and bleomycin (BLM) increased to19.8050, 9.0663, 9.7245, 3.5650 respectively for 4T1/HA117 and 24.2236, 11.0480, 11.3741, 0.9630 respectively for 4T1/MDR1 as compared to the control cells.	Doxorubicin	29-39	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	235-239
20466523-6	2010	One to six hours post-dose, the brain concentrations of venlafaxine, O-desmethylvenlafaxine and N-desmethylvenlafaxine were 2-3, 2-6 and 3-12 times higher in abcb1ab (-/-) mice compared to abcb1ab (+/+) mice, respectively.	Venlafaxine Hydrochloride	56-67	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	158-163
20466523-6	2010	One to six hours post-dose, the brain concentrations of venlafaxine, O-desmethylvenlafaxine and N-desmethylvenlafaxine were 2-3, 2-6 and 3-12 times higher in abcb1ab (-/-) mice compared to abcb1ab (+/+) mice, respectively.	Desvenlafaxine Succinate	69-91	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	158-163
20466523-6	2010	One to six hours post-dose, the brain concentrations of venlafaxine, O-desmethylvenlafaxine and N-desmethylvenlafaxine were 2-3, 2-6 and 3-12 times higher in abcb1ab (-/-) mice compared to abcb1ab (+/+) mice, respectively.	N-desmethylvenlafaxine	96-118	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	158-163
20206183-7	2010	Pharmacological inhibition of MRP1 by MK571 increased intracellular glutathione levels and reduced intracellular reactive oxygen species levels.	verlukast	38-43	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	30-34
20206183-7	2010	Pharmacological inhibition of MRP1 by MK571 increased intracellular glutathione levels and reduced intracellular reactive oxygen species levels.	Glutathione	68-79	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	30-34
20206183-7	2010	Pharmacological inhibition of MRP1 by MK571 increased intracellular glutathione levels and reduced intracellular reactive oxygen species levels.	Reactive Oxygen Species	113-136	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	30-34
20438811-0	2010	Influence of ABCB1 genetic polymorphisms on the pharmacokinetics of levosulpiride in healthy subjects.	levosulpiride	68-81	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	13-18
20438811-8	2010	The results indicate that levosulpiride is a P-glycoprotein substrate in vivo, which is supported by the effects of SNPs 2677G>A/T in exon 21 and 3435C>T in exon 26 of ABCB1 on levosulpiride disposition.	levosulpiride	26-39	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	174-179
20642825-11	2010	The drug resistance index to Adriamycin (ADM), vincristine (VCR), paclitaxel (Taxol) and bleomycin (BLM) increased to19.8050, 9.0663, 9.7245, 3.5650 respectively for 4T1/HA117 and 24.2236, 11.0480, 11.3741, 0.9630 respectively for 4T1/MDR1 as compared to the control cells.	Paclitaxel	66-76	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	235-239
20642825-11	2010	The drug resistance index to Adriamycin (ADM), vincristine (VCR), paclitaxel (Taxol) and bleomycin (BLM) increased to19.8050, 9.0663, 9.7245, 3.5650 respectively for 4T1/HA117 and 24.2236, 11.0480, 11.3741, 0.9630 respectively for 4T1/MDR1 as compared to the control cells.	Paclitaxel	78-83	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	235-239
20642825-11	2010	The drug resistance index to Adriamycin (ADM), vincristine (VCR), paclitaxel (Taxol) and bleomycin (BLM) increased to19.8050, 9.0663, 9.7245, 3.5650 respectively for 4T1/HA117 and 24.2236, 11.0480, 11.3741, 0.9630 respectively for 4T1/MDR1 as compared to the control cells.	Bleomycin	89-98	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	235-239
20421331-0	2010	Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux.	Gefitinib	16-25	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	69-74
20590614-0	2010	Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir.	Lopinavir	136-145	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	80-84
20590614-0	2010	Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir.	Lopinavir	136-145	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	85-90
20590614-1	2010	BACKGROUND AND PURPOSE: Lopinavir is extensively metabolized by cytochrome P450 3A (CYP3A) and is considered to be a substrate for the drug transporters ABCB1 (P-glycoprotein) and ABCC2 (MRP2).	Lopinavir	24-33	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	153-158
20590614-2	2010	Here, we have assessed the individual and combined effects of CYP3A, ABCB1 and ABCC2 on the pharmacokinetics of lopinavir and the relative importance of intestinal and hepatic metabolism.	Lopinavir	112-121	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	69-74
20590614-3	2010	We also evaluated whether ritonavir increases lopinavir oral bioavailability by inhibition of CYP3A, ABCB1 and/or ABCC2.	Ritonavir	26-35	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	101-106
20590614-6	2010	KEY RESULTS: Lopinavir was transported by ABCB1 but not by ABCC2 in vitro.	Lopinavir	13-22	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	42-47
20514403-10	2010	The chemosensitizing effect of catechins may occur directly or indirectly by reversal of multidrug resistance, involving the suppression of MDR1 expression, or by enhancement of intracellular DOX accumulation, involving inhibition of P-gp function.	Catechin	31-40	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	140-144
20154595-3	2010	Our data revealed that triptolide decreases the expression of multidrug resistance protein and MDR in both KB-7D and KB-tax cells.	triptolide	23-33	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	95-98
20460505-0	2010	The skin cancer chemotherapeutic agent ingenol-3-angelate (PEP005) is a substrate for the epidermal multidrug transporter (ABCB1) and targets tumor vasculature.	3-ingenyl angelate	39-57	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	123-128
20460505-0	2010	The skin cancer chemotherapeutic agent ingenol-3-angelate (PEP005) is a substrate for the epidermal multidrug transporter (ABCB1) and targets tumor vasculature.	3-ingenyl angelate	59-65	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	123-128
20212014-2	2010	The three most prevalent ATP-binding cassette efflux transporters at the blood-brain barrier are P-glycoprotein (P-gp), multidrug resistance protein 1 (Mrp1), and breast cancer resistance protein (BCRP).	Adenosine Triphosphate	25-28	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	120-150
20212014-2	2010	The three most prevalent ATP-binding cassette efflux transporters at the blood-brain barrier are P-glycoprotein (P-gp), multidrug resistance protein 1 (Mrp1), and breast cancer resistance protein (BCRP).	Adenosine Triphosphate	25-28	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	152-156
20304939-0	2010	Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.	Erlotinib Hydrochloride	165-174	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	60-65
20304939-0	2010	Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.	alvocidib	176-188	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	60-65
20304939-0	2010	Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.	Mitoxantrone	194-206	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	60-65
19370547-0	2009	Differential involvement of P-glycoprotein (ABCB1) in permeability, tissue distribution, and antinociceptive activity of methadone, buprenorphine, and diprenorphine: in vitro and in vivo evaluation.	Methadone	121-130	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	44-49
20154595-2	2010	In this study, we show that triptolide possesses an anticancer effect on drug-sensitive parental KB cells and multidrug-resistant KB-7D and KB-tax cells that overexpress multidrug resistance protein and MDR, respectively.	triptolide	28-38	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	203-206
19924122-1	2010	Oral administration of the taxanes docetaxel and paclitaxel is hampered by their affinity for drug transporters, especially ABCB1 (P-glycoprotein, Pgp); extensive first-pass metabolism by cytochrome P450 3A (CYP3A); and poor drug solubility.	Taxoids	27-34	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	124-129
19924122-1	2010	Oral administration of the taxanes docetaxel and paclitaxel is hampered by their affinity for drug transporters, especially ABCB1 (P-glycoprotein, Pgp); extensive first-pass metabolism by cytochrome P450 3A (CYP3A); and poor drug solubility.	Docetaxel	35-44	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	124-129
19924122-1	2010	Oral administration of the taxanes docetaxel and paclitaxel is hampered by their affinity for drug transporters, especially ABCB1 (P-glycoprotein, Pgp); extensive first-pass metabolism by cytochrome P450 3A (CYP3A); and poor drug solubility.	Paclitaxel	49-59	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	124-129
19996204-14	2009	CONCLUSIONS: Our data show that ABCB1, ABCC2, and ABCC3 have a profound and partially redundant function in protection from trabectedin-mediated hepatotoxicity, presumably by clearing the liver from hepatotoxic trabectedin metabolites that are primarily formed by CYP3A.	Trabectedin	124-135	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	32-37
19996204-14	2009	CONCLUSIONS: Our data show that ABCB1, ABCC2, and ABCC3 have a profound and partially redundant function in protection from trabectedin-mediated hepatotoxicity, presumably by clearing the liver from hepatotoxic trabectedin metabolites that are primarily formed by CYP3A.	Trabectedin	211-222	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	32-37
19238326-0	2010	Disposition and toxicity of trabectedin (ET-743) in wild-type and mdr1 gene (P-gp) knock-out mice.	Trabectedin	28-39	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	66-70
20028753-0	2010	P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 determine the pharmacokinetics of etoposide.	Etoposide	80-89	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	21-26
20028753-2	2010	We aimed to study the impact of P-glycoprotein (P-gp/ABCB1) and the multidrug resistance proteins ABCC2 (MRP2) and ABCC3 (MRP3) on the pharmacokinetics of etoposide.	Etoposide	155-164	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	53-58
19920203-4	2009	The drug-metabolizing enzyme cytochrome P450 3A (CYP3A) and the drug transporter P-glycoprotein (P-gp; MDR1) are considered to be major determinants of docetaxel pharmacokinetics.	Docetaxel	152-161	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	103-107
19370547-0	2009	Differential involvement of P-glycoprotein (ABCB1) in permeability, tissue distribution, and antinociceptive activity of methadone, buprenorphine, and diprenorphine: in vitro and in vivo evaluation.	Buprenorphine	132-145	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	44-49
19370547-0	2009	Differential involvement of P-glycoprotein (ABCB1) in permeability, tissue distribution, and antinociceptive activity of methadone, buprenorphine, and diprenorphine: in vitro and in vivo evaluation.	Diprenorphine	151-164	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	44-49
19956709-3	2009	As quinacrine is known to be a substrate for P-glycoprotein multi-drug resistance (MDR) transporters, we circumvented its poor BBB permeability by utilizing MDR(0/0) mice that are deficient in mdr1a and mdr1b genes.	Quinacrine	3-13	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	83-86
19956709-3	2009	As quinacrine is known to be a substrate for P-glycoprotein multi-drug resistance (MDR) transporters, we circumvented its poor BBB permeability by utilizing MDR(0/0) mice that are deficient in mdr1a and mdr1b genes.	Quinacrine	3-13	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	203-208
19956709-5	2009	PrP(Sc) levels in the brains of prion-inoculated MDR(0/0) mice diminished upon the initiation of quinacrine treatment.	Quinacrine	97-107	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	49-52
19410561-3	2009	This study was to characterize the actions of FG020326, a newly synthesized triaryl-substituted imidazole derivative, to reverse MDR in vitro and in vivo.	triaryl-substituted imidazole	76-105	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	129-132
19846941-0	2009	Evaluation of cucurbitane-type triterpenoids from Momordica balsamina on P-glycoprotein (ABCB1) by flow cytometry and real-time fluorometry.	triterpenoids	31-44	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	89-94
19846941-6	2009	RESULTS: Among the compounds isolated, the most active was 7-methoxycucurbita-5,24-diene-3beta,23(R)-diol, which inhibited the efflux of ethidium bromide (EB) and rhodamine 123 from the ABCB1-transfected mouse lymphoma cell.	7-methoxycucurbita-5,24-diene-3beta	59-94	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	186-191
19846941-6	2009	RESULTS: Among the compounds isolated, the most active was 7-methoxycucurbita-5,24-diene-3beta,23(R)-diol, which inhibited the efflux of ethidium bromide (EB) and rhodamine 123 from the ABCB1-transfected mouse lymphoma cell.	23(r)-diol	95-105	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	186-191
19846941-6	2009	RESULTS: Among the compounds isolated, the most active was 7-methoxycucurbita-5,24-diene-3beta,23(R)-diol, which inhibited the efflux of ethidium bromide (EB) and rhodamine 123 from the ABCB1-transfected mouse lymphoma cell.	Ethidium	137-153	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	186-191
19846941-6	2009	RESULTS: Among the compounds isolated, the most active was 7-methoxycucurbita-5,24-diene-3beta,23(R)-diol, which inhibited the efflux of ethidium bromide (EB) and rhodamine 123 from the ABCB1-transfected mouse lymphoma cell.	Ethidium	155-157	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	186-191
19631191-1	2009	We assessed the interaction of three electrically neutral detergents (Triton X-100, C(12)EO(8), and Tween 80) with P-glycoprotein (ABCB1, MDR1) and identified the molecular elements responsible for this interaction.	Octoxynol	70-82	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	131-136
19631191-1	2009	We assessed the interaction of three electrically neutral detergents (Triton X-100, C(12)EO(8), and Tween 80) with P-glycoprotein (ABCB1, MDR1) and identified the molecular elements responsible for this interaction.	Octoxynol	70-82	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	138-142
19631191-1	2009	We assessed the interaction of three electrically neutral detergents (Triton X-100, C(12)EO(8), and Tween 80) with P-glycoprotein (ABCB1, MDR1) and identified the molecular elements responsible for this interaction.	Polysorbates	100-108	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	131-136
19821097-8	2009	These results suggested that transfection of pEGFP-H1/mdr1 could efficiently down-regulate the expression of mdr1 mRNA and P-gp in A2780/Taxol cells, and effectively restore the sensitivity of A2780/Taxol cells to Taxol both in vitro and in vivo.	Paclitaxel	137-142	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	54-58
19821097-8	2009	These results suggested that transfection of pEGFP-H1/mdr1 could efficiently down-regulate the expression of mdr1 mRNA and P-gp in A2780/Taxol cells, and effectively restore the sensitivity of A2780/Taxol cells to Taxol both in vitro and in vivo.	Paclitaxel	137-142	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	109-113
19654309-1	2009	We have found previously that acquired doxorubicin resistance in a genetically engineered mouse model for BRCA1-related breast cancer was associated with increased expression of the mouse multidrug resistance (Mdr1) genes, which encode the drug efflux transporter ATP-binding cassette B1/P-glycoprotein (P-gp).	Doxorubicin	39-50	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	210-214
19654309-2	2009	Here, we show that even moderate increases of Mdr1 expression (as low as 5-fold) are sufficient to cause doxorubicin resistance.	Doxorubicin	105-116	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	46-50
19225039-2	2009	Four drugs, flavopiridol, imatinib mesylate (Gleevec), PF-407288, and prazosin, with different transport specificity for BCRP/Bcrp and MDR1/Mdr1a were selected, and the drug levels in plasma, cerebrospinal fluid, and brain of mice were determined.	alvocidib	12-24	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	135-139
19508886-9	2009	At the hepato-biliary interface, we showed the involvement of Abcb1, Abcc2 and Abcg2; indeed, AMI concentration was increased in liver and decreased in bile, where quinidine is the strongest inhibitor, followed by probenecid and novobiocin.	Quinidine	164-173	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	62-67
19567673-1	2009	Topotecan is a substrate of the ATP-binding cassette transporters P-glycoprotein (P-gp/MDR1) and breast cancer resistance protein (BCRP).	Topotecan	0-9	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	87-91
19591692-0	2009	Influence of the dual ABCB1 and ABCG2 inhibitor tariquidar on the disposition of oral imatinib in mice.	Imatinib Mesylate	86-94	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	22-27
19591692-1	2009	BACKGROUND: Imatinib, a tyrosine kinase inhibitor currently approved for treatment of several malignancies, has been shown to be a substrate for multiple efflux-transporter proteins, including ABCB1 (P-glycoprotein) and ABCG2 (BCRP).	Imatinib Mesylate	12-20	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	193-198
19481690-0	2009	Evaluation of the P-glycoprotein (Abcb1) affinity status of a series of morphine analogs: comparative study with meperidine analogs to identify opioids with minimal P-glycoprotein interactions.	Morphine	72-80	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	34-39
19508886-4	2009	5 mg/kg AMI+100 mg/kg quinidine (Abcb1 inhibitor).	Quinidine	22-31	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	33-38
19225039-2	2009	Four drugs, flavopiridol, imatinib mesylate (Gleevec), PF-407288, and prazosin, with different transport specificity for BCRP/Bcrp and MDR1/Mdr1a were selected, and the drug levels in plasma, cerebrospinal fluid, and brain of mice were determined.	Imatinib Mesylate	26-43	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	135-139
19225039-2	2009	Four drugs, flavopiridol, imatinib mesylate (Gleevec), PF-407288, and prazosin, with different transport specificity for BCRP/Bcrp and MDR1/Mdr1a were selected, and the drug levels in plasma, cerebrospinal fluid, and brain of mice were determined.	Imatinib Mesylate	45-52	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	135-139
19225039-2	2009	Four drugs, flavopiridol, imatinib mesylate (Gleevec), PF-407288, and prazosin, with different transport specificity for BCRP/Bcrp and MDR1/Mdr1a were selected, and the drug levels in plasma, cerebrospinal fluid, and brain of mice were determined.	2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid	55-64	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	135-139
19225039-2	2009	Four drugs, flavopiridol, imatinib mesylate (Gleevec), PF-407288, and prazosin, with different transport specificity for BCRP/Bcrp and MDR1/Mdr1a were selected, and the drug levels in plasma, cerebrospinal fluid, and brain of mice were determined.	Prazosin	70-78	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	135-139
19067430-1	2009	BACKGROUND: P-glycoprotein (P-gp), the product of the multidrug resistance gene (MDR), is an ATP-dependent transmembrane pump, which is expressed in multiple cell lineages including epithelial and hematopoetic cells.	Adenosine Triphosphate	93-96	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	81-84
19732497-0	2009	Role of two efflux proteins, ABCB1 and ABCG2 in blood-brain barrier transport of bromocriptine in a murine model of MPTP-induced dopaminergic degeneration.	Bromocriptine	81-94	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	29-34
19093112-8	2009	CONCLUSIONS: Quantified (99m)Tc-MIBI efflux has potential to: (1) noninvasively assign Mdr1 expression levels, (2) predict the therapeutic impact of a P-gp inhibitor, and (3) noninvasively assess the probability of drug resistance.	Technetium Tc 99m Sestamibi	29-36	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	87-91
19234366-1	2009	Efavirenz, an important component of human immunodeficiency virus 1 (HIV-1) therapy, causes substantial drug interactions as an inducer of cytochromes and the transporter ABCB1.	efavirenz	0-9	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	171-176
19276246-0	2009	Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment.	Dasatinib	22-31	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	65-70
19276246-1	2009	PURPOSE: Imatinib, a BCR-ABL tyrosine kinase inhibitor, is a substrate of the efflux transporters P-glycoprotein (P-gp; ABCB1) and ABCG2 (breast cancer resistance protein), and its brain accumulation is restricted by both transporters.	Imatinib Mesylate	9-17	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	120-125
19220323-9	2009	MG132 also suppressed significantly epithelial cell proliferation, cell migration and MDR1 gene expression in vitro.	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	0-5	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	86-90
19161460-1	2009	P-glycoprotein, which is encoded by the multi-drug resistance gene (MDR1), highly restricts the entry of ivermectin into the brain by an ATP-driven efflux mechanism at the blood-brain barrier.	Adenosine Triphosphate	137-140	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	68-72
18722489-2	2008	The formulation contains amphiphilic block copolymers, Pluronics, that exhibit the unique ability to chemosensitize multidrug resistant (MDR) tumors by inhibiting P-glycoprotein (Pgp) drug efflux system and enhancing pro-apoptotic signaling in cancer cells.	copolymers	43-53	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	137-140
18824002-6	2008	Direct comparison of the conventional bi-directional (concentration gradient) assay with the CETA, using MDR1-transfected LLC cells, demonstrated that CETA, but not the conventional assay, identified phenytoin and phenobarbital as substrates of human Pgp.	ceta	93-97	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	105-109
18824002-6	2008	Direct comparison of the conventional bi-directional (concentration gradient) assay with the CETA, using MDR1-transfected LLC cells, demonstrated that CETA, but not the conventional assay, identified phenytoin and phenobarbital as substrates of human Pgp.	ceta	151-155	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	105-109
18824002-6	2008	Direct comparison of the conventional bi-directional (concentration gradient) assay with the CETA, using MDR1-transfected LLC cells, demonstrated that CETA, but not the conventional assay, identified phenytoin and phenobarbital as substrates of human Pgp.	Phenytoin	200-209	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	105-109
18824002-6	2008	Direct comparison of the conventional bi-directional (concentration gradient) assay with the CETA, using MDR1-transfected LLC cells, demonstrated that CETA, but not the conventional assay, identified phenytoin and phenobarbital as substrates of human Pgp.	Phenobarbital	214-227	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	105-109
18759452-1	2008	P-glycoprotein (ABCB1) prevents absorption (e.g., blood-brain barrier) or enhances excretion (e.g., kidney) by moving substrates from the cytosolic to the extracellular membrane leaflet at the expense of ATP hydrolysis.	Adenosine Triphosphate	204-207	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	16-21
18640236-6	2008	Cisplatin-induced renal injury increased mRNA and protein levels of the efflux transporters Mrp2, Mrp4, Mrp5, Mdr1a and Mdr1b.	Cisplatin	0-9	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	120-125
18849167-3	2008	Their ability to promote calcein-AM (CAM) uptake in MDCKII-MDR1 cells and their capacity to be transported by Pgp in monolayers of MDCKII-MDR1 cells were also evaluated.	calcein AM	37-40	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	59-63
18722489-3	2008	This work evaluates whether a representative block copolymer, Pluronic P85 (P85) can also prevent development of Dox-induced MDR in leukemia cells.	Doxorubicin	113-116	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	125-128
18722489-11	2008	In conclusion, Pluronic formulation can prevent development of MDR in leukemia cells in vitro and in vivo.	Poloxamer	15-23	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	63-66
18725505-10	2008	At concentrations (5 and 10 microM) that did not down-regulate PXR gene expression and were not cytotoxic, L-sulforaphane (an hPXR antagonist) decreased CYP3A4, CYP3A5, and ABCB1 gene expression in cells treated with G. biloba extract.	sulforaphane	107-121	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	173-178
18834355-7	2008	Furthermore, by administration of navelbine after transfection with Stealth RNAi targeted on the MDR1 gene, its depression to tumour xenografts dramatically improved by nine times.	Vinorelbine	34-43	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	97-101
18722489-3	2008	This work evaluates whether a representative block copolymer, Pluronic P85 (P85) can also prevent development of Dox-induced MDR in leukemia cells.	copolymer	51-60	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	125-128
18723475-0	2008	Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice.	Erlotinib Hydrochloride	80-103	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	53-58
18723475-0	2008	Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice.	Erlotinib Hydrochloride	105-112	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	53-58
18513966-1	2008	The 1-[4-(2-aminoethoxy)phenylcarbonyl]-3,5-bis-(benzylidene)-4-oxopiperidines 5-8 are a novel cluster of highly potent P-glycoprotein dependent multidrug resistance (MDR) revertants.	1-[4-(2-aminoethoxy)phenylcarbonyl]-3,5-bis-(benzylidene)-4-oxopiperidines 5-8	4-82	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	167-170
18513966-2	2008	Using a concentration of 4mug/mL, these compounds possess 11-43 times the potency of verapamil in reversing MDR in murine L-5178 lymphoma cells transfected with the human MDR1 gene.	Verapamil	85-94	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	108-111
18513966-3	2008	Structure-activity relationships reveal that the attachment of the N-aroyl group to various 3,5-bis(benzylidene)-4-piperidones is essential for MDR reversal to occur.	3,5-bis(benzylidene)-4-piperidone	92-126	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	144-147
18034828-9	2008	Co-administration of C-PC and 2-AAF inhibited the expression of MDR1 by preventing ROS generation, Akt phosphorylation and NF-kappaB nuclear translocation.	Reactive Oxygen Species	83-86	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	64-68
18034828-11	2008	C-PC inhibited the 2-AAF induced expression of MDR1 by interfering at the level of ROS generation, Akt phosphorylation and NF-kappaB translocation.	Reactive Oxygen Species	83-86	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	47-51
17932689-0	2008	Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice.	Paclitaxel	79-89	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	14-19
17635801-2	2007	In this study, the activities of two members of the superfamily of ATP-binding cassette (ABC) transport proteins, ABCB1 and ABCC (measured by rhodamine 123 efflux and Fluo-3 efflux respectively), were compared in murine bone marrow cells and thymocytes of young (3-4 weeks old), adult (2-3 months old) and old (18 months old) mice.	Rhodamines	142-151	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	114-119
18006147-0	2008	Curcumin down-regulates the multidrug-resistance mdr1b gene by inhibiting the PI3K/Akt/NF kappa B pathway.	Curcumin	0-8	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	49-54
18006147-4	2008	Transfection with a series of 5"-deleted constructs of the mdr1b gene promoter indicated that a proximal region between -205 and +42 of the sequence was responsible for the suppression of promoter activity by curcumin.	Curcumin	209-217	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	59-64
17356567-6	2007	In FVB/N controls, desipramine induced a significant upregulation of GR mRNA in the CA1 region (+31%; p=0.045); in contrast, in abcb1ab (-/-) mice, desipramine induced a significant downregulation of GR mRNA in the CA1 region (-45%; p=0.004).	Desipramine	19-30	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	128-133
17356567-8	2007	Desipramine decreased corticosterone levels in both FVB/N controls and in abcb1ab (-/-) mice, but in abcb1ab (-/-) mice the effects were smaller.	Desipramine	0-11	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	74-79
17356567-8	2007	Desipramine decreased corticosterone levels in both FVB/N controls and in abcb1ab (-/-) mice, but in abcb1ab (-/-) mice the effects were smaller.	Corticosterone	22-36	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	74-79
17541583-1	2007	PURPOSE: The purpose of this work was the development of an orthotopic model of osteosarcoma based on luciferase-expressing tumour cells for the in vivo imaging of multidrug resistance (MDR) with (99m)Tc-sestamibi.	Technetium Tc 99m Sestamibi	201-213	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	186-189
17541583-14	2007	The kinetic analysis of (99m)Tc-sestamibi washout provides information on the functional activity of MDR related to P-glycoprotein expression and its pharmacological inhibition in osteosarcoma.	Technetium Tc 99m Sestamibi	29-41	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	101-104
18094612-1	2008	PURPOSE: Chronic imatinib exposure has been shown to result in upregulation of the ABCB1 (P-glycoprotein) and ABCG2 (BCRP) transporters in vitro, for which imatinib is a substrate.	Imatinib Mesylate	17-25	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	83-88
18094612-1	2008	PURPOSE: Chronic imatinib exposure has been shown to result in upregulation of the ABCB1 (P-glycoprotein) and ABCG2 (BCRP) transporters in vitro, for which imatinib is a substrate.	Imatinib Mesylate	156-164	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	83-88
18282104-7	2008	Injection of MDR strains directly into the intestinal tract of surgically injured mice, a known model of phosphate limitation, caused high mortality rates (60%-100%).	Phosphates	105-114	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	13-16
17962372-4	2008	One drug and its metabolite, risperidone and 9-hydroxyrisperidone, of the 32 CNS compounds, and 6 of the 7 non-CNS drugs were determined to have positive efflux using ratio of ratios in MDR1-MDCK versus MDCK transwell assays.	Risperidone	29-40	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	186-190
17962372-4	2008	One drug and its metabolite, risperidone and 9-hydroxyrisperidone, of the 32 CNS compounds, and 6 of the 7 non-CNS drugs were determined to have positive efflux using ratio of ratios in MDR1-MDCK versus MDCK transwell assays.	Paliperidone Palmitate	45-65	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	186-190
17356567-0	2007	The antidepressant desipramine requires the ABCB1 (Mdr1)-type p-glycoprotein to upregulate the glucocorticoid receptor in mice.	Desipramine	19-30	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	44-49
17356567-0	2007	The antidepressant desipramine requires the ABCB1 (Mdr1)-type p-glycoprotein to upregulate the glucocorticoid receptor in mice.	Desipramine	19-30	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	51-55
17356567-4	2007	Here, the tricyclic antidepressant, desipramine (20 mg/kg/day, i.p., for seven days), was administered to abcb1ab MDR PGP knockout mice (congenic on the FVB/N background strain) and to FVB/N controls.	Desipramine	36-47	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	106-111
17356567-4	2007	Here, the tricyclic antidepressant, desipramine (20 mg/kg/day, i.p., for seven days), was administered to abcb1ab MDR PGP knockout mice (congenic on the FVB/N background strain) and to FVB/N controls.	Desipramine	36-47	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	114-117
17959987-2	2007	Systemically administered cyclosporine is prevented from entering into the brain by the action of P-glycoprotein, encoded by the multidrug resistant 1 (mdr1) gene.	Cyclosporine	26-38	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	152-156
17709369-6	2007	Directional flux experiments indicated that abacavir had greater permeability in the basolateral-to-apical direction (1.58E-05 cm/s) than in the apical-to-basolateral direction (3.44E-06 cm/s) in MDR1-transfected monolayers.	abacavir	44-52	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	196-200
17273824-0	2007	Tetrandrine achieved plasma concentrations capable of reversing MDR in vitro and had no apparent effect on doxorubicin pharmacokinetics in mice.	tetrandrine	0-11	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	64-67
17273824-1	2007	PURPOSE: Tetrandrine (Tet), a multidrug resistant (MDR) modulator, was a potential candidate for use in cancer therapy and exhibited potent biological activity in vitro and in vivo when combined with anticancer agents such as doxorubicin, paclitaxel.	tetrandrine	9-20	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	51-54
17273824-1	2007	PURPOSE: Tetrandrine (Tet), a multidrug resistant (MDR) modulator, was a potential candidate for use in cancer therapy and exhibited potent biological activity in vitro and in vivo when combined with anticancer agents such as doxorubicin, paclitaxel.	tetrandrine	9-12	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	51-54
17273824-3	2007	METHODS: Tet of 30 mg/kg dose used to reverse MDR was administrated intraperitoneally in mice.	tetrandrine	9-12	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	46-49
17273824-6	2007	RESULTS: More than 1 micromol/L of Tet could at least tenfold reverse MDR in vitro.	tetrandrine	35-38	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	70-73
17273824-13	2007	CONCLUSIONS: Tet at the tested dose of combination treatment could achieve plasma concentrations that reversed MDR in experimental models and it had no apparent effect on doxorubicin pharmacokinetics in mice and CYP 3A4 activity in human liver microsomes.	tetrandrine	13-16	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	111-114
17881135-7	2007	Investigating the impact of acute MDR1 p-gp inhibition on the glucocorticoid system, we observed a significant attenuation of the mild stress-induced increase of plasma corticosterone after tariquidar administration.	Corticosterone	169-183	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	34-38
17881135-7	2007	Investigating the impact of acute MDR1 p-gp inhibition on the glucocorticoid system, we observed a significant attenuation of the mild stress-induced increase of plasma corticosterone after tariquidar administration.	tariquidar	190-200	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	34-38
17635801-2	2007	In this study, the activities of two members of the superfamily of ATP-binding cassette (ABC) transport proteins, ABCB1 and ABCC (measured by rhodamine 123 efflux and Fluo-3 efflux respectively), were compared in murine bone marrow cells and thymocytes of young (3-4 weeks old), adult (2-3 months old) and old (18 months old) mice.	Fluo-3	167-173	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	114-119
17302433-1	2007	P-glycoprotein (MDR1, ABCB1) is an ATP-dependent efflux transporter of a large variety of compounds.	Adenosine Triphosphate	35-38	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	16-20
17331135-5	2007	Mice transplanted with MDR1-transduced human hematopoietic cells were protected from paclitaxel chemotherapy with higher survival rate and higher level of WBC counts and RBC counts compared with mice transplanted with untransduced HSCs.	Paclitaxel	85-95	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	23-27
17644804-0	2007	Functional changes of mouse placental multidrug resistance phosphoglycoprotein (ABCB1) with advancing gestation and regulation by progesterone.	Progesterone	130-142	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	80-85
17644804-4	2007	The authors demonstrate a significant increase in transplacental transfer of [(3)H]digoxin (an ABCB1 substrate) in late gestation (E18.5; P < .001) when compared to earlier embryonic days.	[(3)h]digoxin	77-90	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	95-100
17302433-1	2007	P-glycoprotein (MDR1, ABCB1) is an ATP-dependent efflux transporter of a large variety of compounds.	Adenosine Triphosphate	35-38	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	22-27
17303067-0	2007	C-Phycocyanin inhibits 2-acetylaminofluorene-induced expression of MDR1 in mouse macrophage cells: ROS mediated pathway determined via combination of experimental and In silico analysis.	2-Acetylaminofluorene	23-44	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	67-71
17303067-0	2007	C-Phycocyanin inhibits 2-acetylaminofluorene-induced expression of MDR1 in mouse macrophage cells: ROS mediated pathway determined via combination of experimental and In silico analysis.	Reactive Oxygen Species	99-102	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	67-71
17303067-1	2007	We studied the effects of C-Phycocyanin (C-PC), a biliprotein from Spirulina platensis on the 2-acetylaminofluorene (2-AAF)-induced expression of MDR1, encoded by the multidrug resistance (MDR1) gene, in mouse macrophage cell line (RAW 264.7).	2-Acetylaminofluorene	94-115	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	146-150
17303067-1	2007	We studied the effects of C-Phycocyanin (C-PC), a biliprotein from Spirulina platensis on the 2-acetylaminofluorene (2-AAF)-induced expression of MDR1, encoded by the multidrug resistance (MDR1) gene, in mouse macrophage cell line (RAW 264.7).	2-Acetylaminofluorene	94-115	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	189-193
17303067-3	2007	MDR1 induction by 2-AAF was dependent on ROS (reactive oxygen species)-Akt (protein kinase B)-NF-kappaB (Nuclear factor kappa B) signaling pathway.	2-Acetylaminofluorene	18-23	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	0-4
17303067-3	2007	MDR1 induction by 2-AAF was dependent on ROS (reactive oxygen species)-Akt (protein kinase B)-NF-kappaB (Nuclear factor kappa B) signaling pathway.	Reactive Oxygen Species	41-44	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	0-4
17303067-3	2007	MDR1 induction by 2-AAF was dependent on ROS (reactive oxygen species)-Akt (protein kinase B)-NF-kappaB (Nuclear factor kappa B) signaling pathway.	Reactive Oxygen Species	46-69	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	0-4
17303067-5	2007	NADPH oxidase inhibitor, DPI (Diphenyl iodide), and pharmacological inhibitor of Akt, Akt inhibitor IV, also showed a reduction in MDR1 expression, although not to the same extent as C-PC mediated inhibition of MDR1 expression.	3-aminodiphenyleneiodium	25-28	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	131-135
17303067-5	2007	NADPH oxidase inhibitor, DPI (Diphenyl iodide), and pharmacological inhibitor of Akt, Akt inhibitor IV, also showed a reduction in MDR1 expression, although not to the same extent as C-PC mediated inhibition of MDR1 expression.	diphenyl iodide	30-45	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	131-135
17303067-8	2007	Also the ROS levels determined through In silico investigation showed that C-PC was more effective in reduction of MDR1 expression than inhibitors of NADPH oxidase and Akt.	Reactive Oxygen Species	9-12	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	115-119
17303067-9	2007	Our experimental and In silico studies collectively suggest that 2-AAF induces MDR1 by ROS dependent pathway and C-PC is a potential negative regulator of MDR1 expression.	Reactive Oxygen Species	87-90	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	79-83
16544145-8	2006	CONCLUSIONS: M4N and maltose-tri-O-methyl nordihydroguaiaretic acid (maltose-M3N), a water-soluble derivative of NDGA, were also able to reverse the MDR phenotype of the tumor cells in a xenograft model system and combination therapy with M4N or maltose-M3N and paclitaxel was effective at inhibiting growth of these tumors in nude mice.	terameprocol	13-16	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	149-152
17407711-0	2007	[Reversal of adriamycin resistance of hepatocellular carcinoma by targeting it with recombined adenovirus carrying antisense multidrug resistance gene 1 RNA].	Doxorubicin	13-23	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	125-152
16387324-1	2007	In earlier studies with P-gp (abcb1) knock-out mice, we showed that P-gp exports the antidepressants citalopram, paroxetine, venlafaxine and amitriptyline and its metabolites across the blood-brain barrier, thereby reducing cerebral bioavailability of some substances up to 9 times.	Citalopram	101-111	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	30-35
16387324-1	2007	In earlier studies with P-gp (abcb1) knock-out mice, we showed that P-gp exports the antidepressants citalopram, paroxetine, venlafaxine and amitriptyline and its metabolites across the blood-brain barrier, thereby reducing cerebral bioavailability of some substances up to 9 times.	Paroxetine	113-123	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	30-35
16387324-1	2007	In earlier studies with P-gp (abcb1) knock-out mice, we showed that P-gp exports the antidepressants citalopram, paroxetine, venlafaxine and amitriptyline and its metabolites across the blood-brain barrier, thereby reducing cerebral bioavailability of some substances up to 9 times.	Venlafaxine Hydrochloride	125-136	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	30-35
16387324-1	2007	In earlier studies with P-gp (abcb1) knock-out mice, we showed that P-gp exports the antidepressants citalopram, paroxetine, venlafaxine and amitriptyline and its metabolites across the blood-brain barrier, thereby reducing cerebral bioavailability of some substances up to 9 times.	Amitriptyline	141-154	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	30-35
16819505-7	2007	Ketoconazole treatment resulted in delayed metabolism of tribromoethanol anesthetic in mice, which was correlated to the inhibition of PXR activation and downmodulation of cyp3a11 and mdr-1 genes and proteins.	Ketoconazole	0-12	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	184-189
16819505-7	2007	Ketoconazole treatment resulted in delayed metabolism of tribromoethanol anesthetic in mice, which was correlated to the inhibition of PXR activation and downmodulation of cyp3a11 and mdr-1 genes and proteins.	tribromoethanol	57-72	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	184-189
16544145-8	2006	CONCLUSIONS: M4N and maltose-tri-O-methyl nordihydroguaiaretic acid (maltose-M3N), a water-soluble derivative of NDGA, were also able to reverse the MDR phenotype of the tumor cells in a xenograft model system and combination therapy with M4N or maltose-M3N and paclitaxel was effective at inhibiting growth of these tumors in nude mice.	maltose-tri-O-methyl nordihydroguaiaretic acid	21-67	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	149-152
16544145-8	2006	CONCLUSIONS: M4N and maltose-tri-O-methyl nordihydroguaiaretic acid (maltose-M3N), a water-soluble derivative of NDGA, were also able to reverse the MDR phenotype of the tumor cells in a xenograft model system and combination therapy with M4N or maltose-M3N and paclitaxel was effective at inhibiting growth of these tumors in nude mice.	maltose-tri-O-methyl nordihydroguaiaretic acid	69-80	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	149-152
16544145-8	2006	CONCLUSIONS: M4N and maltose-tri-O-methyl nordihydroguaiaretic acid (maltose-M3N), a water-soluble derivative of NDGA, were also able to reverse the MDR phenotype of the tumor cells in a xenograft model system and combination therapy with M4N or maltose-M3N and paclitaxel was effective at inhibiting growth of these tumors in nude mice.	Water	85-90	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	149-152
16544145-8	2006	CONCLUSIONS: M4N and maltose-tri-O-methyl nordihydroguaiaretic acid (maltose-M3N), a water-soluble derivative of NDGA, were also able to reverse the MDR phenotype of the tumor cells in a xenograft model system and combination therapy with M4N or maltose-M3N and paclitaxel was effective at inhibiting growth of these tumors in nude mice.	terameprocol	239-242	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	149-152
16544145-8	2006	CONCLUSIONS: M4N and maltose-tri-O-methyl nordihydroguaiaretic acid (maltose-M3N), a water-soluble derivative of NDGA, were also able to reverse the MDR phenotype of the tumor cells in a xenograft model system and combination therapy with M4N or maltose-M3N and paclitaxel was effective at inhibiting growth of these tumors in nude mice.	maltose-tri-O-methyl nordihydroguaiaretic acid	246-257	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	149-152
16544145-8	2006	CONCLUSIONS: M4N and maltose-tri-O-methyl nordihydroguaiaretic acid (maltose-M3N), a water-soluble derivative of NDGA, were also able to reverse the MDR phenotype of the tumor cells in a xenograft model system and combination therapy with M4N or maltose-M3N and paclitaxel was effective at inhibiting growth of these tumors in nude mice.	Paclitaxel	262-272	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	149-152
16955376-0	2006	99mTc-Sestamibi, a sensitive probe for in vivo imaging of P-glycoprotein inhibition by modulators and mdr1 antisense oligodeoxynucleotides.	Technetium Tc 99m Sestamibi	0-15	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	102-106
16955376-0	2006	99mTc-Sestamibi, a sensitive probe for in vivo imaging of P-glycoprotein inhibition by modulators and mdr1 antisense oligodeoxynucleotides.	Oligodeoxyribonucleotides	117-138	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	102-106
16955376-3	2006	A2780/Adr xenograft mice were dosed with mdr1 antisense oligodeoxynucleotides intratumorally for three days; next, mice were treated with WK-X-34, followed by (99m)Tc-sestamibi injection.	Oligodeoxyribonucleotides	56-77	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	41-45
17062689-1	2006	PURPOSE: P-glycoprotein (P-gp; ABCB1) efficiently transports lipophilic amphipathic drugs, including the widely used anticancer drug paclitaxel (Taxol).	Paclitaxel	133-143	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	31-36
17062689-1	2006	PURPOSE: P-glycoprotein (P-gp; ABCB1) efficiently transports lipophilic amphipathic drugs, including the widely used anticancer drug paclitaxel (Taxol).	Paclitaxel	145-150	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	31-36
16651435-5	2006	In our studies, pretreatment of Abcg2(-/-) and Mdr1(a/b)(-/-) mice with gefitinib increased oral absorption and decreased systemic clearance of topotecan, a model substrate, indicating that additional transporters were inhibited.	Gefitinib	72-81	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	47-51
17035174-3	2006	In order to understand the relationship between the resistance to MTX and the transport protein superfamily of ATP-binding cassette, and to investigate the mechanism of resistance to MTX, the study detected the expressions of mdr1, mrp1, mrp2, mrp3, mrp5, mrp6 and abcg2 that encoded the transport proteins by SuperArray analysis and the expressions of MRP1and MRP5 proteins by Western blot analysis.	Adenosine Triphosphate	111-114	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	226-230
16542724-5	2006	Moreover, KT-5720 (at 5 mg/kg) sensitized the bone marrow of MDR1 transgenic mice model towards daunorubicin (at 8 mg/kg) without general toxic effects.	Daunorubicin	96-108	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	61-65
16717428-0	2006	Down-regulation of mdr1b mRNA expression in the kidneys of mice following maternal exposure to tributyltin chloride.	tributyltin	95-115	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	19-24
16717428-1	2006	We investigated the change in renal mdr1b mRNA expression in offspring exposed to tributyltin chloride (TBTC) via the placenta and lactation or via lactation, using the real-time reverse transcription-polymerase chain reaction.	tributyltin	82-102	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	36-41
16717428-1	2006	We investigated the change in renal mdr1b mRNA expression in offspring exposed to tributyltin chloride (TBTC) via the placenta and lactation or via lactation, using the real-time reverse transcription-polymerase chain reaction.	tributyltin	104-108	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	36-41
16651435-5	2006	In our studies, pretreatment of Abcg2(-/-) and Mdr1(a/b)(-/-) mice with gefitinib increased oral absorption and decreased systemic clearance of topotecan, a model substrate, indicating that additional transporters were inhibited.	Topotecan	144-153	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	47-51
16724420-2	2006	We have shown that the ABC transporter, multiple drug resistance protein 1 (MDR1, P-glycoprotein) translocates glucosyl ceramide from the cytosolic to the luminal Golgi surface for neutral, but not acidic, glycosphingolipid (GSL) synthesis.	Glucosylceramides	111-128	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	40-74
16724420-3	2006	Here we show that the MDR1 inhibitor, cyclosporin A (CsA) can deplete Gaucher lymphoid cell lines of accumulated glucosyl ceramide and Fabry cell lines of globotriaosyl ceramide (Gb3), by preventing de novo synthesis.	Glucosylceramides	113-130	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	22-26
16724420-3	2006	Here we show that the MDR1 inhibitor, cyclosporin A (CsA) can deplete Gaucher lymphoid cell lines of accumulated glucosyl ceramide and Fabry cell lines of globotriaosyl ceramide (Gb3), by preventing de novo synthesis.	Ceramides	122-130	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	22-26
16621983-7	2006	We identified the endogenous CD1 ligands sulfatide and monosialoganglioside GM1 as MRP1 substrates, but exogenous addition of these substrates could not restore the defects caused by blocking MRP1 activity during DC differentiation.	Sulfoglycosphingolipids	41-50	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	83-87
16539673-0	2006	The multidrug resistance protein 1 (Mrp1), but not Mrp5, mediates export of glutathione and glutathione disulfide from brain astrocytes.	Glutathione	76-87	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	4-34
16539673-0	2006	The multidrug resistance protein 1 (Mrp1), but not Mrp5, mediates export of glutathione and glutathione disulfide from brain astrocytes.	Glutathione	76-87	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	36-40
16539673-0	2006	The multidrug resistance protein 1 (Mrp1), but not Mrp5, mediates export of glutathione and glutathione disulfide from brain astrocytes.	Glutathione Disulfide	92-113	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	4-34
16539673-0	2006	The multidrug resistance protein 1 (Mrp1), but not Mrp5, mediates export of glutathione and glutathione disulfide from brain astrocytes.	Glutathione Disulfide	92-113	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	36-40
16539673-3	2006	During incubation of wild-type or Mrp5(-/-) astrocytes, GSH accumulated in the medium at a rate of about 3 nmol/(h.mg), whereas the export of GSH from Mrp1(-/-) astrocytes was only one-third of that.	Glutathione	142-145	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	151-155
16539673-4	2006	In addition, Mrp1(-/-) astrocytes had a 50% higher specific GSH content than wild-type or Mrp5(-/-) cells.	Glutathione	60-63	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	13-17
16539673-8	2006	These data demonstrate that in astrocytes Mrp1 mediates 60% of the GSH export, that Mrp1 is exclusively responsible for GSSG export and that Mrp5 does not contribute to these transport processes.	Glutathione	67-70	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	42-46
16539673-8	2006	These data demonstrate that in astrocytes Mrp1 mediates 60% of the GSH export, that Mrp1 is exclusively responsible for GSSG export and that Mrp5 does not contribute to these transport processes.	Glutathione Disulfide	120-124	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	84-88
16724420-2	2006	We have shown that the ABC transporter, multiple drug resistance protein 1 (MDR1, P-glycoprotein) translocates glucosyl ceramide from the cytosolic to the luminal Golgi surface for neutral, but not acidic, glycosphingolipid (GSL) synthesis.	Glucosylceramides	111-128	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	76-80
16724420-2	2006	We have shown that the ABC transporter, multiple drug resistance protein 1 (MDR1, P-glycoprotein) translocates glucosyl ceramide from the cytosolic to the luminal Golgi surface for neutral, but not acidic, glycosphingolipid (GSL) synthesis.	Glycosphingolipids	206-223	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	40-74
16724420-2	2006	We have shown that the ABC transporter, multiple drug resistance protein 1 (MDR1, P-glycoprotein) translocates glucosyl ceramide from the cytosolic to the luminal Golgi surface for neutral, but not acidic, glycosphingolipid (GSL) synthesis.	Glycosphingolipids	206-223	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	76-80
16724420-3	2006	Here we show that the MDR1 inhibitor, cyclosporin A (CsA) can deplete Gaucher lymphoid cell lines of accumulated glucosyl ceramide and Fabry cell lines of globotriaosyl ceramide (Gb3), by preventing de novo synthesis.	Cyclosporine	38-51	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	22-26
16724420-3	2006	Here we show that the MDR1 inhibitor, cyclosporin A (CsA) can deplete Gaucher lymphoid cell lines of accumulated glucosyl ceramide and Fabry cell lines of globotriaosyl ceramide (Gb3), by preventing de novo synthesis.	Cyclosporine	53-56	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	22-26
16568009-5	2006	Previous immunizations of mice using liposomes with mdr1 peptides efficiently improve chemotherapy with doxorubicin and vinblastine against P388 R cells with a 77% increase of survival half time in the immunized group.	Doxorubicin	104-115	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	52-56
16568009-5	2006	Previous immunizations of mice using liposomes with mdr1 peptides efficiently improve chemotherapy with doxorubicin and vinblastine against P388 R cells with a 77% increase of survival half time in the immunized group.	Vinblastine	120-131	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	52-56
16123331-7	2005	Oscillatory shear also caused a robust export of GSSG that was prevented by the MRP1 inhibitor MK571 and by MRP1 small interfering RNA.	Glutathione Disulfide	49-53	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	80-84
16319528-7	2006	In the nude mice xenografts, vincristine (0.2 mg/kg of body weight) inhibited the growth of KBv200/MDR1sh solid tumors by 42.0%, but the same dose of vincristine didn"t inhibit the growth of KBv200 solid tumors significantly.	Vincristine	29-40	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	99-103
16454745-6	2006	Thus we determined the effect of structurally unrelated diterpenes, triterpenes and carotenoids on reversal of multidrug resistance in MDR-1 gene-transfected L1210 mouse lymphoma cells and MDR mediated multidrug resistance of human breast cancer cells MDA-MB-231 (HTB-26) and MCF-7.	Diterpenes	56-66	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	135-140
16454745-6	2006	Thus we determined the effect of structurally unrelated diterpenes, triterpenes and carotenoids on reversal of multidrug resistance in MDR-1 gene-transfected L1210 mouse lymphoma cells and MDR mediated multidrug resistance of human breast cancer cells MDA-MB-231 (HTB-26) and MCF-7.	Triterpenes	68-79	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	135-140
16454745-6	2006	Thus we determined the effect of structurally unrelated diterpenes, triterpenes and carotenoids on reversal of multidrug resistance in MDR-1 gene-transfected L1210 mouse lymphoma cells and MDR mediated multidrug resistance of human breast cancer cells MDA-MB-231 (HTB-26) and MCF-7.	Carotenoids	84-95	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	135-140
16399625-7	2006	Cyclosporine A, verapamil and trifluoperazine inhibited the activity of thymic ABCB1.	Cyclosporine	0-14	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	79-84
16399625-7	2006	Cyclosporine A, verapamil and trifluoperazine inhibited the activity of thymic ABCB1.	Verapamil	16-25	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	79-84
16399625-7	2006	Cyclosporine A, verapamil and trifluoperazine inhibited the activity of thymic ABCB1.	Trifluoperazine	30-45	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	79-84
16433037-1	2006	The ability of fifteen novel phenoxazine derivatives (four phenoxazines and eleven benzo[a]phenoxazines) to modulate multidrug resistance (MDR) in a P-gp-overexpressing mouse T lymphoma cell line (L5178 MDR) was studied.	phenoxazine	29-40	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	139-142
16433037-1	2006	The ability of fifteen novel phenoxazine derivatives (four phenoxazines and eleven benzo[a]phenoxazines) to modulate multidrug resistance (MDR) in a P-gp-overexpressing mouse T lymphoma cell line (L5178 MDR) was studied.	phenoxazine	29-40	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	203-206
16433037-1	2006	The ability of fifteen novel phenoxazine derivatives (four phenoxazines and eleven benzo[a]phenoxazines) to modulate multidrug resistance (MDR) in a P-gp-overexpressing mouse T lymphoma cell line (L5178 MDR) was studied.	phenoxazine	59-71	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	139-142
16433037-1	2006	The ability of fifteen novel phenoxazine derivatives (four phenoxazines and eleven benzo[a]phenoxazines) to modulate multidrug resistance (MDR) in a P-gp-overexpressing mouse T lymphoma cell line (L5178 MDR) was studied.	phenoxazine	91-103	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	139-142
16433037-3	2006	Seven benzo[a]phenoxazines were observed to increase the amount of rhodamine 123 accumulated by resistant cells, i.e. to be new effective MDR modulators.	benzo[a]phenoxazines	6-26	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	138-141
16433037-3	2006	Seven benzo[a]phenoxazines were observed to increase the amount of rhodamine 123 accumulated by resistant cells, i.e. to be new effective MDR modulators.	Rhodamines	67-76	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	138-141
16433037-4	2006	The results allowed us to draw preliminary conclusions about the structural features of benzo[a]phenoxazines which are important for MDR modulation.	benzo[a]	88-96	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	133-136
16433037-4	2006	The results allowed us to draw preliminary conclusions about the structural features of benzo[a]phenoxazines which are important for MDR modulation.	phenoxazine	96-108	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	133-136
16288028-5	2005	The paclitaxel-resistant human (CaOV3TaxR) and mouse (ID8TaxR) ovarian cancer cell lines express large amounts of the multidrug resistance-1 (MDR-1) protein compared with the paclitaxel-sensitive parent cell lines.	Paclitaxel	4-14	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	118-140
16288028-5	2005	The paclitaxel-resistant human (CaOV3TaxR) and mouse (ID8TaxR) ovarian cancer cell lines express large amounts of the multidrug resistance-1 (MDR-1) protein compared with the paclitaxel-sensitive parent cell lines.	Paclitaxel	4-14	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	142-147
16277030-1	2005	The ability of phenothiazine derivatives to inhibit the transport activity of P-glycoprotein in resistant mouse lymphoma and MDR/COLO 320 cells was studied.	phenothiazine	15-28	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	125-128
16787340-2	2005	Studies on the molecular basis of MDR have revealed that a number of proteins over express in multidrug resistant cells viz., multidrug resistant MDR1 gene product P-glycoprotein, the multidrug resistance-associated protein (MRP) and enzymes associated with the glutathione (GSH) metabolism.	Glutathione	262-273	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	34-37
16787340-2	2005	Studies on the molecular basis of MDR have revealed that a number of proteins over express in multidrug resistant cells viz., multidrug resistant MDR1 gene product P-glycoprotein, the multidrug resistance-associated protein (MRP) and enzymes associated with the glutathione (GSH) metabolism.	Glutathione	262-273	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	146-150
16787340-2	2005	Studies on the molecular basis of MDR have revealed that a number of proteins over express in multidrug resistant cells viz., multidrug resistant MDR1 gene product P-glycoprotein, the multidrug resistance-associated protein (MRP) and enzymes associated with the glutathione (GSH) metabolism.	Glutathione	275-278	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	34-37
16787340-2	2005	Studies on the molecular basis of MDR have revealed that a number of proteins over express in multidrug resistant cells viz., multidrug resistant MDR1 gene product P-glycoprotein, the multidrug resistance-associated protein (MRP) and enzymes associated with the glutathione (GSH) metabolism.	Glutathione	275-278	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	146-150
16123331-7	2005	Oscillatory shear also caused a robust export of GSSG that was prevented by the MRP1 inhibitor MK571 and by MRP1 small interfering RNA.	Glutathione Disulfide	49-53	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	108-112
16123331-7	2005	Oscillatory shear also caused a robust export of GSSG that was prevented by the MRP1 inhibitor MK571 and by MRP1 small interfering RNA.	verlukast	95-100	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	80-84
16123331-8	2005	MRP1 inhibition prevented the decline in intracellular GSH, preserved the intracellular GSH Nernst potential, and reduced apoptosis caused by oscillatory shear.	Glutathione	55-58	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	0-4
16123331-8	2005	MRP1 inhibition prevented the decline in intracellular GSH, preserved the intracellular GSH Nernst potential, and reduced apoptosis caused by oscillatory shear.	Glutathione	88-91	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	0-4
16123331-11	2005	GSSG export by MRP1 leads to a perturbation of endothelial redox state and ultimately endothelial cell apoptosis.	Glutathione Disulfide	0-4	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	15-19
16156672-6	2005	We hypothesize that an elevated level of Mdr1 in the spgp(-)(/)(-) knockout mice functions as an alternative pathway to transport bile acids and protects hepatocytes from bile acid-induced cholestasis.	Bile Acids and Salts	130-140	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	41-45
16156672-8	2005	This finding is the first direct evidence that P-glycoprotein (Mdr1) is capable of transporting bile acids.	Bile Acids and Salts	96-106	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	63-67
16101136-5	2005	The reversion of MDR was investigated by using a standard functional assay with rhodamine 123 as a fluorescent substrate analogue of doxorubicin.	Rhodamine 123	80-93	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	17-20
15917342-11	2005	A strong correlation existed between placental Abcb1b mRNA and maternal progesterone concentrations, indicating a potential role of progesterone in regulation of placental Abcb1b mRNA.	Progesterone	72-84	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	47-53
15917342-11	2005	A strong correlation existed between placental Abcb1b mRNA and maternal progesterone concentrations, indicating a potential role of progesterone in regulation of placental Abcb1b mRNA.	Progesterone	132-144	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	47-53
15917342-11	2005	A strong correlation existed between placental Abcb1b mRNA and maternal progesterone concentrations, indicating a potential role of progesterone in regulation of placental Abcb1b mRNA.	Progesterone	132-144	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	172-178
16101136-5	2005	The reversion of MDR was investigated by using a standard functional assay with rhodamine 123 as a fluorescent substrate analogue of doxorubicin.	Doxorubicin	133-144	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	17-20
16026704-1	2005	BACKGROUND: (99m)Tc-sestamibi (MIBI) and (99m)Tc-tetrofosmin (TF) are avid transport substrates recognized by the multidrug resistance (MDR) P-glycoprotein (Pgp).	Technetium Tc 99m Sestamibi	17-29	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	136-139
16046116-7	2005	Isogenic 3T3 cells expressing mdr-1 cDNA (3T3 pHamdr-1) were less sensitive to SJG-136 than the parental 3T3 cells (IC50 208 and 6.3 nM, respectively).	ethyl ~{N}-[6-methyl-5-[3-[2-[[(3~{S})-piperidin-3-yl]amino]pyrimidin-4-yl]pyridin-2-yl]oxy-naphthalen-1-yl]carbamate	79-82	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	30-35
16026704-1	2005	BACKGROUND: (99m)Tc-sestamibi (MIBI) and (99m)Tc-tetrofosmin (TF) are avid transport substrates recognized by the multidrug resistance (MDR) P-glycoprotein (Pgp).	2-methoxyisobutylisonitrile	31-35	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	136-139
16026704-1	2005	BACKGROUND: (99m)Tc-sestamibi (MIBI) and (99m)Tc-tetrofosmin (TF) are avid transport substrates recognized by the multidrug resistance (MDR) P-glycoprotein (Pgp).	tc-tetrofosmin	46-60	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	136-139
16026704-1	2005	BACKGROUND: (99m)Tc-sestamibi (MIBI) and (99m)Tc-tetrofosmin (TF) are avid transport substrates recognized by the multidrug resistance (MDR) P-glycoprotein (Pgp).	technetium tc-99m tetrofosmin	62-64	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	136-139
15936515-5	2005	Budipine concentrations in the abcb1ab knock-out animals were 3.1 times higher than in control mice.	budipine	0-8	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	31-36
15761118-6	2005	By combining in vitro transfection methods and quantitative analyses of gene expression in cell lines and primary human hepatocytes, we here show that artemisinin drugs activate human PXR as well as human and mouse CAR and induce the expression of CYP2B6, CYP3A4, and MDR1 in primary human hepatocytes and in the human intestinal cell line LS174T.	artemisinin	151-162	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	268-272
15858856-2	2005	The efflux transporter mdr1 product P-glycoprotein (P-gp) has been demonstrated to play a role in limiting nelfinavir brain levels.	Nelfinavir	107-117	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	23-27
15826724-8	2005	In vivo, HCC in transgenic mice overexpressed the mdr1 and mdr3 genes and the antitumor drugs efficacy was greatly enhanced after injection of PIHCA-Dox (9.0+/-5.0%; n=15) versus Dox (4.6+/-3.3%; n=13; P=0.01) for apoptotic bodies count.	pihca-dox	143-152	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	50-54
15826724-8	2005	In vivo, HCC in transgenic mice overexpressed the mdr1 and mdr3 genes and the antitumor drugs efficacy was greatly enhanced after injection of PIHCA-Dox (9.0+/-5.0%; n=15) versus Dox (4.6+/-3.3%; n=13; P=0.01) for apoptotic bodies count.	Doxorubicin	149-152	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	50-54
15863366-9	2005	Finally, there was a concomitant decrease in the expression of the hepatic mdr1b gene that correlated with the decrease in plasma cholesterol concentration.	Cholesterol	130-141	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	75-80
15863366-10	2005	Therefore, we conclude that mdr1 is an additional factor to consider in the complexity of alterations in cholesterol metabolism that occur in this model.	Cholesterol	105-116	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	28-32
15805252-3	2005	Imatinib is transported in vitro and in vivo by P-glycoprotein (P-gp; ABCB1), which thereby limits its distribution into the brain in mice.	Imatinib Mesylate	0-8	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	70-75
16257832-2	2005	MDR1 is composed of two repeated fragments, and there are six transmembrane domains (TMD) on the N-terminal of each repeat and a nucleotide (ATP) binding domain (NBD) on the C-terminal.	Adenosine Triphosphate	141-144	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	0-4
15725475-5	2005	The LM1/MDR cell variant is cross-resistant to DOX, COL, ACT D and VBL.	Doxorubicin	47-50	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	8-11
16147897-7	2005	Consistent with the day-night change of P-glycoprotein level, the ex vivo accumulation of digoxin, an Abcb1a P-glycoprotein substrate, into the intestinal segments at the onset of dark phase was significantly lower than it was at the onset of the light phase.	Digoxin	90-97	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	102-107
15449049-0	2004	In vitro detection of mdr1 mRNA in murine leukemia cells with 111In-labeled oligonucleotide.	Oligonucleotides	76-91	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	22-26
15967124-2	2005	The positron-emitting radiotracer hexakis(2-methoxyisobutylisonitrile)-(94m)Tc ((94m)Tc-MIBI) was synthesized and validated in cell transport studies as a substrate for MDR1 Pgp.	hexakis(2-methoxyisobutylisonitrile)-(	34-72	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	169-173
15967124-2	2005	The positron-emitting radiotracer hexakis(2-methoxyisobutylisonitrile)-(94m)Tc ((94m)Tc-MIBI) was synthesized and validated in cell transport studies as a substrate for MDR1 Pgp.	Technetium	76-78	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	169-173
15967124-2	2005	The positron-emitting radiotracer hexakis(2-methoxyisobutylisonitrile)-(94m)Tc ((94m)Tc-MIBI) was synthesized and validated in cell transport studies as a substrate for MDR1 Pgp.	Technetium Tc 99m Sestamibi	85-92	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	169-173
15389547-7	2004	We also report that in the presence of FGF6, the minor (0.5-2%) subpopulation of cells actively excluding Hoechst 33342 in a verapamil-dependent manner (SP phenotype) was increased to 15-20% and the expression of the mdr1a gene (but not mdr1b) was upregulated by 400-fold.	TFF2 protein, human	153-155	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	237-242
15582917-5	2004	The concentration of dextromethorphan in the brain was more than twice as high in abcb1ab (-/-) mice compared to wild-type mice.	Dextromethorphan	21-37	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	82-87
15449049-1	2004	PURPOSE: The feasibility of intracellular mdr1 mRNA expression detection with radiolabeled antisense oligonucleotide (ODN) was investigated in the murine leukemia cell line, P388/S, and its subclonal, adriamycin-resistant cell line, P388/R.	Oligonucleotides	101-116	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	42-46
15449049-1	2004	PURPOSE: The feasibility of intracellular mdr1 mRNA expression detection with radiolabeled antisense oligonucleotide (ODN) was investigated in the murine leukemia cell line, P388/S, and its subclonal, adriamycin-resistant cell line, P388/R.	odn	118-121	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	42-46
15449049-1	2004	PURPOSE: The feasibility of intracellular mdr1 mRNA expression detection with radiolabeled antisense oligonucleotide (ODN) was investigated in the murine leukemia cell line, P388/S, and its subclonal, adriamycin-resistant cell line, P388/R.	Doxorubicin	201-211	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	42-46
15449049-4	2004	A 15-mer phosphorothioate antisense ODN complementary to the sequences located at -1 to 14 of mdr1 mRNA and its corresponding sense ODN were conjugated with the cyclic anhydride of diethylene triamine penta-acetic acid (cDTPA) via an amino group linked to the terminal phosphate at the 5" end at pH 8-9.	Parathion	9-25	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	94-98
15449049-4	2004	A 15-mer phosphorothioate antisense ODN complementary to the sequences located at -1 to 14 of mdr1 mRNA and its corresponding sense ODN were conjugated with the cyclic anhydride of diethylene triamine penta-acetic acid (cDTPA) via an amino group linked to the terminal phosphate at the 5" end at pH 8-9.	cyclic anhydride	161-177	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	94-98
15449049-4	2004	A 15-mer phosphorothioate antisense ODN complementary to the sequences located at -1 to 14 of mdr1 mRNA and its corresponding sense ODN were conjugated with the cyclic anhydride of diethylene triamine penta-acetic acid (cDTPA) via an amino group linked to the terminal phosphate at the 5" end at pH 8-9.	Pentetic Acid	181-218	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	94-98
15449049-4	2004	A 15-mer phosphorothioate antisense ODN complementary to the sequences located at -1 to 14 of mdr1 mRNA and its corresponding sense ODN were conjugated with the cyclic anhydride of diethylene triamine penta-acetic acid (cDTPA) via an amino group linked to the terminal phosphate at the 5" end at pH 8-9.	cdtpa	220-225	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	94-98
15449049-4	2004	A 15-mer phosphorothioate antisense ODN complementary to the sequences located at -1 to 14 of mdr1 mRNA and its corresponding sense ODN were conjugated with the cyclic anhydride of diethylene triamine penta-acetic acid (cDTPA) via an amino group linked to the terminal phosphate at the 5" end at pH 8-9.	Phosphates	269-278	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	94-98
15161038-2	2004	Reversion of MDR was investigated using a standard functional assay with rhodamine 123 as a fluorescent substrate analogue.	Rhodamine 123	73-86	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	13-16
15131241-1	2004	The involvement of multidrug resistance-associated protein 1 (Mrp1) and P-glycoprotein (mdr1) in the tissue distribution and excretion of grepafloxacin (GPFX), a fluoroquinolone antibiotic, was investigated using gene-deficient mice [mdr1a(-/-), mdr1a/1b(-/-), and mrp1(-/-)].	grepafloxacin	138-151	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	88-92
15131241-3	2004	The urinary clearance of GPFX in mdr1a/1b(-/-) was lower than that in mdr1a/1b(+/+), suggesting that the urinary excretion of GPFX is at least partially mediated by mdr1.	grepafloxacin	25-29	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	33-37
15294454-1	2004	Overexpression of human MDR1 P-glycoprotein [Pgp] is associated with cellular resistance to bulky amphipathic drugs, such as taxol, anthracyclines, vinca alkaloids, and epipodophyllotoxins by actively effluxing drugs from cells.	Paclitaxel	125-130	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	24-28
15294454-1	2004	Overexpression of human MDR1 P-glycoprotein [Pgp] is associated with cellular resistance to bulky amphipathic drugs, such as taxol, anthracyclines, vinca alkaloids, and epipodophyllotoxins by actively effluxing drugs from cells.	Anthracyclines	132-146	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	24-28
15294454-1	2004	Overexpression of human MDR1 P-glycoprotein [Pgp] is associated with cellular resistance to bulky amphipathic drugs, such as taxol, anthracyclines, vinca alkaloids, and epipodophyllotoxins by actively effluxing drugs from cells.	Vinca Alkaloids	148-163	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	24-28
15294454-1	2004	Overexpression of human MDR1 P-glycoprotein [Pgp] is associated with cellular resistance to bulky amphipathic drugs, such as taxol, anthracyclines, vinca alkaloids, and epipodophyllotoxins by actively effluxing drugs from cells.	Podophyllotoxin	169-188	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	24-28
14962730-5	2004	Previous immunisations of mice using liposomes with MDR1 peptides increases the efficacy of chemotherapy treatments with doxorubicin and vinblastine against P388 R cells with increase of 77% in the survival half time in the immunised group.	Vinblastine	137-148	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	52-56
14962730-5	2004	Previous immunisations of mice using liposomes with MDR1 peptides increases the efficacy of chemotherapy treatments with doxorubicin and vinblastine against P388 R cells with increase of 77% in the survival half time in the immunised group.	Doxorubicin	121-132	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	52-56
14636953-1	2003	Multidrug resistance of murine leukaemic cell line L1210/VCR (obtained by adaptation of parental drug-sensitive L1210 cells to vincristine) is associated with overexpression of mdr1 gene product P-glycoprotein (Pgp)-the ATP-dependent drug efflux pump.	Vincristine	127-138	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	177-181
14662772-9	2004	Metabolic labeling in wild type and knock-out (MDR1a, 1b, MRP1) mouse fibroblasts showed the same loss of neutral glycosphingolipid (glucosyl ceramide, lactosyl ceramide) but not ganglioside (GM3) synthesis, confirming the proposed role for MDR1 translocase activity.	Glucosylceramides	133-150	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	47-51
14662772-9	2004	Metabolic labeling in wild type and knock-out (MDR1a, 1b, MRP1) mouse fibroblasts showed the same loss of neutral glycosphingolipid (glucosyl ceramide, lactosyl ceramide) but not ganglioside (GM3) synthesis, confirming the proposed role for MDR1 translocase activity.	CDw17 antigen	152-169	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	47-51
14662772-9	2004	Metabolic labeling in wild type and knock-out (MDR1a, 1b, MRP1) mouse fibroblasts showed the same loss of neutral glycosphingolipid (glucosyl ceramide, lactosyl ceramide) but not ganglioside (GM3) synthesis, confirming the proposed role for MDR1 translocase activity.	Gangliosides	179-190	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	47-51
14662772-9	2004	Metabolic labeling in wild type and knock-out (MDR1a, 1b, MRP1) mouse fibroblasts showed the same loss of neutral glycosphingolipid (glucosyl ceramide, lactosyl ceramide) but not ganglioside (GM3) synthesis, confirming the proposed role for MDR1 translocase activity.	gm3	192-195	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	47-51
14755051-0	2004	Imaging reversal of multidrug resistance in living mice with bioluminescence: MDR1 P-glycoprotein transports coelenterazine.	coelenterazine	109-123	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	78-82
14755051-3	2004	Interestingly, coelenterazine analogues share structural and physiochemical properties of compounds transported by the multidrug resistance MDR1 P-glycoprotein (Pgp).	coelenterazine	15-29	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	140-144
14755051-4	2004	Herein, we report that living cells stably transfected with a codon-humanized Rluc show coelenterazine-mediated bioluminescence in a highly MDR1 Pgp-modulated manner.	coelenterazine	88-102	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	140-144
14636953-1	2003	Multidrug resistance of murine leukaemic cell line L1210/VCR (obtained by adaptation of parental drug-sensitive L1210 cells to vincristine) is associated with overexpression of mdr1 gene product P-glycoprotein (Pgp)-the ATP-dependent drug efflux pump.	Adenosine Triphosphate	220-223	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	177-181
14583783-2	2003	By using an in vitro colony-forming assay, we found that bone marrow of Mdr1ab, Mrp1, Mdr1ab/Mrp1 knockout (KO) mice was two-, five- to 10- and 25-fold, respectively, more sensitive to vincristine than wild-type mice bone marrow.	Vincristine	185-196	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	72-76
14583783-7	2003	However, the tissue accumulation of vincristine in tissues of these Mdr1ab/Mrp1 KO mice was further increased.	Vincristine	36-47	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	68-72
12888779-6	2003	Abcb1ab (-/-) mice showed consistently lower plasma ACTH levels and lower evening plasma corticosterone levels.	Corticosterone	89-103	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	0-5
14550684-3	2003	RESULTS: The cerebrum concentrations of doxepin, venlafaxine, and paroxetine were higher in knockout mice, demonstrating that these substances are substrates of P-gp and that abcb1ab activity at the level of the blood-brain barrier reduces the penetration of these substances into the brain.	Doxepin	40-47	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	175-180
14502537-7	2003	Rhodamine 123 efflux was reduced by dexloxiglumide from 4.06 (+/-0.34) to 2.84 (+/-0.15) across Caco-2 monolayers, and from 17.3 (+/-0.9) to 8.26 (+/-1.38) across MDR1-MDCK monolayers, further indicating dexloxiglumide interaction with P-gp.	Rhodamines	0-9	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	163-167
14502537-7	2003	Rhodamine 123 efflux was reduced by dexloxiglumide from 4.06 (+/-0.34) to 2.84 (+/-0.15) across Caco-2 monolayers, and from 17.3 (+/-0.9) to 8.26 (+/-1.38) across MDR1-MDCK monolayers, further indicating dexloxiglumide interaction with P-gp.	dexloxiglumide	36-50	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	163-167
14502547-3	2003	In vitro MDR1-MDCKII monolayer efflux assays demonstrated that cetirizine was a Pgp substrate (B-->A/A-->B + GF120918 ratio = 5.47) with low/moderate passive permeability (PappB-->A = 56.5 nm/s).	Cetirizine	63-73	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	9-13
14680568-3	2003	An orthotopic mdr1 hepatoma was produced by implanting the tumor fragment subserosally to the mice liver, and intermittent chemotherapy with Pharmorubicin given to induce drug resistance.	Epirubicin	141-154	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	14-18
14680568-5	2003	RT-PCR and SP method by the monoclonal antibody JSB-1 were adoped to detect the expression of mdr1-mRNA and p-gp protein.	TFF2 protein, human	11-13	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	94-98
14550684-3	2003	RESULTS: The cerebrum concentrations of doxepin, venlafaxine, and paroxetine were higher in knockout mice, demonstrating that these substances are substrates of P-gp and that abcb1ab activity at the level of the blood-brain barrier reduces the penetration of these substances into the brain.	Venlafaxine Hydrochloride	49-60	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	175-180
14680568-8	2003	The expressions of mdr1-mRNA and p-gp in the Pharmorubicin group were 23 folds and 13 folds of the control group, respectively.	Epirubicin	45-58	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	19-23
14550684-3	2003	RESULTS: The cerebrum concentrations of doxepin, venlafaxine, and paroxetine were higher in knockout mice, demonstrating that these substances are substrates of P-gp and that abcb1ab activity at the level of the blood-brain barrier reduces the penetration of these substances into the brain.	Paroxetine	66-76	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	175-180
12381268-5	2003	Upon treatment of wild-type mice with ciprofibrate (0.05%, w/w, in diet for 2 weeks), the expression of Mdr2 (+3-fold), Mdr1a (+6-fold) and Mdr1b (+11-fold) mRNAs was clearly induced, while that of Oatp1 (-5-fold) was reduced.	ciprofibrate	38-50	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	140-145
12623853-0	2003	Hydrolytically activated etoposide prodrugs inhibit MDR-1 function and eradicate established MDR-1 multidrug-resistant T-cell leukemia.	Etoposide	25-34	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	52-57
12623853-0	2003	Hydrolytically activated etoposide prodrugs inhibit MDR-1 function and eradicate established MDR-1 multidrug-resistant T-cell leukemia.	Etoposide	25-34	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	93-98
12623853-8	2003	In summary, the hydrolytically activated etoposide prodrugs proved effective against multidrug-resistant T-cell leukemia in vitro and in vivo and provide proof of concept for a highly promising new strategy for the treatment of MDR-1 drug-resistant malignancies.	Etoposide	41-50	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	228-233
12536246-0	2003	Sestamibi is a substrate for MDR1 and MDR2 P-glycoprotein genes.	Technetium Tc 99m Sestamibi	0-9	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	29-33
12536246-6	2003	In double knockout mice lacking both mdr1a and mdr1b homologs of the human MDR1 ( ABCB1) gene, 88%+/-11% of maximal sestamibi activity was retained in the liver after 1 h ( P<0.001).	Technetium Tc 99m Sestamibi	116-125	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	47-52
12536246-10	2003	Sestamibi appears to be a substrate for both ABCB1 and ABCB4 genes, although the former utilizes it far more efficiently.	Technetium Tc 99m Sestamibi	0-9	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	45-50
12584158-6	2003	In addition, certirizine, desloratadine, diphenhydramine, and triprolidine (2 microM) were tested as substrates for MDR1 using MDR1-MDCK cells.	certirizine	13-24	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	116-120
12584158-6	2003	In addition, certirizine, desloratadine, diphenhydramine, and triprolidine (2 microM) were tested as substrates for MDR1 using MDR1-MDCK cells.	desloratadine	26-39	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	116-120
12584158-6	2003	In addition, certirizine, desloratadine, diphenhydramine, and triprolidine (2 microM) were tested as substrates for MDR1 using MDR1-MDCK cells.	Triprolidine	62-74	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	116-120
12584158-6	2003	In addition, certirizine, desloratadine, diphenhydramine, and triprolidine (2 microM) were tested as substrates for MDR1 using MDR1-MDCK cells.	Triprolidine	62-74	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	127-131
12584158-9	2003	Likewise, the efflux ratio between basolateral to apical and apical to basolateral was 4.6- and 6.6-fold higher in MDR1-MDCK than the parental MDCK for certirizine and desloratadine, respectively, whereas it was approximately 1 for diphenhydramine and triprolidine.	certirizine	152-163	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	115-119
12584158-9	2003	Likewise, the efflux ratio between basolateral to apical and apical to basolateral was 4.6- and 6.6-fold higher in MDR1-MDCK than the parental MDCK for certirizine and desloratadine, respectively, whereas it was approximately 1 for diphenhydramine and triprolidine.	desloratadine	168-181	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	115-119
12584158-9	2003	Likewise, the efflux ratio between basolateral to apical and apical to basolateral was 4.6- and 6.6-fold higher in MDR1-MDCK than the parental MDCK for certirizine and desloratadine, respectively, whereas it was approximately 1 for diphenhydramine and triprolidine.	Diphenhydramine	232-247	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	115-119
12584158-9	2003	Likewise, the efflux ratio between basolateral to apical and apical to basolateral was 4.6- and 6.6-fold higher in MDR1-MDCK than the parental MDCK for certirizine and desloratadine, respectively, whereas it was approximately 1 for diphenhydramine and triprolidine.	Triprolidine	252-264	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	115-119
12650738-0	2003	abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice.	Citalopram	52-62	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	0-5
12650738-0	2003	abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice.	Trimipramine	67-79	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	0-5
12650738-4	2003	In the present study, we have examined the uptake of the antidepressants citalopram and trimipramine into the brain of abcb1ab knockout mice compared with controls.	Citalopram	73-83	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	119-124
12650738-4	2003	In the present study, we have examined the uptake of the antidepressants citalopram and trimipramine into the brain of abcb1ab knockout mice compared with controls.	Trimipramine	88-100	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	119-124
12589934-12	2002	Thus, this paper provides insight into the mechanisms of glucocorticoid transport in cells and demonstrates a diversity of two independent mechanisms of transport of glucocorticoids by Abcb1a/Abcb1b and Abcc1a with individual patterns of steroid specificity.	Steroids	238-245	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	192-198
14552591-9	2003	Animals treated with a combination of a known MDR modulator, cyclosporin A, and a cytotoxic drug, doxorubicin, exhibited significantly reduced tumor growth compared with untreated controls or animals treated with either cyclosporin A or doxorubicin alone.	Cyclosporine	220-233	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	46-49
14552591-9	2003	Animals treated with a combination of a known MDR modulator, cyclosporin A, and a cytotoxic drug, doxorubicin, exhibited significantly reduced tumor growth compared with untreated controls or animals treated with either cyclosporin A or doxorubicin alone.	Doxorubicin	237-248	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	46-49
14552591-10	2003	Similarly, a novel P-gp-specific MDR modulator, PGP-4008, in combination with doxorubicin showed inhibition of tumor growth.	Doxorubicin	78-89	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	33-36
12195819-7	2002	These results indicate that the efflux of [14C]ramosetron is partly mediated by mdr1a P-glycoprotein, but not by mdr1b P-glycoprotein, and that there is a difference in substrate specificity between mdr1a P-glycoprotein and mdr1b P-glycoprotein.	Carbon-14	43-46	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	224-229
12589934-7	2002	Functional Abcb1a/Abcb1b was detected by inhibition of rhodamine efflux by these drugs and mRNA for Abcb1a and Abcb1b were detected in these cells.	Rhodamines	55-64	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	18-24
12391288-0	2002	Evidence for the locations of distinct steroid and Vinca alkaloid interaction domains within the murine mdr1b P-glycoprotein.	Steroids	39-46	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	104-109
12391288-0	2002	Evidence for the locations of distinct steroid and Vinca alkaloid interaction domains within the murine mdr1b P-glycoprotein.	Vinca Alkaloids	51-65	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	104-109
12138119-0	2002	Photolabeling of human and murine multidrug resistance protein 1 with the high affinity inhibitor [125I]LY475776 and azidophenacyl-[35S]glutathione.	LY 475776	104-112	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	34-64
12138119-0	2002	Photolabeling of human and murine multidrug resistance protein 1 with the high affinity inhibitor [125I]LY475776 and azidophenacyl-[35S]glutathione.	azidophenacyl-[35s]glutathione	117-147	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	34-64
12122045-4	2002	Mdr mRNA measured by RT-PCR increased by 85% on average in the mouse hippocampus 3-24 hr after kainic acid-induced limbic seizures, returning to control levels by 72 hr.	Kainic Acid	95-106	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	0-3
12213137-0	2002	Penetration of endogenous steroid hormones corticosterone, cortisol, aldosterone and progesterone into the brain is enhanced in mice deficient for both mdr1a and mdr1b P-glycoproteins.	Steroids	26-33	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	162-167
12213137-0	2002	Penetration of endogenous steroid hormones corticosterone, cortisol, aldosterone and progesterone into the brain is enhanced in mice deficient for both mdr1a and mdr1b P-glycoproteins.	Corticosterone	43-57	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	162-167
12213137-0	2002	Penetration of endogenous steroid hormones corticosterone, cortisol, aldosterone and progesterone into the brain is enhanced in mice deficient for both mdr1a and mdr1b P-glycoproteins.	Hydrocortisone	59-67	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	162-167
12213137-0	2002	Penetration of endogenous steroid hormones corticosterone, cortisol, aldosterone and progesterone into the brain is enhanced in mice deficient for both mdr1a and mdr1b P-glycoproteins.	Aldosterone	69-80	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	162-167
12213137-0	2002	Penetration of endogenous steroid hormones corticosterone, cortisol, aldosterone and progesterone into the brain is enhanced in mice deficient for both mdr1a and mdr1b P-glycoproteins.	Progesterone	85-97	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	162-167
11920652-6	2002	These results reveal that the lethal, dose-limiting hematotoxicity of an intensified post-transplantation chemotherapy with paclitaxel can be prevented by retroviral transfer of the MDR1 gene to a minor proportion of repopulating cells.	Paclitaxel	124-134	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	182-186
12107761-9	2002	Taurine uptake in MDR1 transfected NIH/3T3 mouse fibroblasts was in contrast to the findings in Ehrlich cells increased compared to the parental fibroblasts.	Taurine	0-7	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	18-22
11836025-1	2002	The multidrug resistance protein 1 (MRP1) protects cells from xenobiotics by extruding from the intracellular compartment glutathione (GSH)-S-conjugates, glucuronyl conjugates and sulfate conjugates and by the co-export of xenobiotic(s) and GSH.	Glutathione	135-138	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	4-34
11836025-1	2002	The multidrug resistance protein 1 (MRP1) protects cells from xenobiotics by extruding from the intracellular compartment glutathione (GSH)-S-conjugates, glucuronyl conjugates and sulfate conjugates and by the co-export of xenobiotic(s) and GSH.	Glutathione	122-133	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	4-34
11836025-1	2002	The multidrug resistance protein 1 (MRP1) protects cells from xenobiotics by extruding from the intracellular compartment glutathione (GSH)-S-conjugates, glucuronyl conjugates and sulfate conjugates and by the co-export of xenobiotic(s) and GSH.	Glutathione	122-133	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	36-40
12479061-3	2002	Selection was performed by vincristine (VCR) and 4-hydroperoxycyclophosphamide(4-HC) to obtain ALDH1 and MDR1 stably expressing cells.	perfosfamide	79-83	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	105-109
11862425-4	2002	METHODS: Paclitaxel was administered to mdr1ab P-glycoprotein knockout mice with either the conventional (controls) or a seven-fold higher amount of Cremophor EL (test group).	Paclitaxel	9-19	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	40-44
11855834-0	2002	Role of the Multidrug Resistance Protein 1 in protection from heavy metal oxyanions: investigations in vitro and in MRP1-deficient mice.	Metals	68-73	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	12-42
11855834-3	2002	We now report that the retroviral vector-mediated overexpression of MRP1 and of the two subunits of gamma-GCS (heavy and light) resulted in higher intracellular glutathione levels and in a greater level of resistance to sodium arsenite and antimony potassium tartrate, compared to the overexpression of MRP1 and gamma-GCS heavy alone.	Glutathione	161-172	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	68-72
11855834-3	2002	We now report that the retroviral vector-mediated overexpression of MRP1 and of the two subunits of gamma-GCS (heavy and light) resulted in higher intracellular glutathione levels and in a greater level of resistance to sodium arsenite and antimony potassium tartrate, compared to the overexpression of MRP1 and gamma-GCS heavy alone.	sodium arsenite	220-235	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	68-72
11855834-3	2002	We now report that the retroviral vector-mediated overexpression of MRP1 and of the two subunits of gamma-GCS (heavy and light) resulted in higher intracellular glutathione levels and in a greater level of resistance to sodium arsenite and antimony potassium tartrate, compared to the overexpression of MRP1 and gamma-GCS heavy alone.	tartaric acid	249-267	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	68-72
11855834-4	2002	These observations further demonstrate that glutathione is an important component of MRP1-mediated cellular resistance to arsenite and antimony.	Glutathione	44-55	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	85-89
11855834-4	2002	These observations further demonstrate that glutathione is an important component of MRP1-mediated cellular resistance to arsenite and antimony.	arsenite	122-130	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	85-89
11855834-7	2002	It is conceivable that, in vivo, other pump(s) effectively vicariate for MRP1-mediated transport of heavy metal oxyanions.	Metals	106-111	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	73-77
11836025-1	2002	The multidrug resistance protein 1 (MRP1) protects cells from xenobiotics by extruding from the intracellular compartment glutathione (GSH)-S-conjugates, glucuronyl conjugates and sulfate conjugates and by the co-export of xenobiotic(s) and GSH.	Glutathione	135-138	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	36-40
11836025-1	2002	The multidrug resistance protein 1 (MRP1) protects cells from xenobiotics by extruding from the intracellular compartment glutathione (GSH)-S-conjugates, glucuronyl conjugates and sulfate conjugates and by the co-export of xenobiotic(s) and GSH.	Sulfates	180-187	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	4-34
11836025-1	2002	The multidrug resistance protein 1 (MRP1) protects cells from xenobiotics by extruding from the intracellular compartment glutathione (GSH)-S-conjugates, glucuronyl conjugates and sulfate conjugates and by the co-export of xenobiotic(s) and GSH.	Sulfates	180-187	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	36-40
11836025-1	2002	The multidrug resistance protein 1 (MRP1) protects cells from xenobiotics by extruding from the intracellular compartment glutathione (GSH)-S-conjugates, glucuronyl conjugates and sulfate conjugates and by the co-export of xenobiotic(s) and GSH.	Glutathione	241-244	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	4-34
11836025-1	2002	The multidrug resistance protein 1 (MRP1) protects cells from xenobiotics by extruding from the intracellular compartment glutathione (GSH)-S-conjugates, glucuronyl conjugates and sulfate conjugates and by the co-export of xenobiotic(s) and GSH.	Glutathione	241-244	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	36-40
11836025-2	2002	An ATP-dependent transport of aflatoxin B1 (AFB1) and its GSH conjugates by MRP1 has been previously demonstrated in vitro.	Adenosine Triphosphate	3-6	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	76-80
11836025-2	2002	An ATP-dependent transport of aflatoxin B1 (AFB1) and its GSH conjugates by MRP1 has been previously demonstrated in vitro.	Aflatoxin B1	30-42	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	76-80
11836025-2	2002	An ATP-dependent transport of aflatoxin B1 (AFB1) and its GSH conjugates by MRP1 has been previously demonstrated in vitro.	Glutathione	58-61	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	76-80
11836025-7	2002	Due to the redundancy of transmembrane export pumps, other pump(s) may effectively vicariate for MRP1-mediated transport of AFB1 and its glutathione conjugates.	Glutathione	137-148	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	97-101
11696858-6	2001	In contrast, overexpression of MDR1 in NIH 3T3 cells increased ATP release rates.	Adenosine Triphosphate	63-66	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	31-35
11429411-14	2001	They also reveal a highly specific functional relationship between nonconserved amino acids in TM helices 14 and 17 of both mrp1 and MRP1 that enables both proteins to confer similar levels of resistance to vincristine and VP-16.	Vincristine	207-218	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	124-128
11429411-2	2001	By mutating variant residues in mrp1 to those present in MRP1, we identified Glu(1089) of MRP1 as being critical for anthracycline resistance.	Glutamic Acid	77-80	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	32-36
11429411-2	2001	By mutating variant residues in mrp1 to those present in MRP1, we identified Glu(1089) of MRP1 as being critical for anthracycline resistance.	Anthracyclines	117-130	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	32-36
11429411-4	2001	We have now identified a nonconserved amino acid within the highly conserved COOH-proximal transmembrane helix of MRP1/mrp1 that is important for transport of the conjugated estrogen.	Carbonic Acid	77-81	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	119-123
11429411-5	2001	Converting Ala(1239) in mrp1 to Thr, as in the corresponding position (1242) in MRP1, increased E(2)17betaG transport 3-fold.	Alanine	11-14	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	24-28
11429411-5	2001	Converting Ala(1239) in mrp1 to Thr, as in the corresponding position (1242) in MRP1, increased E(2)17betaG transport 3-fold.	17betag	100-107	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	24-28
11429411-6	2001	Any mutation of mrp1 Ala(1239), including substitution with Thr, decreased resistance to vincristine and VP-16 without altering anthracycline resistance.	Alanine	21-24	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	16-20
11429411-6	2001	Any mutation of mrp1 Ala(1239), including substitution with Thr, decreased resistance to vincristine and VP-16 without altering anthracycline resistance.	Threonine	60-63	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	16-20
11429411-6	2001	Any mutation of mrp1 Ala(1239), including substitution with Thr, decreased resistance to vincristine and VP-16 without altering anthracycline resistance.	Vincristine	89-100	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	16-20
11518757-0	2001	Decreased hepatic accumulation and enhanced esterification of cholesterol in mice deficient in mdr1a and mdr1b P-glycoproteins.	Cholesterol	62-73	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	105-110
11408605-1	2001	Murine thymoma cell lines expressing mutated forms of the mdr1b P-glycoprotein were isolated using a novel taxane-based P-glycoprotein inhibitor tRA-96023 (SB-RA-31012).	taxane	107-113	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	58-63
11369136-0	2001	Induction of apoptosis in MDR1 expressing cells by daunorubicin with combinations of suboptimal concentrations of P-glycoprotein modulators.	Daunorubicin	51-63	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	26-30
11313959-5	2001	Both IR and DEN induced mdr1b in wild-type animals, but not in the p53-/- mice.	Diethylnitrosamine	12-15	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	24-29
11264984-5	2001	The finding that a lipid sensitive subgroup of ABC transporters is able to translocate cholesterol and phospholipids supports the concept that in ABCA1 deficiency, compensatory mechanisms possibly involving MDR1, MDR3 and MRP-family members could be active.	Cholesterol	87-98	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	207-211
11264984-5	2001	The finding that a lipid sensitive subgroup of ABC transporters is able to translocate cholesterol and phospholipids supports the concept that in ABCA1 deficiency, compensatory mechanisms possibly involving MDR1, MDR3 and MRP-family members could be active.	Phospholipids	103-116	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	207-211
11238654-5	2001	These findings were related to an effect of mrp1 on LT metabolism, because survival was similar in mrp1(-/-) and wild-type mice treated with the 5-lipoxygenase-activating protein inhibitor MK-886.	MK-886	189-195	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	44-48
11313959-8	2001	Further studies using acridine orange and ethidium bromide to measure apoptosis revealed that mdr1b caused apoptosis and this was enhanced by p53, however the increased apoptosis required a functional p53 transactivation domain.	Acridine Orange	22-37	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	94-99
11313959-8	2001	Further studies using acridine orange and ethidium bromide to measure apoptosis revealed that mdr1b caused apoptosis and this was enhanced by p53, however the increased apoptosis required a functional p53 transactivation domain.	Ethidium	42-58	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	94-99
10933194-4	2000	Evidence for simultaneous drug resistance of genetically modified primary murine progenitor cells to colchicine or the podophyllotoxin etoposide, both covered by MDR1-mediated efflux activity, and the nitrosourea BCNU, which is counteracted by hATPA/GA, is presented using in vitro colony assays.	podophyllotoxin etoposide	119-144	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	162-166
11360920-5	2001	A significant reduction in the hepatic expression of mdr1a, mdr1b, mdr2 and spgp genes were seen in endotoxin (lipopolysaccharide (LPS)) and turpentine-treated mice.	Turpentine	141-151	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	60-65
11235562-2	2000	METHODS: The mdr1 gene was transfected into murine and human bone marrow cells by Lipofectin.	1,2-dielaidoylphosphatidylethanolamine	82-92	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	13-17
11235562-4	2000	The functional activity of mdr1 in transfected cells was examined by rhodamine retention assay.	Rhodamines	69-78	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	27-31
11235562-8	2000	Bone marrow cells transfected with mdr1 gene reconstituted the hematopoietic function and offered resistance to doxorubicin in recipient mice.	Doxorubicin	112-123	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	35-39
10910903-3	2000	It is now reported that MDR1-mediated stem cell expansion is associated with an increase in side population (SP) stem cells, defined by Hoechst dye staining.	hoechst dye	136-147	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	24-28
10910903-4	2000	Transduction of murine bone marrow cells with an MDR1 retroviral vector resulted in an almost 2 log increase in SP cell numbers over 12 days in culture, whereas there was a rapid loss of SP cells from control cultures.	sp	112-114	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	49-53
10945636-8	2000	Pretreatment with verapamil reversed the MDR phenotype.	Verapamil	18-27	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	41-44
10999959-7	2000	Nevertheless, the rate of (14)CO(2) appearance in the breath showed no relationship with these measurements of CYP3A, but changed proportionally to expression of mdr1.	co(2)	30-35	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	162-166
9698374-0	1998	Identification of the domains of photoincorporation of the 3"- and 7-benzophenone analogues of taxol in the carboxyl-terminal half of murine mdr1b P-glycoprotein.	3"- and 7-benzophenone	59-81	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	141-146
10623820-4	2000	In this study, we report that Fluo-3 is indeed transported by murine mrp1 or its human ortholog MRP1, as revealed by transfection of HEK 293 cells with mrp1 or MRP1 cDNA.	Fluo-3	30-36	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	69-73
10623820-11	2000	Finally, mrp1 was functionally relevant during the activation process of Th1 cells, because T cell activation could be suppressed by exposure of cells to the mrp1 inhibitor MK571.	verlukast	173-178	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	9-13
10623820-11	2000	Finally, mrp1 was functionally relevant during the activation process of Th1 cells, because T cell activation could be suppressed by exposure of cells to the mrp1 inhibitor MK571.	verlukast	173-178	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	158-162
10617675-8	2000	Further comparison revealed that although MDR1 easily impaired uptake of vincristine, daunomycin, paclitaxel, and digoxin, SPGP had no effect on uptake of these drugs.	Vincristine	73-84	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	42-46
10617675-8	2000	Further comparison revealed that although MDR1 easily impaired uptake of vincristine, daunomycin, paclitaxel, and digoxin, SPGP had no effect on uptake of these drugs.	Daunorubicin	86-96	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	42-46
10617675-8	2000	Further comparison revealed that although MDR1 easily impaired uptake of vincristine, daunomycin, paclitaxel, and digoxin, SPGP had no effect on uptake of these drugs.	Paclitaxel	98-108	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	42-46
10617675-8	2000	Further comparison revealed that although MDR1 easily impaired uptake of vincristine, daunomycin, paclitaxel, and digoxin, SPGP had no effect on uptake of these drugs.	Digoxin	114-121	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	42-46
10617675-9	2000	However, further studies demonstrated that, like MDR1, SPGP effluxed calcein-acetoxymethyl ester (AM).	calcein AM	69-96	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	49-53
10330452-1	1999	The multidrug resistance-associated protein (MRP) that is involved in drug resistance and the export of glutathione-conjugated substrates may not have the same epithelial cell membrane distribution as the P-glycoprotein encoded by the MDR gene.	Glutathione	104-115	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	235-238
9826540-4	1998	In mouse liver treated with dexamethasone, mdr1b and Cyp3a were induced (5- and 2-fold, respectively).	Dexamethasone	28-41	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	43-48
9826540-8	1998	In vivo murine mdr1b and Cyp3a are coregulated by dexamethasone in liver and inversely regulated in adrenals.	Dexamethasone	50-63	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	15-20
9866690-0	1998	Identification of multidrug resistant protein 1 of mouse leukemia P388 cells on a PVDF membrane using 6-aminoquinolyl-carbamyl (AQC)-amino acid analysis and World Wide Web (WWW)-accessible tools.	polyvinylidene fluoride	82-86	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	18-47
9866690-0	1998	Identification of multidrug resistant protein 1 of mouse leukemia P388 cells on a PVDF membrane using 6-aminoquinolyl-carbamyl (AQC)-amino acid analysis and World Wide Web (WWW)-accessible tools.	6-aminoquinolyl-carbamyl	102-126	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	18-47
9866690-1	1998	Multidrug resistant protein 1 (MDR1) in a doxorubicin-resistant mouse leukemia cell line (P388/DOX) was identified using its amino acid composition combined with protein database searching (ExPASy and EMBL PROPSEARCH) via the World Wide Web.	Doxorubicin	42-53	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	0-29
9866690-1	1998	Multidrug resistant protein 1 (MDR1) in a doxorubicin-resistant mouse leukemia cell line (P388/DOX) was identified using its amino acid composition combined with protein database searching (ExPASy and EMBL PROPSEARCH) via the World Wide Web.	Doxorubicin	42-53	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	31-35
9866690-1	1998	Multidrug resistant protein 1 (MDR1) in a doxorubicin-resistant mouse leukemia cell line (P388/DOX) was identified using its amino acid composition combined with protein database searching (ExPASy and EMBL PROPSEARCH) via the World Wide Web.	Doxorubicin	95-98	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	0-29
9866690-1	1998	Multidrug resistant protein 1 (MDR1) in a doxorubicin-resistant mouse leukemia cell line (P388/DOX) was identified using its amino acid composition combined with protein database searching (ExPASy and EMBL PROPSEARCH) via the World Wide Web.	Doxorubicin	95-98	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	31-35
9866690-9	1998	MDR1 in P388/DOX was ranked first by both databases with high reliability (score 14 for ExPASy, distance 1.34 for EMBL).	Doxorubicin	13-16	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	0-4
10724034-4	2000	Transfer of either mutant or wild-type MDR1 to K562 erythroleukemia cells or primary murine bone marrow resulted in reduced accumulation of daunomycin and vinblastine because of increased drug efflux.trans-(E)-Flupentixol at concentrations up to 10 microM failed to reverse drug efflux mediated by the product of the mutant MDR1 while wild-type P-glycoprotein was inhibited.	(E)-Flupenthixol	200-221	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	324-328
10617675-11	2000	Although cyclosporine A and reserpine blocked calcein-AM transport by MDR1, these drugs had either minimal or no effect, respectively, on blocking SPGP efflux of calcein-AM.	Cyclosporine	9-23	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	70-74
10617675-11	2000	Although cyclosporine A and reserpine blocked calcein-AM transport by MDR1, these drugs had either minimal or no effect, respectively, on blocking SPGP efflux of calcein-AM.	Reserpine	28-37	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	70-74
10617675-11	2000	Although cyclosporine A and reserpine blocked calcein-AM transport by MDR1, these drugs had either minimal or no effect, respectively, on blocking SPGP efflux of calcein-AM.	calcein AM	46-56	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	70-74
10484077-4	1999	We previously demonstrated that mdr1 gene expression in murine thymoma cells correlated well with a decrease in their ability to accumulate the glucocorticoid dexamethasone and their increased resistance to glucocorticoid-induced apoptosis.	Dexamethasone	159-172	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	32-36
10484077-6	1999	Specifically, introduction and expression of the mouse mdr1 gene in the human HEK 293T cell line conveys a multidrug resistance phenotype that includes a reduced capacity to accumulate dexamethasone.	Dexamethasone	185-198	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	55-59
10484077-7	1999	Moreover, isolation of additional mdr1-expressing mouse lymphoid cells, without using steroids in the selection, confirms the linkage between multidrug resistance conveyed by the mdr1 P-glycoprotein and resistance to dexamethasone.	Dexamethasone	217-230	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	34-38
10484077-7	1999	Moreover, isolation of additional mdr1-expressing mouse lymphoid cells, without using steroids in the selection, confirms the linkage between multidrug resistance conveyed by the mdr1 P-glycoprotein and resistance to dexamethasone.	Dexamethasone	217-230	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	179-183
10484077-9	1999	The results support the concept that the mdr1 and mdr3 P-glycoproteins may serve alternative roles in the transport of endogenous substances such as steroids.	Steroids	149-157	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	41-45
11776553-3	1999	Pgp, a product of mdr1 gene expression, and its function were detected by flow cytometry, immunohistochemistry, and rhodamine test respectively.	Rhodamines	116-125	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	18-22
10206323-10	1999	In conclusion, our results suggest that BTL is transported from brain to blood by mdr1a P-gp in mice and by MDR1 in humans, and this presumably accounts for the low brain distribution of BTL.	bunitrolol	40-43	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	108-112
9698374-0	1998	Identification of the domains of photoincorporation of the 3"- and 7-benzophenone analogues of taxol in the carboxyl-terminal half of murine mdr1b P-glycoprotein.	Paclitaxel	95-100	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	141-146
9698374-3	1998	The contact domains between the murine mdr1b P-glycoprotein and two photoreactive Taxol analogues have been mapped by a combination of CNBr digestion and immunoprecipitation studies.	Paclitaxel	82-87	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	39-44
9698374-4	1998	We had demonstrated previously that the 3"-p-benzoyldihydrocinnamoyl (BzDC) analogue of Taxol specifically photolabeled mdr1b P-glycoprotein and now show that the corresponding C-7 analogue likewise specifically photoincorporates into the transporter.	3"-p-benzoyldihydrocinnamoyl	40-68	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	120-125
9698374-4	1998	We had demonstrated previously that the 3"-p-benzoyldihydrocinnamoyl (BzDC) analogue of Taxol specifically photolabeled mdr1b P-glycoprotein and now show that the corresponding C-7 analogue likewise specifically photoincorporates into the transporter.	bzdc	70-74	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	120-125
9698374-4	1998	We had demonstrated previously that the 3"-p-benzoyldihydrocinnamoyl (BzDC) analogue of Taxol specifically photolabeled mdr1b P-glycoprotein and now show that the corresponding C-7 analogue likewise specifically photoincorporates into the transporter.	Paclitaxel	88-93	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	120-125
9698374-6	1998	The CNBr fragment generated from the 3"-BzDC-Taxol-photolabeled P-glycoprotein was immunoprecipitated by a polyclonal antibody (Ab7) raised against amino acid residues 1008-1019 of the mdr1b isoform.	3"-bzdc-taxol	37-50	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	185-190
9698071-8	1998	Treatment with 50 microM of reduced polymer of spermine and glutaraldehyde, a selective blocker of the polyamine transport system, reduced MDR activity in mdr-1-transfected CHO cells and restored cellular accumulation of etoposide and taxol to control levels, effects not observed in mdr-1-transfected CHOMGBG cells.	Spermine	47-55	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	155-160
9820176-10	1998	In contrast, induction seemed to determine resistance in EHR2 cells in vitro exposed to daunorubicin 10(-8) M. The revertant EHR2/0.8/R was treated in vivo with daunorubicin for 24 h. After treatment, P-glycoprotein increased in EHR2/0.8/R (sevenfold) and the cell line developed resistance to daunorubicin (12-fold), suggesting that in EHR2/0.8/R the mdr1 gene was activated by induction.	Daunorubicin	161-173	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	352-356
9820176-10	1998	In contrast, induction seemed to determine resistance in EHR2 cells in vitro exposed to daunorubicin 10(-8) M. The revertant EHR2/0.8/R was treated in vivo with daunorubicin for 24 h. After treatment, P-glycoprotein increased in EHR2/0.8/R (sevenfold) and the cell line developed resistance to daunorubicin (12-fold), suggesting that in EHR2/0.8/R the mdr1 gene was activated by induction.	Daunorubicin	161-173	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	352-356
9698071-0	1998	A unique interaction between polyamine and multidrug resistance (P-glycoprotein) transporters in cultured Chinese hamster ovary cells transfected with mouse mdr-1 gene.	Polyamines	29-38	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	157-162
9698071-5	1998	The mdr-1b-transfected CHO cells accumulated 2- to 3-fold less taxol and etoposide than the controls, an accumulation defect reversed by the potent MDR modulator PSC-833.	Paclitaxel	63-68	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	4-10
9698071-5	1998	The mdr-1b-transfected CHO cells accumulated 2- to 3-fold less taxol and etoposide than the controls, an accumulation defect reversed by the potent MDR modulator PSC-833.	Etoposide	73-82	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	4-10
9698071-8	1998	Treatment with 50 microM of reduced polymer of spermine and glutaraldehyde, a selective blocker of the polyamine transport system, reduced MDR activity in mdr-1-transfected CHO cells and restored cellular accumulation of etoposide and taxol to control levels, effects not observed in mdr-1-transfected CHOMGBG cells.	Polymers	36-43	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	155-160
9698071-8	1998	Treatment with 50 microM of reduced polymer of spermine and glutaraldehyde, a selective blocker of the polyamine transport system, reduced MDR activity in mdr-1-transfected CHO cells and restored cellular accumulation of etoposide and taxol to control levels, effects not observed in mdr-1-transfected CHOMGBG cells.	Polymers	36-43	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	284-289
9873828-5	1998	These results were well consistent with the finding that the treatment of quercetin decreased the expression level of P-gp, MDR1 gene product, in dose-dependent manner, and markedly increased the sensitivity of MDR cells to vincristine or vinblastine.	Quercetin	74-83	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	124-128
9873828-5	1998	These results were well consistent with the finding that the treatment of quercetin decreased the expression level of P-gp, MDR1 gene product, in dose-dependent manner, and markedly increased the sensitivity of MDR cells to vincristine or vinblastine.	Vinblastine	239-250	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	124-128
9713496-4	1998	In the present work single-cell fluorescence digital imaging has been applied to characterize the kinetics and inhibitor-sensitivity of calcein accumulation in a mixture of HL60 MRP1 and NIH 3T3 MDR1 cells.	fluorexon	136-143	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	195-199
9698071-8	1998	Treatment with 50 microM of reduced polymer of spermine and glutaraldehyde, a selective blocker of the polyamine transport system, reduced MDR activity in mdr-1-transfected CHO cells and restored cellular accumulation of etoposide and taxol to control levels, effects not observed in mdr-1-transfected CHOMGBG cells.	Spermine	47-55	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	284-289
9698071-8	1998	Treatment with 50 microM of reduced polymer of spermine and glutaraldehyde, a selective blocker of the polyamine transport system, reduced MDR activity in mdr-1-transfected CHO cells and restored cellular accumulation of etoposide and taxol to control levels, effects not observed in mdr-1-transfected CHOMGBG cells.	Glutaral	60-74	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	155-160
9698071-8	1998	Treatment with 50 microM of reduced polymer of spermine and glutaraldehyde, a selective blocker of the polyamine transport system, reduced MDR activity in mdr-1-transfected CHO cells and restored cellular accumulation of etoposide and taxol to control levels, effects not observed in mdr-1-transfected CHOMGBG cells.	Glutaral	60-74	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	284-289
9698071-8	1998	Treatment with 50 microM of reduced polymer of spermine and glutaraldehyde, a selective blocker of the polyamine transport system, reduced MDR activity in mdr-1-transfected CHO cells and restored cellular accumulation of etoposide and taxol to control levels, effects not observed in mdr-1-transfected CHOMGBG cells.	Polyamines	103-112	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	155-160
9698071-8	1998	Treatment with 50 microM of reduced polymer of spermine and glutaraldehyde, a selective blocker of the polyamine transport system, reduced MDR activity in mdr-1-transfected CHO cells and restored cellular accumulation of etoposide and taxol to control levels, effects not observed in mdr-1-transfected CHOMGBG cells.	Polyamines	103-112	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	284-289
9698071-8	1998	Treatment with 50 microM of reduced polymer of spermine and glutaraldehyde, a selective blocker of the polyamine transport system, reduced MDR activity in mdr-1-transfected CHO cells and restored cellular accumulation of etoposide and taxol to control levels, effects not observed in mdr-1-transfected CHOMGBG cells.	cho	173-176	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	155-160
9698071-8	1998	Treatment with 50 microM of reduced polymer of spermine and glutaraldehyde, a selective blocker of the polyamine transport system, reduced MDR activity in mdr-1-transfected CHO cells and restored cellular accumulation of etoposide and taxol to control levels, effects not observed in mdr-1-transfected CHOMGBG cells.	Etoposide	221-230	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	155-160
9698071-8	1998	Treatment with 50 microM of reduced polymer of spermine and glutaraldehyde, a selective blocker of the polyamine transport system, reduced MDR activity in mdr-1-transfected CHO cells and restored cellular accumulation of etoposide and taxol to control levels, effects not observed in mdr-1-transfected CHOMGBG cells.	Paclitaxel	235-240	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	155-160
9698071-9	1998	Notably, mdr-1-transfected CHO cells were 4- to 16-fold more resistant to the cytotoxic effects of the P-gp substrates doxorubicin, taxol, and etoposide than were the mdr-1-transfected CHOMGBG cells.	Doxorubicin	119-130	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	9-14
9698071-9	1998	Notably, mdr-1-transfected CHO cells were 4- to 16-fold more resistant to the cytotoxic effects of the P-gp substrates doxorubicin, taxol, and etoposide than were the mdr-1-transfected CHOMGBG cells.	Paclitaxel	132-137	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	9-14
9698071-9	1998	Notably, mdr-1-transfected CHO cells were 4- to 16-fold more resistant to the cytotoxic effects of the P-gp substrates doxorubicin, taxol, and etoposide than were the mdr-1-transfected CHOMGBG cells.	Etoposide	143-152	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	9-14
9698071-10	1998	CHO cells transfected with the mdr-1 gene exhibited a 23% reduction in cellular uptake of [14C]spermidine compared with untransfected controls; spermidine accumulation in CHOMGBG cells was no different than that in untransfected controls.	[14c]spermidine	90-105	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	31-36
9698071-10	1998	CHO cells transfected with the mdr-1 gene exhibited a 23% reduction in cellular uptake of [14C]spermidine compared with untransfected controls; spermidine accumulation in CHOMGBG cells was no different than that in untransfected controls.	Spermidine	95-105	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	31-36
9508799-8	1998	In contrast, pretreatment with TPA reduced ICl(swell) in MDR1(G185V)-expressing transfected NIH3T3 fibroblasts.	Tetradecanoylphorbol Acetate	31-34	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	57-61
9473310-0	1998	Human MDR1 and mouse mdr1a P-glycoprotein alter the cellular retention and disposition of erythromycin, but not of retinoic acid or benzo(a)pyrene.	Erythromycin	90-102	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	6-10
9473310-0	1998	Human MDR1 and mouse mdr1a P-glycoprotein alter the cellular retention and disposition of erythromycin, but not of retinoic acid or benzo(a)pyrene.	Tretinoin	115-128	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	6-10
9525472-7	1998	Results demonstrated that 1) IGF-I significantly inhibited the cell death and apoptosis of MCLM cells treated with Act-D, LOV, or DOX; 2) IGF-I increased mRNA expression for mdr-1, c-H-ras, and MnSOD; 3) the p-glycoproteins in cells treated with IGF-I or stably transfected with c-H-ras were elevated when compared with control.	Doxorubicin	130-133	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	174-179
9890669-5	1998	Action of verapamil (well-known inhibitor of PGP activity) on multidrug resistance was often used as evidence that MDR is mediated by PGP.	Verapamil	10-19	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	115-118
9426231-0	1997	Transport of glutathione prostaglandin A conjugates by the multidrug resistance protein 1.	Glutathione	13-24	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	59-89
9426231-0	1997	Transport of glutathione prostaglandin A conjugates by the multidrug resistance protein 1.	Prostaglandins A	25-40	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	59-89
9366556-1	1997	Mice lacking mdr1-type P-glycoproteins (mdr1a/1b [-/-] mice) display large changes in the pharmacokinetics of digoxin and other drugs.	Digoxin	110-117	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	13-17
9366556-5	1997	Hepatobiliary excretion of [3H]digoxin was markedly decreased in both wild-type and mdr1a/1b (-/-) mice by PSC833, the latter effect indicating that in vivo, PSC833 inhibits not only mdr1-type P-glycoproteins, but also other drug transporters.	Digoxin	27-38	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	84-88
9108099-7	1997	However, both mdr1a and mdr1b P-gps contributed to the extrusion of rhodamine from hematopoietic progenitor cells, suggesting a potential role for the endogenous mdr1-type P-gps in protection of bone marrow against cytotoxic anticancer drugs.	Rhodamines	68-77	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	24-29
9260924-0	1997	Transcriptional regulation of the murine multidrug resistance gene mdr1b by progesterone occurs via an indirect mechanism.	Progesterone	76-88	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	67-72
9260924-15	1997	On the basis of our studies using 540 bp of upstream sequence, mdr1b is activated transcriptionally by progesterone, in an indirect manner dependent on basal factors.	Progesterone	103-115	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	63-68
9542528-1	1997	Selection of cells for resistance to vincristine or doxorubicin often induces overexpression of the multidrug resistance (MDR) genes, which encode the cell surface P-glycoproteins, as a result of gene amplification, transcriptional activation, or mRNA stabilization.	Vincristine	37-48	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	122-125
9542528-1	1997	Selection of cells for resistance to vincristine or doxorubicin often induces overexpression of the multidrug resistance (MDR) genes, which encode the cell surface P-glycoproteins, as a result of gene amplification, transcriptional activation, or mRNA stabilization.	Doxorubicin	52-63	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	122-125
9378810-0	1997	A new mdr-1 encoded P-170 specific monoclonal antibody: (6/1C) on paraffin wax embedded tissue without pretreatment of sections.	Paraffin	66-78	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	6-11
9378810-1	1997	AIMS: The generation and characterisation of a monoclonal antibody that specifically recognises the mdr-1 encoded protein, P-glycoprotein (P-170), on routinely processed formalin fixed, paraffin wax embedded tissue sections.	Formaldehyde	170-178	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	100-105
9378810-1	1997	AIMS: The generation and characterisation of a monoclonal antibody that specifically recognises the mdr-1 encoded protein, P-glycoprotein (P-170), on routinely processed formalin fixed, paraffin wax embedded tissue sections.	Paraffin	186-198	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	100-105
9378810-7	1997	Immunohistochemical studies on formalin fixed, paraffin wax embedded normal adult kidney, liver, and breast tissue and a range of fetal tissues exhibited staining patterns of a variety of secretory surfaces consistent with documented mdr-1 specific staining.	Paraffin	47-59	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	234-239
9378810-10	1997	CONCLUSIONS: This new monoclonal antibody, chosen for its specificity with the mdr-1 encoded P-170 and its reactivity on routinely fixed paraffin wax embedded tissue samples without pretreatment, appears to be useful for the investigation of P-170 in archival material.	Paraffin	137-149	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	79-84
9176156-14	1997	Cl-/HCO3- exchange activity is significantly reduced in the drug-selected derivatives overexpressing MDR 1 but not the parental CFTR clones.	Bicarbonates	4-8	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	101-106
9446255-14	1997	Indeed, SDZ PSC 833 concentrations that fully reverse MDR in vitro are achievable in vivo, plasma samples from patients treated with SDZ PSC 833 restored the sensitivity of MDR human sarcoma cells to paclitaxel, etoposide and doxorubicin.	Sulfadiazine	133-136	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	173-176
9446255-14	1997	Indeed, SDZ PSC 833 concentrations that fully reverse MDR in vitro are achievable in vivo, plasma samples from patients treated with SDZ PSC 833 restored the sensitivity of MDR human sarcoma cells to paclitaxel, etoposide and doxorubicin.	Paclitaxel	200-210	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	173-176
9108099-7	1997	However, both mdr1a and mdr1b P-gps contributed to the extrusion of rhodamine from hematopoietic progenitor cells, suggesting a potential role for the endogenous mdr1-type P-gps in protection of bone marrow against cytotoxic anticancer drugs.	Rhodamines	68-77	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	14-18
9010037-4	1997	Low-level expression of mdr1 and P-glycoprotein (P-gp), as well as a modest impairment of cellular drug accumulation and partial reversion of resistance to DOX and VP-16 by cyclosporine, confirmed a moderate role of P-gp in conferring drug resistance in P388/SPR cells.	Doxorubicin	156-159	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	24-28
9038209-4	1997	Three of the consensus phosphorylation sites for basic-directed kinases in murine mdr1b P-glycoprotein are utilized in vivo and have been identified as serines 665, 669, and 681.	Serine	152-159	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	82-87
9010037-4	1997	Low-level expression of mdr1 and P-glycoprotein (P-gp), as well as a modest impairment of cellular drug accumulation and partial reversion of resistance to DOX and VP-16 by cyclosporine, confirmed a moderate role of P-gp in conferring drug resistance in P388/SPR cells.	Etoposide	164-169	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	24-28
9010037-4	1997	Low-level expression of mdr1 and P-glycoprotein (P-gp), as well as a modest impairment of cellular drug accumulation and partial reversion of resistance to DOX and VP-16 by cyclosporine, confirmed a moderate role of P-gp in conferring drug resistance in P388/SPR cells.	Cyclosporine	173-185	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	24-28
9272128-8	1997	Major pharmacokinetic interactions result from the coadministration of CsA or PSC 833 with MDR-related anticancer agents (e.g., doxorubicin, daunorubicin, etoposide, paclitaxel, and vinblastine).	Cyclosporine	71-74	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	91-94
9272128-8	1997	Major pharmacokinetic interactions result from the coadministration of CsA or PSC 833 with MDR-related anticancer agents (e.g., doxorubicin, daunorubicin, etoposide, paclitaxel, and vinblastine).	Doxorubicin	128-139	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	91-94
8813118-3	1996	In this study, in vitro and in vivo reversion of MDR was attempted in a human leukemia cell line resistant to vincristine (HL-60/Vinc) using an 18-mer mdr1 antisense phosphorothioate oligodeoxynucleotide ([S]ODN) in combination with vincristine.	hl-60	123-128	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	49-52
9309248-1	1997	To overcome multidrug resistance in a P-glycoprotein-overexpressing P388/ADR murine leukemia cell line, antisense mdr1 phosphorothioate-oligodeoxynucleotide (AS-oligomer) was constructed.	phosphorothioate-oligodeoxynucleotide	119-156	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	114-118
8813118-3	1996	In this study, in vitro and in vivo reversion of MDR was attempted in a human leukemia cell line resistant to vincristine (HL-60/Vinc) using an 18-mer mdr1 antisense phosphorothioate oligodeoxynucleotide ([S]ODN) in combination with vincristine.	Vincristine	110-121	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	49-52
8813118-3	1996	In this study, in vitro and in vivo reversion of MDR was attempted in a human leukemia cell line resistant to vincristine (HL-60/Vinc) using an 18-mer mdr1 antisense phosphorothioate oligodeoxynucleotide ([S]ODN) in combination with vincristine.	Parathion	166-182	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	49-52
8813118-3	1996	In this study, in vitro and in vivo reversion of MDR was attempted in a human leukemia cell line resistant to vincristine (HL-60/Vinc) using an 18-mer mdr1 antisense phosphorothioate oligodeoxynucleotide ([S]ODN) in combination with vincristine.	Oligodeoxyribonucleotides	183-203	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	49-52
8813118-3	1996	In this study, in vitro and in vivo reversion of MDR was attempted in a human leukemia cell line resistant to vincristine (HL-60/Vinc) using an 18-mer mdr1 antisense phosphorothioate oligodeoxynucleotide ([S]ODN) in combination with vincristine.	[s]odn	205-211	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	49-52
8813118-3	1996	In this study, in vitro and in vivo reversion of MDR was attempted in a human leukemia cell line resistant to vincristine (HL-60/Vinc) using an 18-mer mdr1 antisense phosphorothioate oligodeoxynucleotide ([S]ODN) in combination with vincristine.	Vincristine	233-244	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	49-52
8813118-8	1996	In vivo reversal of MDR was obtained in SCID mice given injections of HL-60/Vinc cells and systemically treated with [S]ODNs plus vincristine, as indicated by a significantly prolonged survival of SCID mice that received the combination therapy of mdr1 antisense [S]ODNs + vincristine.	Vincristine	130-141	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	20-23
8813118-8	1996	In vivo reversal of MDR was obtained in SCID mice given injections of HL-60/Vinc cells and systemically treated with [S]ODNs plus vincristine, as indicated by a significantly prolonged survival of SCID mice that received the combination therapy of mdr1 antisense [S]ODNs + vincristine.	Vincristine	130-141	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	248-252
8813118-8	1996	In vivo reversal of MDR was obtained in SCID mice given injections of HL-60/Vinc cells and systemically treated with [S]ODNs plus vincristine, as indicated by a significantly prolonged survival of SCID mice that received the combination therapy of mdr1 antisense [S]ODNs + vincristine.	Vincristine	273-284	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	20-23
8863825-2	1996	We demonstrate that phosphorothioate antisense oligonucleotides can reduce levels of MDR1 message, inhibit expression of P-glyco protein, and affect drug uptake in MDR mouse 3T3 fibroblasts.	Parathion	20-36	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	85-89
8863825-2	1996	We demonstrate that phosphorothioate antisense oligonucleotides can reduce levels of MDR1 message, inhibit expression of P-glyco protein, and affect drug uptake in MDR mouse 3T3 fibroblasts.	Oligonucleotides	47-63	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	85-89
8863825-3	1996	An obligonucleotide (5995) directed against a sequence overlapping the AUG start codon was effective in reduction MDR1 transcript and protein levels when used at submicromolar concentrations in conjunction with cationic liposomes, whereas a scrambled control oligonucleotide (10221) was ineffective.	obligonucleotide	3-19	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	114-118
8863825-3	1996	An obligonucleotide (5995) directed against a sequence overlapping the AUG start codon was effective in reduction MDR1 transcript and protein levels when used at submicromolar concentrations in conjunction with cationic liposomes, whereas a scrambled control oligonucleotide (10221) was ineffective.	Oligonucleotides	259-274	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	114-118
8863825-6	1996	The 5" cholesterol 5995, but the not 5" cholesterol 10221, reduced MDR1 message and P-glycoprotein levels by 50-60% when used at low micromolar concentrations.	Cholesterol	7-18	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	67-71
8650203-4	1996	Expression of mouse Mdr1 in the mutant confers cross-resistance to daunomycin, quinidine, chloroquine, rhodamine 6G, and puromycin.	Daunorubicin	67-77	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	20-24
8913437-1	1996	The effects of nine reversers of P-glycoprotein on the uptake of daunomycin into MDR1-transfected P388 cells were quantitatively determined in undiluted human or mouse plasma and compared with their effects when measurements are made in a conventional cell culture medium (RPMI 1640) containing only 10% serum.	Daunorubicin	65-75	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	81-85
8650203-4	1996	Expression of mouse Mdr1 in the mutant confers cross-resistance to daunomycin, quinidine, chloroquine, rhodamine 6G, and puromycin.	Quinidine	79-88	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	20-24
8650203-4	1996	Expression of mouse Mdr1 in the mutant confers cross-resistance to daunomycin, quinidine, chloroquine, rhodamine 6G, and puromycin.	Chloroquine	90-101	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	20-24
8650203-4	1996	Expression of mouse Mdr1 in the mutant confers cross-resistance to daunomycin, quinidine, chloroquine, rhodamine 6G, and puromycin.	rhodamine 6	103-114	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	20-24
8650203-4	1996	Expression of mouse Mdr1 in the mutant confers cross-resistance to daunomycin, quinidine, chloroquine, rhodamine 6G, and puromycin.	Puromycin	121-130	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	20-24
8650203-5	1996	Most importantly, reserpine and doxorubicin completely abolish Mdr1-mediated rhodamine resistance.	Reserpine	18-27	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	63-67
8650203-5	1996	Most importantly, reserpine and doxorubicin completely abolish Mdr1-mediated rhodamine resistance.	Doxorubicin	32-43	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	63-67
8650203-5	1996	Most importantly, reserpine and doxorubicin completely abolish Mdr1-mediated rhodamine resistance.	Rhodamines	77-86	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	63-67
7866993-3	1995	Substrate specificity of the MDR1 gene product can be altered by a point mutation at amino acid residue 185 in which valine is substituted for glycine, but the effect of this mutation on inhibition of PGP is unknown.	Valine	117-123	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	29-33
9816258-2	1996	In vitro, MDR1-expressing cell lines are highly cross-resistant to bisantrene, and low levels of P-glycoprotein (the MDR1 gene product cell surface protein) confer resistance to the drug.	bisantrene	67-77	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	10-14
9816258-9	1996	Double-staining with MRK16 (a monoclonal antibody specific for P-glycoprotein) demonstrated that a single dose of bisantrene increased the relative number of MDR1-transduced positive B cells, macrophages, and (to some extent) granulocytes when compared to the number found in MDR1-untreated mice or the bisantrene-treated neomycin-transduced control mice.	bisantrene	114-124	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	158-162
9816258-9	1996	Double-staining with MRK16 (a monoclonal antibody specific for P-glycoprotein) demonstrated that a single dose of bisantrene increased the relative number of MDR1-transduced positive B cells, macrophages, and (to some extent) granulocytes when compared to the number found in MDR1-untreated mice or the bisantrene-treated neomycin-transduced control mice.	bisantrene	114-124	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	276-280
9816258-10	1996	These results provide in vivo evidence that bisantrene is a hematotoxic drug capable of selecting for MDR1-transduced hematopoietic cells.	bisantrene	44-54	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	102-106
9816258-11	1996	Bisantrene might be useful for gene therapy as an in vivo selective agent for cells transduced with MDR1 vectors that also coexpress therapeutic genes of interest.	bisantrene	0-10	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	100-104
8611717-7	1996	The drug combination CCE (cyclophosphamide, cisplatin, and etoposide) alone could increase the lifespan of the Namalwa/mdr-1 tumor-burdened mice by 129% compared with untreated controls.	Cyclophosphamide	26-42	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	119-124
8611717-7	1996	The drug combination CCE (cyclophosphamide, cisplatin, and etoposide) alone could increase the lifespan of the Namalwa/mdr-1 tumor-burdened mice by 129% compared with untreated controls.	Etoposide	59-68	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	119-124
8638674-9	1996	The differential expression of mdr1 and mdr3 in mouse mesangial cell clones, the ability of mdr1 PGP to transport R-123, and the impairment of PGP-mediated transport in TKGM-F12 cells, coexpressing mdr1 and mdr3 products, are demonstrated.	Rhodamine 123	114-119	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	92-96
8801335-2	1995	The phosphorothioate analogs, the sequences of which are sense or antisense to the initiation codon of mouse mdr1 mRNA, were tested against murine leukemic P388/S and adriamycin-resistant P388/ADR cell lines.	Parathion	4-20	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	109-113
7654009-1	1995	Resistance to the classical anthracyclines may be due to one or several mechanisms, most notably p-glycoprotein (pGP) associated multidrug resistance (mdr1, "typical mdr") and altered activity of topoisomerase II (topo II) ("atypical mdr").	Anthracyclines	28-42	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	151-155
7790384-4	1995	Levels of mdr1b mRNA were elevated to levels comparable to those observed during pregnancy, in the UE of ovariectomized mice following 5-8 days of estrogen and progesterone administration.	Progesterone	160-172	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	10-15
7790384-6	1995	These results suggested that steroid hormones alone can account for increased mdr1b mRNA expression and do not require the presence of other placenta/embryo-derived factors.	Steroids	29-45	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	78-83
7790384-12	1995	The rate of mdr1b mRNA decay in primary d-15 UE cells was decreased by treatment with alpha-amanitin or cycloheximide, suggesting that the decay pathway requires both transcription and de novo protein synthesis.	Alpha-Amanitin	86-100	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	12-17
7790384-12	1995	The rate of mdr1b mRNA decay in primary d-15 UE cells was decreased by treatment with alpha-amanitin or cycloheximide, suggesting that the decay pathway requires both transcription and de novo protein synthesis.	Cycloheximide	104-117	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	12-17
8611717-4	1996	In vivo cyclophosphamide, cisplatin, vincristine, doxorubicin, and etoposide as single agents, were effective in prolonging the survival of SCID mice burdened with the Namalwa tumor, whereas only cyclophosphamide and cisplatin were effective on Namalwa/mdr-1 tumors.	Cyclophosphamide	8-24	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	253-258
8611717-4	1996	In vivo cyclophosphamide, cisplatin, vincristine, doxorubicin, and etoposide as single agents, were effective in prolonging the survival of SCID mice burdened with the Namalwa tumor, whereas only cyclophosphamide and cisplatin were effective on Namalwa/mdr-1 tumors.	Cisplatin	26-35	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	253-258
8611717-4	1996	In vivo cyclophosphamide, cisplatin, vincristine, doxorubicin, and etoposide as single agents, were effective in prolonging the survival of SCID mice burdened with the Namalwa tumor, whereas only cyclophosphamide and cisplatin were effective on Namalwa/mdr-1 tumors.	Vincristine	37-48	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	253-258
8611717-4	1996	In vivo cyclophosphamide, cisplatin, vincristine, doxorubicin, and etoposide as single agents, were effective in prolonging the survival of SCID mice burdened with the Namalwa tumor, whereas only cyclophosphamide and cisplatin were effective on Namalwa/mdr-1 tumors.	Doxorubicin	50-61	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	253-258
8611717-4	1996	In vivo cyclophosphamide, cisplatin, vincristine, doxorubicin, and etoposide as single agents, were effective in prolonging the survival of SCID mice burdened with the Namalwa tumor, whereas only cyclophosphamide and cisplatin were effective on Namalwa/mdr-1 tumors.	Etoposide	67-76	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	253-258
8633005-4	1996	In both MDR1 cDNA-overexpressing clones, rifampicin induction of CYP3A mRNA and protein was decreased and required greater rifampicin concentrations compared with parental cells.	Rifampin	41-51	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	8-12
8638674-9	1996	The differential expression of mdr1 and mdr3 in mouse mesangial cell clones, the ability of mdr1 PGP to transport R-123, and the impairment of PGP-mediated transport in TKGM-F12 cells, coexpressing mdr1 and mdr3 products, are demonstrated.	Rhodamine 123	114-119	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	92-96
7697825-3	1995	We describe here that the continuous treatment of murine NIH 3T3 fibroblast cell cultures with okadaci acid resulted in a 50-fold amplification of two genes, mdr-1a and mdr-1b, that conferred multidrug resistance.	okadaci acid	95-107	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	169-175
7866993-3	1995	Substrate specificity of the MDR1 gene product can be altered by a point mutation at amino acid residue 185 in which valine is substituted for glycine, but the effect of this mutation on inhibition of PGP is unknown.	Glycine	143-150	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	29-33
22358644-6	1995	MDR gene transduction corrects the sensitivity of CD34(+) cells to taxol, an MDR drug substrate, and enriches the marrow for MDR-transduced cells.	Paclitaxel	67-72	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	0-3
7841045-1	1995	We have characterised sites of photodamage catalysed by the cationic photosensitiser tetrabromorhodamine 123, using P388 murine leukaemia cells and a subline (P388/ADR) which has a multidrug resistance phenotype and hyperexpresses mdr1 mRNA for P-glycoprotein.	tetrabromorhodamine	85-104	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	231-235
7718262-1	1995	A non-immunosuppressive cyclosporin, SDZ PSC 833 (PSC833), shows a reversal effect on multidrug resistance (MDR) by functional modulation of MDR1 gene product, P-glycoprotein.	Cyclosporine	24-35	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	141-145
22358644-6	1995	MDR gene transduction corrects the sensitivity of CD34(+) cells to taxol, an MDR drug substrate, and enriches the marrow for MDR-transduced cells.	Paclitaxel	67-72	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	77-80
22358644-6	1995	MDR gene transduction corrects the sensitivity of CD34(+) cells to taxol, an MDR drug substrate, and enriches the marrow for MDR-transduced cells.	Paclitaxel	67-72	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	77-80
7659186-1	1995	A set of multidrug resistant (MDR) murine leukemia P388 sublines processing 30-50-fold mdr1 gene amplification was obtained as a result of experimental chemotherapy with rubomycin, ruboxyl, vinblastine, vincristine, or combination of rubomycin and vincristine.	Daunorubicin	170-179	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	30-33
7628053-1	1995	SDZ PSC 833 (PSC 833) is a cyclosporin A analogue that is under clinical investigation in combination with doxorubicin (Dx) or other anticancer agents as a type-1 multidrug resistance (MDR-1)-reversing agent.	Cyclosporine	27-40	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	185-190
7659186-1	1995	A set of multidrug resistant (MDR) murine leukemia P388 sublines processing 30-50-fold mdr1 gene amplification was obtained as a result of experimental chemotherapy with rubomycin, ruboxyl, vinblastine, vincristine, or combination of rubomycin and vincristine.	Vinblastine	190-201	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	30-33
7659186-1	1995	A set of multidrug resistant (MDR) murine leukemia P388 sublines processing 30-50-fold mdr1 gene amplification was obtained as a result of experimental chemotherapy with rubomycin, ruboxyl, vinblastine, vincristine, or combination of rubomycin and vincristine.	Vincristine	203-214	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	30-33
7659186-1	1995	A set of multidrug resistant (MDR) murine leukemia P388 sublines processing 30-50-fold mdr1 gene amplification was obtained as a result of experimental chemotherapy with rubomycin, ruboxyl, vinblastine, vincristine, or combination of rubomycin and vincristine.	Daunorubicin	234-243	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	30-33
7659186-1	1995	A set of multidrug resistant (MDR) murine leukemia P388 sublines processing 30-50-fold mdr1 gene amplification was obtained as a result of experimental chemotherapy with rubomycin, ruboxyl, vinblastine, vincristine, or combination of rubomycin and vincristine.	Vincristine	248-259	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	30-33
7659186-2	1995	Significant differences of developed MDR sublines in response to treatment with cisplatin, tiophosphamide, sarcolysin, and dopad were found.	Cisplatin	80-89	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	37-40
7659186-2	1995	Significant differences of developed MDR sublines in response to treatment with cisplatin, tiophosphamide, sarcolysin, and dopad were found.	tiophosphamide	91-105	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	37-40
7659186-4	1995	The dependence of sensitivity to cisplatin on sorcin gene co-amplification was confirmed by analysis of Djungarian hamster DM15 cell sublines that selected for MDR in vitro by colchicine.	Cisplatin	33-42	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	160-163
7847840-5	1994	This indicates that the rhodamine efflux is a more function-related marker for MDR than the mdr1 gene and the pgp.	Rhodamines	24-33	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	92-96
7634376-1	1995	MS-209 is a novel quinoline compound which can overcome multidrug resistance (MDR) both in vitro and in vivo, while having a low level of side effects, and is now being evaluated in a clinical phase II study.	dofequidar	0-6	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	78-81
7634376-1	1995	MS-209 is a novel quinoline compound which can overcome multidrug resistance (MDR) both in vitro and in vivo, while having a low level of side effects, and is now being evaluated in a clinical phase II study.	quinoline	18-27	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	78-81
7734012-2	1994	The MDR1 Pgp can transport drugs; the murine homologue of MDR3, mdr2, was recently shown by us to be involved in transport of the phospholipid phosphatidylcholine (lecithin) into bile.	phospholipid phosphatidylcholine	130-162	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	4-8
7734012-2	1994	The MDR1 Pgp can transport drugs; the murine homologue of MDR3, mdr2, was recently shown by us to be involved in transport of the phospholipid phosphatidylcholine (lecithin) into bile.	Lecithins	164-172	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	4-8
8076364-1	1994	We have investigated the effect of the ionophore nigericin (NIG) in multidrug resistant (MDR) cells, using intracellular accumulation of the fluorescent dye rhodamine 123 (R123).	Nigericin	49-58	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	89-92
8076364-1	1994	We have investigated the effect of the ionophore nigericin (NIG) in multidrug resistant (MDR) cells, using intracellular accumulation of the fluorescent dye rhodamine 123 (R123).	Nigericin	60-63	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	89-92
7911394-4	1994	We report that the antiprogestin RU 486 can reverse multidrug resistance in cells overexpressing the mouse mdr1 gene.	Mifepristone	33-39	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	107-111
7911682-0	1994	Transfection of mu MDR 1 inhibits Na(+)-independent Cl-/-HCO3 exchange in Chinese hamster ovary cells.	Bicarbonates	57-61	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	19-24
8172879-2	1994	We have recently shown that a serine residue within the predicted transmembrane (TM) domain 11 of P-gps encoded by mouse mdr1 (Ser941) and mdr3 (Ser939) plays an important role in the substrate specificity of P-gp.	Serine	30-36	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	121-125
7910854-16	1994	The expression level of mdr-specific mRNA (predominance of mdr-1) and P-glycoprotein was directly associated with resistance to doxorubicin.	Doxorubicin	128-139	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	59-64
7654329-4	1994	We found that expression of the mdr1 P-glycoprotein gene produces a reduced accumulation of dexamethasone in WEHI-7 cells.	Dexamethasone	92-105	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	32-36
8104940-2	1993	This dye extrusion is blocked by competing substrates and inhibitors of the multidrug transporters, e.g. by verapamil, vincristine, sodium orthovanadate, oligomycin, and a monoclonal anti-MDR1 antibody.	Verapamil	108-117	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	188-192
7910372-3	1994	The initial rate of vinblastine uptake was reduced approximately 5-fold by glucose feeding of ATP-depleted wild-type (MDR1-G185) cells but was only halved in MDR1-V185 transfectants.	Vinblastine	20-31	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	118-122
7910372-3	1994	The initial rate of vinblastine uptake was reduced approximately 5-fold by glucose feeding of ATP-depleted wild-type (MDR1-G185) cells but was only halved in MDR1-V185 transfectants.	Vinblastine	20-31	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	158-162
7910372-3	1994	The initial rate of vinblastine uptake was reduced approximately 5-fold by glucose feeding of ATP-depleted wild-type (MDR1-G185) cells but was only halved in MDR1-V185 transfectants.	Glucose	75-82	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	118-122
7910372-3	1994	The initial rate of vinblastine uptake was reduced approximately 5-fold by glucose feeding of ATP-depleted wild-type (MDR1-G185) cells but was only halved in MDR1-V185 transfectants.	Adenosine Triphosphate	94-97	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	118-122
7910372-4	1994	In contrast, glucose feeding decreased the initial rate of colchicine uptake approximately 4-fold in the MDR1-V185 (mutant) transfectant but not in the MDR1-G185 (wild-type) transfectant.	Glucose	13-20	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	105-109
7910372-4	1994	In contrast, glucose feeding decreased the initial rate of colchicine uptake approximately 4-fold in the MDR1-V185 (mutant) transfectant but not in the MDR1-G185 (wild-type) transfectant.	Colchicine	59-69	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	105-109
7910372-5	1994	Efflux of colchicine was accelerated > 5-fold in both the MDR1-V185 (mutant) and MDR1-G185 (wild-type) transfectants when glucose was given to raise ATP levels.	Colchicine	10-20	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	61-65
7910372-5	1994	Efflux of colchicine was accelerated > 5-fold in both the MDR1-V185 (mutant) and MDR1-G185 (wild-type) transfectants when glucose was given to raise ATP levels.	Colchicine	10-20	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	84-88
7910372-5	1994	Efflux of colchicine was accelerated > 5-fold in both the MDR1-V185 (mutant) and MDR1-G185 (wild-type) transfectants when glucose was given to raise ATP levels.	Glucose	125-132	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	61-65
7910372-5	1994	Efflux of colchicine was accelerated > 5-fold in both the MDR1-V185 (mutant) and MDR1-G185 (wild-type) transfectants when glucose was given to raise ATP levels.	Glucose	125-132	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	84-88
7910372-6	1994	The effects on initial rates of colchicine uptake accounted semiquantitatively for the increased colchicine resistance of MDR1-V185 (mutant) transfectants.	Colchicine	32-42	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	122-126
7910372-6	1994	The effects on initial rates of colchicine uptake accounted semiquantitatively for the increased colchicine resistance of MDR1-V185 (mutant) transfectants.	Colchicine	97-107	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	122-126
7907953-2	1994	Several phenotypic features that are characteristic of MDR have been described; these include (1) resistance to many structurally and functionally unrelated drugs that have different cellular targets and modes of action; (2) reversal of MDR by certain agents, including verapamil and cyclosporin A; and (3) reduced intracellular drug accumulation relative to that of drug-sensitive cells.	Verapamil	270-279	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	55-58
7907953-2	1994	Several phenotypic features that are characteristic of MDR have been described; these include (1) resistance to many structurally and functionally unrelated drugs that have different cellular targets and modes of action; (2) reversal of MDR by certain agents, including verapamil and cyclosporin A; and (3) reduced intracellular drug accumulation relative to that of drug-sensitive cells.	Verapamil	270-279	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	237-240
7907953-2	1994	Several phenotypic features that are characteristic of MDR have been described; these include (1) resistance to many structurally and functionally unrelated drugs that have different cellular targets and modes of action; (2) reversal of MDR by certain agents, including verapamil and cyclosporin A; and (3) reduced intracellular drug accumulation relative to that of drug-sensitive cells.	Cyclosporine	284-297	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	55-58
7907953-2	1994	Several phenotypic features that are characteristic of MDR have been described; these include (1) resistance to many structurally and functionally unrelated drugs that have different cellular targets and modes of action; (2) reversal of MDR by certain agents, including verapamil and cyclosporin A; and (3) reduced intracellular drug accumulation relative to that of drug-sensitive cells.	Cyclosporine	284-297	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	237-240
7909724-2	1994	The hybrid cells expressed multidrug resistance (MDR), i.e., resistance to VCR and cross-resistance to Adriamycin (ADM) and actinomycin D (Act.	Doxorubicin	103-113	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	49-52
7909724-2	1994	The hybrid cells expressed multidrug resistance (MDR), i.e., resistance to VCR and cross-resistance to Adriamycin (ADM) and actinomycin D (Act.	Doxorubicin	115-118	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	49-52
7909724-2	1994	The hybrid cells expressed multidrug resistance (MDR), i.e., resistance to VCR and cross-resistance to Adriamycin (ADM) and actinomycin D (Act.	Dactinomycin	124-137	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	49-52
7896537-2	1994	Among 8 compounds tested at nontoxic concentrations, flupentixol, a piperazine-substituted thioxanthene, was the most potent in enhancing the cytotoxicity of anticancer drugs commonly associated with the multidrug resistant (MDR) phenotype, such as Adriamycin, actinomycin D, vinblastine, and vincristine, but not 5-fluorouracil, a drug usually unaffected by MDR.	Flupenthixol	53-64	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	225-228
7896537-2	1994	Among 8 compounds tested at nontoxic concentrations, flupentixol, a piperazine-substituted thioxanthene, was the most potent in enhancing the cytotoxicity of anticancer drugs commonly associated with the multidrug resistant (MDR) phenotype, such as Adriamycin, actinomycin D, vinblastine, and vincristine, but not 5-fluorouracil, a drug usually unaffected by MDR.	Flupenthixol	53-64	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	359-362
7896537-2	1994	Among 8 compounds tested at nontoxic concentrations, flupentixol, a piperazine-substituted thioxanthene, was the most potent in enhancing the cytotoxicity of anticancer drugs commonly associated with the multidrug resistant (MDR) phenotype, such as Adriamycin, actinomycin D, vinblastine, and vincristine, but not 5-fluorouracil, a drug usually unaffected by MDR.	Thioxanthenes	91-103	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	225-228
7896537-2	1994	Among 8 compounds tested at nontoxic concentrations, flupentixol, a piperazine-substituted thioxanthene, was the most potent in enhancing the cytotoxicity of anticancer drugs commonly associated with the multidrug resistant (MDR) phenotype, such as Adriamycin, actinomycin D, vinblastine, and vincristine, but not 5-fluorouracil, a drug usually unaffected by MDR.	Doxorubicin	249-259	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	225-228
7896537-2	1994	Among 8 compounds tested at nontoxic concentrations, flupentixol, a piperazine-substituted thioxanthene, was the most potent in enhancing the cytotoxicity of anticancer drugs commonly associated with the multidrug resistant (MDR) phenotype, such as Adriamycin, actinomycin D, vinblastine, and vincristine, but not 5-fluorouracil, a drug usually unaffected by MDR.	Dactinomycin	261-274	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	225-228
7896537-2	1994	Among 8 compounds tested at nontoxic concentrations, flupentixol, a piperazine-substituted thioxanthene, was the most potent in enhancing the cytotoxicity of anticancer drugs commonly associated with the multidrug resistant (MDR) phenotype, such as Adriamycin, actinomycin D, vinblastine, and vincristine, but not 5-fluorouracil, a drug usually unaffected by MDR.	Vinblastine	276-287	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	225-228
7896537-2	1994	Among 8 compounds tested at nontoxic concentrations, flupentixol, a piperazine-substituted thioxanthene, was the most potent in enhancing the cytotoxicity of anticancer drugs commonly associated with the multidrug resistant (MDR) phenotype, such as Adriamycin, actinomycin D, vinblastine, and vincristine, but not 5-fluorouracil, a drug usually unaffected by MDR.	Vincristine	293-304	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	225-228
7896537-2	1994	Among 8 compounds tested at nontoxic concentrations, flupentixol, a piperazine-substituted thioxanthene, was the most potent in enhancing the cytotoxicity of anticancer drugs commonly associated with the multidrug resistant (MDR) phenotype, such as Adriamycin, actinomycin D, vinblastine, and vincristine, but not 5-fluorouracil, a drug usually unaffected by MDR.	Fluorouracil	314-328	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	225-228
7903303-0	1993	Targeted disruption of the mouse mdr1b gene reveals that steroid hormones enhance mdr gene expression.	Steroids	57-73	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	33-38
7903303-3	1993	1) The expression of mdr1b is enhanced by steroid hormones, in a feedback regulatory mechanism.	Steroids	42-58	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	21-26
7903303-4	1993	Inhibition of steroid biosynthesis by 2-aminoglutethimide blocks the adrenocorticotropin (ACTH)-induced increase in mdr1b mRNA levels.	Steroids	14-21	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	116-121
7903303-4	1993	Inhibition of steroid biosynthesis by 2-aminoglutethimide blocks the adrenocorticotropin (ACTH)-induced increase in mdr1b mRNA levels.	2-aminoglutethimide	38-57	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	116-121
7903303-6	1993	This decreased steroid secretion in the mutant cells occurs despite an increase in the levels of mdr1b mRNA and P-glycoprotein.	Steroids	15-22	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	97-102
7912874-1	1993	Human multidrug resistance gene (mdr1) was introduced into mouse embryonic stem cells (ES-5 line) by calcium phosphate mediated transfection, and transfected ES-5 cells were then selected by stepwise increase in colchicine concentration (30, 50, 100, and 200 ng/ml respectively).	calcium phosphate	101-118	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	33-37
7912874-1	1993	Human multidrug resistance gene (mdr1) was introduced into mouse embryonic stem cells (ES-5 line) by calcium phosphate mediated transfection, and transfected ES-5 cells were then selected by stepwise increase in colchicine concentration (30, 50, 100, and 200 ng/ml respectively).	Colchicine	212-222	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	33-37
8287370-0	1993	Inhibition of MDR1 gene expression by H-87, a selective inhibitor of cAMP-dependent protein kinase.	N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide	38-42	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	14-18
7901220-3	1993	Domain mapping, utilizing a combination of cyanogen bromide digestion and immunoblot analysis, was used to reveal the major phosphorylation sites in murine mdr1b P-glycoprotein.	Cyanogen Bromide	43-59	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	156-161
8104940-2	1993	This dye extrusion is blocked by competing substrates and inhibitors of the multidrug transporters, e.g. by verapamil, vincristine, sodium orthovanadate, oligomycin, and a monoclonal anti-MDR1 antibody.	Vincristine	119-130	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	188-192
8104940-2	1993	This dye extrusion is blocked by competing substrates and inhibitors of the multidrug transporters, e.g. by verapamil, vincristine, sodium orthovanadate, oligomycin, and a monoclonal anti-MDR1 antibody.	Sodium orthovanadate	132-152	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	188-192
8103679-8	1993	While introducing tyrosine, tryptophan, or aspartic acid caused an almost complete loss of colchicine and adriamycin resistance in both mdr1 and mdr3, the replacement to tyrosine or tryptophan had the opposite effect on mdr1 and mdr3 for actinomycin D resistance, causing either a 3-fold increase or a 4-8-fold decrease in resistance to this drug, respectively.	Tryptophan	182-192	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	220-224
8103679-1	1993	The serine residue located at position 939 and 941 in the predicted transmembrane segment 11 of P-glycoprotein (P-gp) encoded by mouse mdr3 and mdr1, respectively, appears to be important for interaction of chemotherapeutic drugs and reversal agents with P-gp.	Serine	4-10	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	144-148
8103679-2	1993	To further understand the role of this residue in this process and to identify the structural requirements involved, we have replaced this serine residue by alanine, cysteine, threonine, tyrosine, tryptophan, and aspartic acid and tested the effect of these mutations on the overall activity and substrate specificity of mdr1 and mdr3.	Serine	139-145	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	321-325
8103679-4	1993	All introduced mutations had limited effect on the capacity of mdr1 and mdr3 to confer resistance to vinblastine.	Vinblastine	101-112	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	63-67
8103679-8	1993	While introducing tyrosine, tryptophan, or aspartic acid caused an almost complete loss of colchicine and adriamycin resistance in both mdr1 and mdr3, the replacement to tyrosine or tryptophan had the opposite effect on mdr1 and mdr3 for actinomycin D resistance, causing either a 3-fold increase or a 4-8-fold decrease in resistance to this drug, respectively.	Tyrosine	18-26	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	136-140
8103679-8	1993	While introducing tyrosine, tryptophan, or aspartic acid caused an almost complete loss of colchicine and adriamycin resistance in both mdr1 and mdr3, the replacement to tyrosine or tryptophan had the opposite effect on mdr1 and mdr3 for actinomycin D resistance, causing either a 3-fold increase or a 4-8-fold decrease in resistance to this drug, respectively.	Tyrosine	18-26	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	220-224
8103679-8	1993	While introducing tyrosine, tryptophan, or aspartic acid caused an almost complete loss of colchicine and adriamycin resistance in both mdr1 and mdr3, the replacement to tyrosine or tryptophan had the opposite effect on mdr1 and mdr3 for actinomycin D resistance, causing either a 3-fold increase or a 4-8-fold decrease in resistance to this drug, respectively.	Tryptophan	28-38	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	136-140
8103679-8	1993	While introducing tyrosine, tryptophan, or aspartic acid caused an almost complete loss of colchicine and adriamycin resistance in both mdr1 and mdr3, the replacement to tyrosine or tryptophan had the opposite effect on mdr1 and mdr3 for actinomycin D resistance, causing either a 3-fold increase or a 4-8-fold decrease in resistance to this drug, respectively.	Aspartic Acid	43-56	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	136-140
8103679-8	1993	While introducing tyrosine, tryptophan, or aspartic acid caused an almost complete loss of colchicine and adriamycin resistance in both mdr1 and mdr3, the replacement to tyrosine or tryptophan had the opposite effect on mdr1 and mdr3 for actinomycin D resistance, causing either a 3-fold increase or a 4-8-fold decrease in resistance to this drug, respectively.	Aspartic Acid	43-56	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	220-224
8103679-8	1993	While introducing tyrosine, tryptophan, or aspartic acid caused an almost complete loss of colchicine and adriamycin resistance in both mdr1 and mdr3, the replacement to tyrosine or tryptophan had the opposite effect on mdr1 and mdr3 for actinomycin D resistance, causing either a 3-fold increase or a 4-8-fold decrease in resistance to this drug, respectively.	Doxorubicin	106-116	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	136-140
7682843-1	1993	The substitution of a single serine to phenylalanine residue within the predicted transmembrane domain 11 of P-glycoproteins (P-gps) encoded by mouse mdr1 (Ser941, 1S;Phe941, 1F) or mdr3 (Ser939, 3S; Phe939, 3F) strongly modulates both the overall activity and substrate specificity of the two P-gps.	Serine	29-35	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	150-154
7682843-1	1993	The substitution of a single serine to phenylalanine residue within the predicted transmembrane domain 11 of P-glycoproteins (P-gps) encoded by mouse mdr1 (Ser941, 1S;Phe941, 1F) or mdr3 (Ser939, 3S; Phe939, 3F) strongly modulates both the overall activity and substrate specificity of the two P-gps.	Phenylalanine	39-52	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	150-154
8101516-8	1993	In addition, the gene for the calcium-binding protein, sorcin, was coamplified in eight of the nine MDR sublines.	Calcium	30-37	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	100-103
1371401-2	1992	Hamster cells transfected with and overexpressing mouse mdr1 or mouse mdr3 exhibit high levels of resistance to TPP+ and TPA+ (20-fold) and somewhat lower levels of resistance to TPMP+ and DDP+ (3-12-fold).	tetraphenylporphine sulfonate	112-116	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	56-60
7903407-1	1993	The effect of multidrug-resistant P-glycoprotein gene expression (MDR1) in 3T3 cells on cellular concentrations and cytotoxicity induced by the photodynamic agent chloroaluminum tetrasulfonate phthalocyanine (AlSPc) was evaluated.	chloroaluminum tetrasulfonate phthalocyanine	163-207	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	66-70
1352414-2	1992	When mice transplanted with bone marrow cells containing a transferred MDR1 gene were treated with the cytotoxic drug taxol, a substantial enrichment for transduced bone marrow cells was observed.	Paclitaxel	118-123	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	71-75
1371401-2	1992	Hamster cells transfected with and overexpressing mouse mdr1 or mouse mdr3 exhibit high levels of resistance to TPP+ and TPA+ (20-fold) and somewhat lower levels of resistance to TPMP+ and DDP+ (3-12-fold).	Tetradecanoylphorbol Acetate	121-124	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	56-60
1371401-2	1992	Hamster cells transfected with and overexpressing mouse mdr1 or mouse mdr3 exhibit high levels of resistance to TPP+ and TPA+ (20-fold) and somewhat lower levels of resistance to TPMP+ and DDP+ (3-12-fold).	triphenylmethylphosphonium	179-184	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	56-60
1371401-2	1992	Hamster cells transfected with and overexpressing mouse mdr1 or mouse mdr3 exhibit high levels of resistance to TPP+ and TPA+ (20-fold) and somewhat lower levels of resistance to TPMP+ and DDP+ (3-12-fold).	ddp	189-192	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	56-60
1371401-3	1992	Transfected cell clones expressing mdr1 or mdr3 mutants with decreased activity against drugs of the MDR spectrum (e.g., Vinca alkaloids and anthracyclines) also show reduced resistance to lipophilic cations.	Vinca Alkaloids	121-136	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	35-39
1371401-3	1992	Transfected cell clones expressing mdr1 or mdr3 mutants with decreased activity against drugs of the MDR spectrum (e.g., Vinca alkaloids and anthracyclines) also show reduced resistance to lipophilic cations.	Anthracyclines	141-155	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	35-39
1371401-4	1992	Studies with radiolabeled TPP+ and TPA+ demonstrate that increased resistance to cytotoxic concentrations of these lipophilic cations is correlated quantitatively with a decrease in intracellular accumulation in mdr1- and mdr3-transfected cells.	tetraphenylporphine sulfonate	26-29	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	212-216
1371401-4	1992	Studies with radiolabeled TPP+ and TPA+ demonstrate that increased resistance to cytotoxic concentrations of these lipophilic cations is correlated quantitatively with a decrease in intracellular accumulation in mdr1- and mdr3-transfected cells.	Tetradecanoylphorbol Acetate	35-38	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	212-216
1737094-7	1992	Finally, the chemoprotection afforded by the MDR1 gene could readily be reversed by adding chemosensitizers such as cyclosporin A and R-verapamil to chemotherapy.	Cyclosporine	116-129	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	45-49
1737094-7	1992	Finally, the chemoprotection afforded by the MDR1 gene could readily be reversed by adding chemosensitizers such as cyclosporin A and R-verapamil to chemotherapy.	Verapamil	134-145	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	45-49
1356238-4	1992	Moreover, hybridization of mRNA from vincristine resistant cells with radiolabeled MDR1 cDNA probe gave evidence about the expression of MDR1 gene.	Vincristine	37-48	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	83-87
1356238-4	1992	Moreover, hybridization of mRNA from vincristine resistant cells with radiolabeled MDR1 cDNA probe gave evidence about the expression of MDR1 gene.	Vincristine	37-48	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	137-141
1357667-4	1992	Clones have been isolated by exposure of the retrovirally transfected cells (MDR producer cells) to colchicine (60 ng/ml), a selective agent that kills MDR-negative cells.	Colchicine	100-110	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	77-80
1357667-4	1992	Clones have been isolated by exposure of the retrovirally transfected cells (MDR producer cells) to colchicine (60 ng/ml), a selective agent that kills MDR-negative cells.	Colchicine	100-110	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	152-155
1357667-5	1992	Flow cytometry analysis (fluorescence-activated cell sorting) with an antibody to MDR demonstrates expression of human MDR protein on the surface of these colchicine-resistant producer clones.	Colchicine	155-165	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	82-85
1357667-5	1992	Flow cytometry analysis (fluorescence-activated cell sorting) with an antibody to MDR demonstrates expression of human MDR protein on the surface of these colchicine-resistant producer clones.	Colchicine	155-165	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	119-122
1357667-12	1992	In addition, the bone marrow cells of several mice initially positive for MDR gene by PCR, and subsequently negative, were exposed to taxol, a drug whose detoxification depends on MDR gene expression; a positive signal was obtained in all of these mice, indicating drug selection of MDR-positive marrow cells.	Paclitaxel	134-139	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	74-77
1357667-12	1992	In addition, the bone marrow cells of several mice initially positive for MDR gene by PCR, and subsequently negative, were exposed to taxol, a drug whose detoxification depends on MDR gene expression; a positive signal was obtained in all of these mice, indicating drug selection of MDR-positive marrow cells.	Paclitaxel	134-139	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	180-183
1357667-12	1992	In addition, the bone marrow cells of several mice initially positive for MDR gene by PCR, and subsequently negative, were exposed to taxol, a drug whose detoxification depends on MDR gene expression; a positive signal was obtained in all of these mice, indicating drug selection of MDR-positive marrow cells.	Paclitaxel	134-139	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	180-183
1357667-13	1992	Cell sorting studies of these mice also show an increased number of high-MDR-expressing marrow cells, selected after exposure to taxol.	Paclitaxel	129-134	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	73-76
1357667-14	1992	Thus, in this live animal model MDR transduction is effective in selecting a human MDR-expressing population of marrow cells resistant to taxol chemotherapy.	Paclitaxel	138-143	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	32-35
1357667-14	1992	Thus, in this live animal model MDR transduction is effective in selecting a human MDR-expressing population of marrow cells resistant to taxol chemotherapy.	Paclitaxel	138-143	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	83-86
1363885-0	1992	Down-regulation of ras and myc expression associated with mdr-1 overexpression in adriamycin-resistant tumor cells.	Doxorubicin	82-92	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	58-63
1352702-2	1992	While the mdr1 and mdr3F clones confer comparable levels of vinblastine (VBL) resistance, mdr3F confers actinomycin D (ACT) resistance levels 2-fold greater than mdr1, while mdr1 confers resistance to colchicine at levels 7-fold greater than mdr3F.	Vinblastine	60-71	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	10-14
1675425-1	1991	We show that D- but not L-hexoses modulate the accumulation of radioactive vinblastine in injected Xenopus laevis oocytes expressing the murine Mdr1b P-glycoprotein.	Vinblastine	75-86	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	144-149
1678520-2	1991	We have introduced a single Ser----Phe substitution within the predicted TM11 domain of mdr1 (position 941) and mdr3 (position 939) and analyzed the effect of these substitutions on the drug-resistance profiles of these two proteins.	Serine	28-31	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	88-92
1678520-2	1991	We have introduced a single Ser----Phe substitution within the predicted TM11 domain of mdr1 (position 941) and mdr3 (position 939) and analyzed the effect of these substitutions on the drug-resistance profiles of these two proteins.	Phenylalanine	35-38	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	88-92
1678520-4	1991	The modulating effect of this mutation on mdr1 and mdr3 varied for the drugs tested: it was very strong for colchicine and adriamycin and moderate for vinblastine.	Colchicine	108-118	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	42-46
1678520-4	1991	The modulating effect of this mutation on mdr1 and mdr3 varied for the drugs tested: it was very strong for colchicine and adriamycin and moderate for vinblastine.	Doxorubicin	123-133	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	42-46
1678520-4	1991	The modulating effect of this mutation on mdr1 and mdr3 varied for the drugs tested: it was very strong for colchicine and adriamycin and moderate for vinblastine.	Vinblastine	151-162	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	42-46
1678520-5	1991	For mdr1, the Ser941----Phe941 substitution produced a unique mutant protein that retained the capacity to confer vinblastine resistance but lost the ability to confer adriamycin and colchicine resistance.	Vinblastine	114-125	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	4-8
1678520-5	1991	For mdr1, the Ser941----Phe941 substitution produced a unique mutant protein that retained the capacity to confer vinblastine resistance but lost the ability to confer adriamycin and colchicine resistance.	Doxorubicin	168-178	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	4-8
1678520-5	1991	For mdr1, the Ser941----Phe941 substitution produced a unique mutant protein that retained the capacity to confer vinblastine resistance but lost the ability to confer adriamycin and colchicine resistance.	Colchicine	183-193	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	4-8
1868977-3	1991	Transgenic mice that express the MDR1 gene in their bone marrow have been developed, and because of this expression these mice are resistant to the bone marrow-suppressive effects of daunomycin, doxorubicin, taxol, and several other anticancer drugs.	Daunorubicin	183-193	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	33-37
1868977-3	1991	Transgenic mice that express the MDR1 gene in their bone marrow have been developed, and because of this expression these mice are resistant to the bone marrow-suppressive effects of daunomycin, doxorubicin, taxol, and several other anticancer drugs.	Doxorubicin	195-206	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	33-37
1868977-3	1991	Transgenic mice that express the MDR1 gene in their bone marrow have been developed, and because of this expression these mice are resistant to the bone marrow-suppressive effects of daunomycin, doxorubicin, taxol, and several other anticancer drugs.	Paclitaxel	208-213	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	33-37
2069718-2	1991	It has been reported that 2,3,6,7-tetrachlorodibenzo-p-dioxin (TCDD) might increase hepatic MDR transcripts in the Fischer rat and the C57BL/6 (B6) inbred mouse strain having the high-affinity aromatic hydrocarbon (Ah) receptor, but not in the DBA/2 (D2) strain having the low-affinity Ah receptor.	2,3,6,7-tetrachlorodibenzo-p-dioxin	26-61	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	92-95
2069718-2	1991	It has been reported that 2,3,6,7-tetrachlorodibenzo-p-dioxin (TCDD) might increase hepatic MDR transcripts in the Fischer rat and the C57BL/6 (B6) inbred mouse strain having the high-affinity aromatic hydrocarbon (Ah) receptor, but not in the DBA/2 (D2) strain having the low-affinity Ah receptor.	Polychlorinated Dibenzodioxins	63-67	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	92-95
2069718-3	1991	These intriguing results suggest that TCDD might activate MDR gene expression by way of an Ah receptor-mediated signal transduction pathway.	Polychlorinated Dibenzodioxins	38-42	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	58-61
2069718-9	1991	Therefore, we conclude that any effects that TCDD might have on MDR expression must be substantially different from TCDD effects on genes known to be induced via the Ah receptor.	Polychlorinated Dibenzodioxins	45-49	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	64-67
1675425-3	1991	Cytochalasin B and phloretin, two inhibitors of the mammalian facilitative glucose transporters, can overcome the reduced drug accumulation conferred by expression of the rat GLUT1 protein in Xenopus oocytes but have no significant effect on the accumulation of drug by Xenopus oocytes expressing the mouse Mdr1b P-glycoprotein.	Cytochalasin B	0-14	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	307-312
1677815-11	1991	In situ hybridization revealed that injected recombinant myocytes remain in discrete foci in adult rodent skeletal muscle and express MDR1 mRNA for at least 30 days in nude mice and cyclosporine-treated rats.	Cyclosporine	182-194	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	134-138
1671863-3	1991	A domain by domain comparison of this protein with p-glycoproteins capable of supporting multidrug resistance, i.e. human mdr1, mouse mdr1/mdr1b, and mouse mdr3/mdr1a, shows that, in addition to the ATP binding sites, the second, fourth, and eleventh transmembrane domains and the four small intracellular loops, IC-1, IC-2, IC-4, and IC-5, are highly conserved and are therefore likely to be important for the maintenance of p-glycoprotein function.	Adenosine Triphosphate	199-202	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	134-138
1676579-0	1991	Time course of MDR gene amplification during in vivo selection for doxorubicin-resistance and during reversal in murine leukemia L 1210.	Doxorubicin	67-78	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	15-18
1676579-1	1991	MDR gene expression in murine leukemia L 1210 cells was investigated during treatment in vivo with 0.5 mg doxorubicin/kg body weight (BW).	Doxorubicin	106-117	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	0-3
2304382-1	1990	Two vinblastine-resistant sublines of the murine macrophage-like cell line J774.2, J7.V1-1 and J7.V3-1, overproduce unique forms of P-glycoprotein that are encoded by distinct mdr genes, mdr1b and mdr1a, respectively.	Vinblastine	4-15	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	187-192
1671173-6	1991	The resistance conferred by the MDR1 gene can be circumvented in a dose-dependent manner by simultaneous administration of agents previously shown to be inhibitors of the multidrug transporter in vitro, including verapamil isomers, quinidine, and quinine.	Verapamil	213-222	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	32-36
1671173-6	1991	The resistance conferred by the MDR1 gene can be circumvented in a dose-dependent manner by simultaneous administration of agents previously shown to be inhibitors of the multidrug transporter in vitro, including verapamil isomers, quinidine, and quinine.	Quinidine	232-241	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	32-36
1671173-6	1991	The resistance conferred by the MDR1 gene can be circumvented in a dose-dependent manner by simultaneous administration of agents previously shown to be inhibitors of the multidrug transporter in vitro, including verapamil isomers, quinidine, and quinine.	Quinine	247-254	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	32-36
1675425-3	1991	Cytochalasin B and phloretin, two inhibitors of the mammalian facilitative glucose transporters, can overcome the reduced drug accumulation conferred by expression of the rat GLUT1 protein in Xenopus oocytes but have no significant effect on the accumulation of drug by Xenopus oocytes expressing the mouse Mdr1b P-glycoprotein.	Phloretin	19-28	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	307-312
1972378-5	1990	It is concluded that 1) the mdr1a gene product is a more efficient efflux pump than the mdr1b gene product, and 2) whereas a single class of vinblastine binding sites is present in J7.V1-1 membrane vesicles, there appears to be two classes of such sites in J7.V3-1 membrane vesicles.	Vinblastine	141-152	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	88-93
1968358-8	1990	Furthermore, trans-flupenthixol fully reversed resistance to doxorubicin, vincristine, and colchicine in MDR MCF-7 and NIH 3T3 cells transfected with the mdr1 gene.	(E)-Flupenthixol	13-31	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	154-158
1968358-8	1990	Furthermore, trans-flupenthixol fully reversed resistance to doxorubicin, vincristine, and colchicine in MDR MCF-7 and NIH 3T3 cells transfected with the mdr1 gene.	Doxorubicin	61-72	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	154-158
1968358-8	1990	Furthermore, trans-flupenthixol fully reversed resistance to doxorubicin, vincristine, and colchicine in MDR MCF-7 and NIH 3T3 cells transfected with the mdr1 gene.	Vincristine	74-85	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	154-158
1968358-8	1990	Furthermore, trans-flupenthixol fully reversed resistance to doxorubicin, vincristine, and colchicine in MDR MCF-7 and NIH 3T3 cells transfected with the mdr1 gene.	Colchicine	91-101	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	154-158
1980424-7	1990	Mutational analysis indicates that both predicted ATP binding domains in mdr1 are absolutely essential for biological activity.	Adenosine Triphosphate	50-53	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	73-77
1980424-8	1990	The study of chimeric proteins constructed between biologically active mdr1 and inactive mdr2 indicate that both ATP binding domains of mdr2 are functional and suggest that transmembrane domains of mdr1 are essential for the drug resistance phenotype conferred by this protein.	Adenosine Triphosphate	113-116	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	71-75
1980424-8	1990	The study of chimeric proteins constructed between biologically active mdr1 and inactive mdr2 indicate that both ATP binding domains of mdr2 are functional and suggest that transmembrane domains of mdr1 are essential for the drug resistance phenotype conferred by this protein.	Adenosine Triphosphate	113-116	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	198-202
33810134-3	2021	Previously, we established that avermectin compounds (ivermectin [IVM] and moxidectin) reduce alcohol (ethanol/EtOH) consumption in mice, but these effects are limited by P-glycoprotein (Pgp/ABCB1) efflux.	Ivermectin	54-64	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	191-196
1983720-2	1990	In man and mouse, the MDR 1 (mdr 1) genes confer resistance to relatively hydrophobic cationic anti-cancer drugs (i.e., vinblastin, adriamycin).	Vinblastine	120-130	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	22-27
1983720-2	1990	In man and mouse, the MDR 1 (mdr 1) genes confer resistance to relatively hydrophobic cationic anti-cancer drugs (i.e., vinblastin, adriamycin).	Vinblastine	120-130	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	29-34
1983720-2	1990	In man and mouse, the MDR 1 (mdr 1) genes confer resistance to relatively hydrophobic cationic anti-cancer drugs (i.e., vinblastin, adriamycin).	Doxorubicin	132-142	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	22-27
1983720-2	1990	In man and mouse, the MDR 1 (mdr 1) genes confer resistance to relatively hydrophobic cationic anti-cancer drugs (i.e., vinblastin, adriamycin).	Doxorubicin	132-142	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	29-34
33810134-3	2021	Previously, we established that avermectin compounds (ivermectin [IVM] and moxidectin) reduce alcohol (ethanol/EtOH) consumption in mice, but these effects are limited by P-glycoprotein (Pgp/ABCB1) efflux.	Ivermectin	66-69	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	191-196
33810134-3	2021	Previously, we established that avermectin compounds (ivermectin [IVM] and moxidectin) reduce alcohol (ethanol/EtOH) consumption in mice, but these effects are limited by P-glycoprotein (Pgp/ABCB1) efflux.	moxidectin	75-85	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	191-196
34832869-0	2021	P-Glycoprotein (ABCB1/MDR1) and BCRP (ABCG2) Limit Brain Accumulation and Cytochrome P450-3A (CYP3A) Restricts Oral Exposure of the RET Inhibitor Selpercatinib (RETEVMO).	Selpercatinib	146-159	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	16-21
32164732-6	2020	The modulation of ABCB1 activity was measured by colorimetric ATPase assay and [125I]-iodoarylazidoprazosin (IAAP) photolabeling assay.	azidoprazosin	84-107	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	18-23
32164732-6	2020	The modulation of ABCB1 activity was measured by colorimetric ATPase assay and [125I]-iodoarylazidoprazosin (IAAP) photolabeling assay.	azidoprazosin	109-113	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	18-23
34952136-13	2022	Similar to rifampin, dual-inhibition functions of ritonavir affecting both CYP3A enzymes and enterohepatic Abcb1 transporters enhanced larotrectinib oral availability.	Ritonavir	50-59	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	107-112
34952136-13	2022	Similar to rifampin, dual-inhibition functions of ritonavir affecting both CYP3A enzymes and enterohepatic Abcb1 transporters enhanced larotrectinib oral availability.	larotrectinib	135-148	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	107-112
34730366-0	2021	P-Glycoprotein (ABCB1/MDR1) Controls Brain Penetration and Intestinal Disposition of the PARP1/2 Inhibitor Niraparib.	niraparib	107-116	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	16-21
34730366-0	2021	P-Glycoprotein (ABCB1/MDR1) Controls Brain Penetration and Intestinal Disposition of the PARP1/2 Inhibitor Niraparib.	niraparib	107-116	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	22-26
34613635-4	2022	The reduction in ATP levels and its low affinity for the ABCB1 and ABCG2 transporters (which mediate MDR) significantly increased the retention of RuZ by MDR cancer cells.	Adenosine Triphosphate	17-20	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	57-62
34613635-4	2022	The reduction in ATP levels and its low affinity for the ABCB1 and ABCG2 transporters (which mediate MDR) significantly increased the retention of RuZ by MDR cancer cells.	[(2~{R},3~{S},4~{R},5~{R})-5-[7-azanyl-5-(hydroxymethyl)benzimidazol-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methyl ~{N}-[(2~{S})-2-azanyl-3-oxidanyl-propanoyl]sulfamate	147-150	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	57-62
34952136-2	2022	Here larotrectinib pharmacokinetic behavior upon co-administration with prototypical inhibitors of the efflux transporters ABCB1/ABCG2 (elacridar), the SLCO1A/1B (OATP1A/1B) uptake transporters (rifampin), and the drug-metabolizing enzyme CYP3A (ritonavir), respectively, was investigated.	larotrectinib	5-18	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	123-128
34832869-0	2021	P-Glycoprotein (ABCB1/MDR1) and BCRP (ABCG2) Limit Brain Accumulation and Cytochrome P450-3A (CYP3A) Restricts Oral Exposure of the RET Inhibitor Selpercatinib (RETEVMO).	Selpercatinib	146-159	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	22-26
34832869-6	2021	The ABCB1/ABCG2 inhibitor elacridar boosted selpercatinib brain penetration in wild-type mice to the levels seen in Abcb1a/1b;Abcg2-/- mice.	Selpercatinib	44-57	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	4-9
34116183-7	2021	Importantly several TICs showed potent inhibition of Ta-ABCB1, such as the organochlorine pesticides Endrin (EC50 = 1.2 +- 0.2 muM) and Mirex (EC50 = 2.3 +- 0.9 muM).	Hydrocarbons, Chlorinated	75-89	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	56-61
34834176-0	2021	ABCB1 and ABCG2 Control Brain Accumulation and Intestinal Disposition of the Novel ROS1/TRK/ALK Inhibitor Repotrectinib, While OATP1A/1B, ABCG2, and CYP3A Limit Its Oral Availability.	Repotrectinib	106-119	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	0-5
34834176-10	2021	Collectively, Abcb1 and Abcg2 restrict repotrectinib brain accumulation and possibly toxicity, and control its intestinal disposition.	Repotrectinib	39-52	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	14-19
34116183-8	2021	However, unlike the effects observed on mouse ABCB1, low concentrations of the organochlorine pesticide TICs p,p"-DDT and its metabolite p,p"-DDD co-stimulated verapamil-induced Ta-ABCB1 ATPase activity possibly suggesting a low transport activity for these ligands in tuna.	DDT	109-117	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	181-186
34116183-8	2021	However, unlike the effects observed on mouse ABCB1, low concentrations of the organochlorine pesticide TICs p,p"-DDT and its metabolite p,p"-DDD co-stimulated verapamil-induced Ta-ABCB1 ATPase activity possibly suggesting a low transport activity for these ligands in tuna.	Dichlorodiphenyldichloroethane	137-145	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	181-186
34116183-8	2021	However, unlike the effects observed on mouse ABCB1, low concentrations of the organochlorine pesticide TICs p,p"-DDT and its metabolite p,p"-DDD co-stimulated verapamil-induced Ta-ABCB1 ATPase activity possibly suggesting a low transport activity for these ligands in tuna.	Verapamil	160-169	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	181-186
35040123-8	2022	Furthermore, PAK was colocalized in the mitochondria and initiated mitochondrial injury by selectively inhibiting the mitochondrial complex V. Besides, ABCB1 and ABCC1 were found to be redistributed from the plasma membrane to the cytoplasm through the disruption of lipid rafts, which was attributed to the low energy state and the decrease of cholesterol levels.	Cholesterol	345-356	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	152-157
34452213-0	2021	Folate-Equipped Cationic Liposomes Deliver Anti-MDR1-siRNA to the Tumor and Increase the Efficiency of Chemotherapy.	Folic Acid	0-6	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	48-52
34309393-4	2021	We show that a lead macrocyclic compound DB-60 (20) effectively inhibits the catalytic activity of iP in ABCB1-overexpressing cells (IC50: 105 nM) and has metabolic stability superior to its linear counterpart.	furimidazoline	41-46	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	105-110
34650521-11	2021	However, the skin level of MRI-1867, an MDR1 substrate, was dramatically lower in B6 mice (0.023 microM) than in Mdr1a/b-Bcrp KO mice (8.8 microM) due to a bleomycin-induced increase in efflux activity of MDR1 in fibrotic skin.	Bleomycin	156-165	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	40-44
34650521-11	2021	However, the skin level of MRI-1867, an MDR1 substrate, was dramatically lower in B6 mice (0.023 microM) than in Mdr1a/b-Bcrp KO mice (8.8 microM) due to a bleomycin-induced increase in efflux activity of MDR1 in fibrotic skin.	Bleomycin	156-165	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	205-209
34483846-10	2021	The latter was a consequence of the activated NF-kappaB pathway, stimulating MMP-9 and ABCB1 transporter activity on the luminal side of the endothelium.	Phenobarbital	121-128	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	87-92
2573836-8	1989	However, the ability to bind the photoactivatable ATP analog 8-azido ATP was retained in the five inactive MDR1 mutants.	8-azidoadenosine 5'-triphosphate	61-72	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	107-111
35406579-5	2022	RESULTS: In ID8, cells with a HR proficient background, olaparib resistance was mainly caused by overexpression of multidrug resistance 1 gene (MDR1), while multiple heterogeneous co-existing mechanisms were found in ID8 Brca1-/- HR-deficient cells resistant to olaparib, including overexpression of MDR1, a decrease in PARP1 protein level and partial reactivation of HR repair.	olaparib	56-64	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	144-148
35406579-5	2022	RESULTS: In ID8, cells with a HR proficient background, olaparib resistance was mainly caused by overexpression of multidrug resistance 1 gene (MDR1), while multiple heterogeneous co-existing mechanisms were found in ID8 Brca1-/- HR-deficient cells resistant to olaparib, including overexpression of MDR1, a decrease in PARP1 protein level and partial reactivation of HR repair.	olaparib	56-64	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	300-304
35406579-5	2022	RESULTS: In ID8, cells with a HR proficient background, olaparib resistance was mainly caused by overexpression of multidrug resistance 1 gene (MDR1), while multiple heterogeneous co-existing mechanisms were found in ID8 Brca1-/- HR-deficient cells resistant to olaparib, including overexpression of MDR1, a decrease in PARP1 protein level and partial reactivation of HR repair.	olaparib	262-270	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	144-148
35192958-0	2022	ABCB1 limits brain exposure of the KRASG12C inhibitor sotorasib, whereas ABCB1, CYP3A, and possibly OATP1a/1b restrict its oral availability.	AMG-510	54-63	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	0-5
35192958-5	2022	Upon coadministering elacridar, an ABCB1/ABCG2 inhibitor, sotorasib brain accumulation increased 7.5-fold, approaching the levels observed in Abcb1a/1b-deficient mice.	AMG-510	58-67	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	35-40
2573836-1	1989	In cells stably transfected and overexpressing the mouse mdr1 gene, multidrug resistance is associated with an increased ATP-dependent drug efflux.	Adenosine Triphosphate	121-124	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	57-61
2573836-8	1989	However, the ability to bind the photoactivatable ATP analog 8-azido ATP was retained in the five inactive MDR1 mutants.	Adenosine Triphosphate	50-53	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	107-111
35083640-6	2022	The fetal-to-maternal plasma concentration ratio of digoxin was only marginally affected in Mdr1a-/-/Mdr1b-/- mice, while that of paclitaxel showed a several-fold increase.	Digoxin	52-59	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	101-106
35083640-8	2022	The impact per single MDR1 molecule on the fetal distribution of digoxin was calculated to be much lower than that on the brain distribution, but this was not the case for paclitaxel.	Digoxin	65-72	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	22-26
35083640-10	2022	CONCLUSION: Our findings indicate that murine placental MDR1 has a minimal influence on the fetal concentration of certain substrates, such as digoxin, due to bypass transfer, probably via connexin26 gap junctions.	Digoxin	143-150	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	56-60
35022006-0	2022	Panax notoginseng saponins reverse P-gp-mediated steroid resistance in lupus: involvement in the suppression of the SIRT1/FoxO1/MDR1 signalling pathway in lymphocytes.	Saponins	18-26	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	128-132
2790781-1	1989	Resistance to Adriamycin (ADR) is frequently dependent upon enhanced efflux associated with the expression of the MDR1-encoded P membrane glycoprotein.	Doxorubicin	14-24	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	114-118
2565763-4	1989	This protein was present in membrane enriched fractions and could be metabolically labeled with [3H )glucosamine, confirming that the transfected mdr1 gene encodes a membrane glycoprotein.	Tritium	96-101	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	146-150
2473069-6	1989	This same correlation was observed in a single cell line during the course of stepwise selection for resistance to vinblastine in which a switch in gene expression from mdr1b to mdr1a resulted in a switch from the 125- to 120-kDa P-glycoprotein precursor.	Vinblastine	115-126	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	169-174
2567301-2	1989	NIH3T3 cells expressing a transfected MDR1 gene (NIH3T3-MDR) were treated with vinblastine or daunomycin.	Vinblastine	79-90	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	38-42
2567301-2	1989	NIH3T3 cells expressing a transfected MDR1 gene (NIH3T3-MDR) were treated with vinblastine or daunomycin.	Daunorubicin	94-104	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	38-42
2565763-4	1989	This protein was present in membrane enriched fractions and could be metabolically labeled with [3H )glucosamine, confirming that the transfected mdr1 gene encodes a membrane glycoprotein.	Glucosamine	101-112	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	146-150
34051306-0	2021	Roflumilast ameliorates cognitive deficits in a mouse model of amyloidogenesis and tauopathy: Involvement of nitric oxide status, Abeta extrusion transporter ABCB1, and reversal by PKA inhibitor H89.	Roflumilast	0-11	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	158-163
2825978-7	1988	Coincubation with forskolin partially reversed doxorubicin resistance in the MDR lines in a dose-dependent fashion.	Colforsin	18-27	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	77-80
2825978-7	1988	Coincubation with forskolin partially reversed doxorubicin resistance in the MDR lines in a dose-dependent fashion.	Doxorubicin	47-58	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	77-80
2825978-9	1988	Incubation with DF resulted in no elevation of cAMP levels in the sensitive or resistant cell lines; however, DF also partially reversed doxorubicin resistance in the MDR variants.	Doxorubicin	137-148	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	167-170
33172753-1	2021	ABCB1 (P-glycoprotein/MDR1) is a multidrug efflux transporter that has previously been involved in cholesterol and vitamin D metabolism.	Vitamin D	115-124	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	0-5
33948561-8	2021	Inhibition of ABCB1 was mediated by vardenafil, and TWIST1 expression was reduced by either Harmine or shRNA.	Vardenafil Dihydrochloride	36-46	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	14-19
33172753-1	2021	ABCB1 (P-glycoprotein/MDR1) is a multidrug efflux transporter that has previously been involved in cholesterol and vitamin D metabolism.	Vitamin D	115-124	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	22-26
33172753-2	2021	Our aim was to explore whether ABCB1 is also involved in vitamin K efflux.	Vitamin K	57-66	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	31-36
33172753-4	2021	In vivo, the vitamin K postprandial response was higher in male Abcb1-/- mice after gavage compared to control animals (+115%; p < 0.05), but was unchanged in female mice.	Vitamin K	13-22	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	64-69
33172753-6	2021	Overall, we showed for the first time that ABCB1 is involved in enterocyte vitamin K efflux in both cell and mouse models and regulates vitamin K absorption in mice.	Vitamin K	75-84	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	43-48
33172753-6	2021	Overall, we showed for the first time that ABCB1 is involved in enterocyte vitamin K efflux in both cell and mouse models and regulates vitamin K absorption in mice.	Vitamin K	136-145	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	43-48
33524505-0	2021	The role of drug efflux and uptake transporters ABCB1 (P-gp), ABCG2 (BCRP) and OATP1A/1B and of CYP3A4 in the pharmacokinetics of the CDK inhibitor milciclib.	Milciclib	148-157	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	48-53
33524505-5	2021	Milciclib showed good brain penetration even in wild-type mice (brain-to-plasma ratio of 1.2), but this was further increased by 5.2-fold when both Abcb1 and Abcg2 were ablated, and to a lesser extent in single Abcb1- or Abcg2-deficient mice.	Milciclib	0-9	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	211-216
33785654-0	2021	ABCB1 and ABCG2 restrict brain and testis accumulation and, alongside CYP3A, limit oral availability of the novel TRK inhibitor selitrectinib.	Selitrectinib	128-141	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	0-5
33172753-0	2021	P-glycoprotein (ABCB1) is involved in vitamin K efflux.	Vitamin K	38-47	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	16-21
33172753-1	2021	ABCB1 (P-glycoprotein/MDR1) is a multidrug efflux transporter that has previously been involved in cholesterol and vitamin D metabolism.	Cholesterol	99-110	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	0-5
33172753-1	2021	ABCB1 (P-glycoprotein/MDR1) is a multidrug efflux transporter that has previously been involved in cholesterol and vitamin D metabolism.	Cholesterol	99-110	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	22-26
33392922-10	2021	Interestingly, the use of FO alongwith 5-FU also significantly declined the expression of drug transporters (ABCB1,ABCC5) and consequently resulted in an increased cellular uptake of 5-FU and its metabolite, 5-FdUMP at target site (colon).	Fluorouracil	39-43	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	109-114
32395078-0	2020	Oncogenic Ras downregulates mdr1b expression through generation of reactive oxygen species.	Reactive Oxygen Species	67-90	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	28-33
33488977-2	2021	Starting from a literature-reported M1 antagonist, linker replacement and structure-activity relationship investigations of the eastern 1-(pyridinyl)piperazine led to the identification of a novel, potent, and selective antagonist with good MDCKII-MDR1 permeability.	1-(pyridinyl)piperazine	136-159	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	248-252
33335181-0	2020	MEK reduces cancer-specific PpIX accumulation through the RSK-ABCB1 and HIF-1alpha-FECH axes.	protoporphyrin IX	28-32	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	62-67
33335181-2	2020	We previously reported that inhibition of oncogenic Ras/MEK increases PpIX accumulation in cancer cells by reducing PpIX efflux through ATP-binding cassette sub-family B member 1 (ABCB1) and ferrochelatase (FECH)-catalysed PpIX conversion to haem.	protoporphyrin IX	70-74	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	136-178
33335181-2	2020	We previously reported that inhibition of oncogenic Ras/MEK increases PpIX accumulation in cancer cells by reducing PpIX efflux through ATP-binding cassette sub-family B member 1 (ABCB1) and ferrochelatase (FECH)-catalysed PpIX conversion to haem.	protoporphyrin IX	70-74	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	180-185
33335181-2	2020	We previously reported that inhibition of oncogenic Ras/MEK increases PpIX accumulation in cancer cells by reducing PpIX efflux through ATP-binding cassette sub-family B member 1 (ABCB1) and ferrochelatase (FECH)-catalysed PpIX conversion to haem.	protoporphyrin IX	116-120	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	136-178
33335181-2	2020	We previously reported that inhibition of oncogenic Ras/MEK increases PpIX accumulation in cancer cells by reducing PpIX efflux through ATP-binding cassette sub-family B member 1 (ABCB1) and ferrochelatase (FECH)-catalysed PpIX conversion to haem.	protoporphyrin IX	116-120	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	180-185
33335181-2	2020	We previously reported that inhibition of oncogenic Ras/MEK increases PpIX accumulation in cancer cells by reducing PpIX efflux through ATP-binding cassette sub-family B member 1 (ABCB1) and ferrochelatase (FECH)-catalysed PpIX conversion to haem.	protoporphyrin IX	116-120	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	136-178
33335181-2	2020	We previously reported that inhibition of oncogenic Ras/MEK increases PpIX accumulation in cancer cells by reducing PpIX efflux through ATP-binding cassette sub-family B member 1 (ABCB1) and ferrochelatase (FECH)-catalysed PpIX conversion to haem.	protoporphyrin IX	116-120	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	180-185
33335181-3	2020	Here, we sought to identify the downstream pathways of Ras/MEK involved in the regulation of PpIX accumulation via ABCB1 and FECH.	protoporphyrin IX	93-97	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	115-120
32934734-0	2020	Emodin alleviates gemcitabine resistance in pancreatic cancer by inhibiting MDR1/P-glycoprotein and MRPs expression.	Emodin	0-6	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	76-80
32934734-0	2020	Emodin alleviates gemcitabine resistance in pancreatic cancer by inhibiting MDR1/P-glycoprotein and MRPs expression.	gemcitabine	18-29	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	76-80
32934734-14	2020	Taken together, these results demonstrated that emodin enhanced gemcitabine efficacy in tumor treatment and alleviated gemcitabine resistance in PANC-1 cell xenografts in mice via suppressing MDR1/P-glycoprotein and MRP expression.	Emodin	48-54	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	192-196
33080008-3	2020	Using a library of more than 5700 bioactive compounds, we screened for approaches that could sensitize AML cells to birinapant and identified multidrug resistance protein 1 inhibitors (MDR1i) as a class of clinically approved drugs that can enhance the efficacy of SM therapy.	Samarium	265-267	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	142-172
33080008-4	2020	Genetic or pharmacological inhibition of MDR1 increased intracellular levels of birinapant and sensitized AML cells from leukemia murine models, human leukemia cell lines, and primary AML samples to killing by birinapant.	birinapant	80-90	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	41-45
33080008-4	2020	Genetic or pharmacological inhibition of MDR1 increased intracellular levels of birinapant and sensitized AML cells from leukemia murine models, human leukemia cell lines, and primary AML samples to killing by birinapant.	birinapant	210-220	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	41-45
32960603-7	2020	Furthermore, cedrol reduced the expression of proteins associated with drug resistance, including O6-methlyguanine-DNA-methyltransferase (MGMT), multidrug resistance protein 1 (MDR1), and CD133 in TMZ-treated GBM cells.	cedrol	13-19	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	145-175
32960603-7	2020	Furthermore, cedrol reduced the expression of proteins associated with drug resistance, including O6-methlyguanine-DNA-methyltransferase (MGMT), multidrug resistance protein 1 (MDR1), and CD133 in TMZ-treated GBM cells.	cedrol	13-19	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	177-181
33081568-0	2021	Complete inhibition of ABCB1 and ABCG2 at the blood-brain barrier by co-infusion of erlotinib and tariquidar to improve brain delivery of the model ABCB1/ABCG2 substrate [11C]erlotinib.	Erlotinib Hydrochloride	84-93	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	23-28
33081568-0	2021	Complete inhibition of ABCB1 and ABCG2 at the blood-brain barrier by co-infusion of erlotinib and tariquidar to improve brain delivery of the model ABCB1/ABCG2 substrate [11C]erlotinib.	Erlotinib Hydrochloride	84-93	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	148-153
33081568-0	2021	Complete inhibition of ABCB1 and ABCG2 at the blood-brain barrier by co-infusion of erlotinib and tariquidar to improve brain delivery of the model ABCB1/ABCG2 substrate [11C]erlotinib.	tariquidar	98-108	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	23-28
33081568-0	2021	Complete inhibition of ABCB1 and ABCG2 at the blood-brain barrier by co-infusion of erlotinib and tariquidar to improve brain delivery of the model ABCB1/ABCG2 substrate [11C]erlotinib.	tariquidar	98-108	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	148-153
33081568-0	2021	Complete inhibition of ABCB1 and ABCG2 at the blood-brain barrier by co-infusion of erlotinib and tariquidar to improve brain delivery of the model ABCB1/ABCG2 substrate [11C]erlotinib.	Erlotinib Hydrochloride	175-184	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	23-28
33081568-0	2021	Complete inhibition of ABCB1 and ABCG2 at the blood-brain barrier by co-infusion of erlotinib and tariquidar to improve brain delivery of the model ABCB1/ABCG2 substrate [11C]erlotinib.	Erlotinib Hydrochloride	175-184	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	148-153
33081568-4	2021	co-infusion of erlotinib and tariquidar by studying brain distribution of the model ABCB1/ABCG2 substrate [11C]erlotinib in mice and rhesus macaques with PET.	Erlotinib Hydrochloride	15-24	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	84-89
33081568-4	2021	co-infusion of erlotinib and tariquidar by studying brain distribution of the model ABCB1/ABCG2 substrate [11C]erlotinib in mice and rhesus macaques with PET.	tariquidar	29-39	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	84-89
33081568-4	2021	co-infusion of erlotinib and tariquidar by studying brain distribution of the model ABCB1/ABCG2 substrate [11C]erlotinib in mice and rhesus macaques with PET.	Erlotinib Hydrochloride	111-120	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	84-89
33081568-9	2021	Co-infusion of erlotinib/tariquidar may potentially allow for complete ABCB1/ABCG2 inhibition at the BBB, while simultaneously achieving brain-targeted EGFR inhibition.	Erlotinib Hydrochloride	15-24	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	71-76
33081568-9	2021	Co-infusion of erlotinib/tariquidar may potentially allow for complete ABCB1/ABCG2 inhibition at the BBB, while simultaneously achieving brain-targeted EGFR inhibition.	tariquidar	25-35	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	71-76
32087611-0	2020	OATP1A/1B, CYP3A, ABCB1, and ABCG2 limit oral availability of NTRK inhibitor larotrectinib, while ABCB1 and ABCG2 also restrict its brain accumulation.	larotrectinib	77-90	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	18-23
32087611-10	2020	CONCLUSIONS AND IMPLICATIONS: ABCG2 and especially ABCB1 limit the oral availability and brain and testis penetration of larotrectinib, while OATP1A/1B transporters restrict its systemic exposure by mediating hepatic uptake, thus allowing hepatobiliary excretion.	larotrectinib	121-134	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	51-56
32525624-8	2020	Furthermore, sitravatinib inhibited hydrolysis of ATP and synchronously decreased the efflux function of ABCB1.	sitravatinib	13-25	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	105-110
32525624-11	2020	More importantly, sitravatinib could remarkably restore the antitumor activity of vincristine in ABCB1-mediated xenograft model without observable toxic effect.	sitravatinib	18-30	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	97-102
32525624-11	2020	More importantly, sitravatinib could remarkably restore the antitumor activity of vincristine in ABCB1-mediated xenograft model without observable toxic effect.	Vincristine	82-93	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	97-102
32525624-12	2020	CONCLUSIONS: The findings in this study suggest that the combination of sitrvatinib and substrate antineoplastic drugs of ABCB1 could attenuate the MDR mediated by the overexpression of ABCB1.	sitrvatinib	72-83	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	122-127
32525624-12	2020	CONCLUSIONS: The findings in this study suggest that the combination of sitrvatinib and substrate antineoplastic drugs of ABCB1 could attenuate the MDR mediated by the overexpression of ABCB1.	sitrvatinib	72-83	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	186-191
31729540-12	2020	Compared with that in drug-sensitive tumors, uptake of [18F]AVT-011 was 32% lower in doxorubicin-resistant tumors with highest ABCB1 expression and increased by 40% with tariquidar administration.	Doxorubicin	85-96	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	127-132
31806767-4	2020	The aim of this study was to investigate whether PET with the weak ABCB1 substrate radiotracer 11C-metoclopramide can measure ABCB1 induction at the BBB in a beta-amyloidosis mouse model (APP/PS1-21 mice) and in wild-type mice.	11c-metoclopramide	95-113	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	67-72
31806767-4	2020	The aim of this study was to investigate whether PET with the weak ABCB1 substrate radiotracer 11C-metoclopramide can measure ABCB1 induction at the BBB in a beta-amyloidosis mouse model (APP/PS1-21 mice) and in wild-type mice.	11c-metoclopramide	95-113	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	126-131
31806767-9	2020	Immunohistochemical analysis confirmed ABCB1 induction in the brains of PCN-treated APP/PS1-21 mice with a concomitant decrease in Abeta levels.	PREGNENOLONE CARBONITRILE	72-75	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	39-44
31806767-13	2020	Conclusion: 11C-metoclopramide can measure ABCB1 induction in the mouse brain without the need to consider an arterial input function and may find potential application in Alzheimer disease patients to noninvasively evaluate strategies to enhance the clearance properties of the BBB.	11c-metoclopramide	12-30	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	43-48
33335181-10	2020	These results demonstrate that the RSK-ABCB1 and HIF-1alpha-FECH axes are the downstream pathways of Ras/MEK involved in the regulation of PpIX accumulation.	protoporphyrin IX	139-143	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	39-44
32616652-6	2020	Unlike for genistein and the other vitamin E compounds, the GA-induced restoration of ApoE efflux was not affected by pharmacological inhibition of PPARgamma activity, and specific activation of pregnane X receptor (PXR) was observed together with ApoE and multidrug resistance protein 1 (MDR1) membrane transporter up-regulation in both the mouse astrocytes and brain tissue.	Gallium	60-62	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	257-287
32616652-6	2020	Unlike for genistein and the other vitamin E compounds, the GA-induced restoration of ApoE efflux was not affected by pharmacological inhibition of PPARgamma activity, and specific activation of pregnane X receptor (PXR) was observed together with ApoE and multidrug resistance protein 1 (MDR1) membrane transporter up-regulation in both the mouse astrocytes and brain tissue.	Gallium	60-62	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	289-293
32278067-0	2020	A novel pharmacotherapy approach using P-glycoprotein (PGP/ABCB1) efflux inhibitor combined with ivermectin to reduce alcohol drinking and preference in mice.	Alcohols	118-125	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	59-64
32278067-5	2020	However, avermectin compounds are readily effluxed by P-glycoprotein (Pgp/ABCB1) in the blood-brain barrier (BBB), resulting in reduced retention time by the drugs in the central nervous system (CNS).	avermectin	9-19	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	74-79
32234426-0	2020	Brain accumulation of tivozanib is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein) in mice.	tivozanib	22-31	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	49-54
32234426-2	2020	We used wild-type, knockout, and transgenic mouse strains to study the effects of the drug transporters ABCB1, ABCG2, and OATP1A/1B, and of the CYP3A enzymes on the oral availability and tissue distribution of tivozanib.	tivozanib	210-219	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	104-109
32032656-4	2020	STS blocked the activity of TKI-resistant protein kinases and strongly inhibited adaptive dynamics in RCC cells promoted by MDR1 and GLUT1 to overcome sunitinib resistance.	Staurosporine	0-3	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	124-128
32032656-4	2020	STS blocked the activity of TKI-resistant protein kinases and strongly inhibited adaptive dynamics in RCC cells promoted by MDR1 and GLUT1 to overcome sunitinib resistance.	sunitinib	151-160	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	124-128
32114029-0	2020	Donepezil, a cholinesterase inhibitor used in Alzheimer"s disease therapy, is actively exported out of the brain by abcb1ab p-glycoproteins in mice.	Donepezil	0-9	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	116-121
32392918-0	2020	Oncogenic Ras downregulates mdr1b expression through generation of reactive oxygen species.	Reactive Oxygen Species	67-90	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	28-33
32392918-3	2020	The doxorubicin-induced mdr1b promoter activity of the H-RasV12 expressing NIH3T3 cells was markedly lower than that of control NIH3T3 cells.	Doxorubicin	4-15	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	24-29
32392918-6	2020	Pretreating cells with either NAC or DPI significantly enhanced the oncogenic H-Ras-mediated down-regulation of mdr1b expression and markedly prevented doxorubicin-induced cell death.	Acetylcysteine	30-33	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	112-117
32392918-6	2020	Pretreating cells with either NAC or DPI significantly enhanced the oncogenic H-Ras-mediated down-regulation of mdr1b expression and markedly prevented doxorubicin-induced cell death.	diphenyleneiodonium	37-40	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	112-117
32392918-7	2020	Moreover, NAC and DPI treatment led to a decrease in ERK activity, and the ERK inhibitors PD98059 or U0126 enhanced the mdr1b-Luc activity of H-RasV12-NIH3T3 and reduced doxorubicin-induced apoptosis.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	90-97	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	120-125
32392918-7	2020	Moreover, NAC and DPI treatment led to a decrease in ERK activity, and the ERK inhibitors PD98059 or U0126 enhanced the mdr1b-Luc activity of H-RasV12-NIH3T3 and reduced doxorubicin-induced apoptosis.	U 0126	101-106	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	120-125
32392918-8	2020	These data suggest that RasV12 expression could downregulate mdr1b expression through intracellular reactive oxygen species (ROS) production, and ERK activation induced by ROS, is at least in part, contributed to the downregulation of mdr1b expression.	Reactive Oxygen Species	172-175	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	235-240
32395078-3	2020	The doxorubicin-induced mdr1b promoter activity of the H-RasV12 expressing NIH3T3 cells was markedly lower than that of control NIH3T3 cells.	Doxorubicin	4-15	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	24-29
32395078-6	2020	Pretreating cells with either NAC or DPI significantly enhanced the oncogenic H-Ras-mediated down-regulation of mdr1b expression and markedly prevented doxorubicin-induced cell death.	Acetylcysteine	30-33	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	112-117
32395078-6	2020	Pretreating cells with either NAC or DPI significantly enhanced the oncogenic H-Ras-mediated down-regulation of mdr1b expression and markedly prevented doxorubicin-induced cell death.	diphenyleneiodonium	37-40	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	112-117
32395078-7	2020	Moreover, NAC and DPI treatment led to a decrease in ERK activity, and the ERK inhibitors PD98059 or U0126 enhanced the mdr1b-Luc activity of H-RasV12-NIH3T3 and reduced doxorubicin-induced apoptosis.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	90-97	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	120-125
32395078-7	2020	Moreover, NAC and DPI treatment led to a decrease in ERK activity, and the ERK inhibitors PD98059 or U0126 enhanced the mdr1b-Luc activity of H-RasV12-NIH3T3 and reduced doxorubicin-induced apoptosis.	U 0126	101-106	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	120-125
32395078-8	2020	These data suggest that RasV12 expression could downregulate mdr1b expression through intracellular reactive oxygen species (ROS) production, and ERK activation induced by ROS, is at least in part, contributed to the downregulation of mdr1b expression.	Reactive Oxygen Species	172-175	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	235-240
32252200-0	2020	[Compound matrine injection reduces morphine tolerance of the mice with lung cancer by inhibiting expression of multidrug resistance gene 1 and P-glycoprotein].	matrine	10-17	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	112-139
32365663-6	2020	Surprisingly, celecoxib, a known COX-2 inhibitor, prevented the emergence of drug-induced MDR in murine and canine lymphoma cell lines.	Celecoxib	14-23	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	90-93
32365663-7	2020	CONCLUSIONS: Our findings suggest that celecoxib could significantly improve the efficiency of chemotherapy by preventing the development of MDR in B-cell lymphoma.	Celecoxib	39-48	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	141-144
31304590-0	2020	P-glycoprotein (MDR1/ABCB1) controls brain accumulation and intestinal disposition of the novel TGF-beta signaling pathway inhibitor galunisertib.	LY-2157299	133-145	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	16-20
31304590-0	2020	P-glycoprotein (MDR1/ABCB1) controls brain accumulation and intestinal disposition of the novel TGF-beta signaling pathway inhibitor galunisertib.	LY-2157299	133-145	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	21-26
31304590-7	2020	Oral coadministration of the ABCB1/ABCG2 inhibitor elacridar boosted galunisertib brain accumulation in wild-type mice to equal the levels seen in Abcb1a/1b;Abcg2-/- mice.	LY-2157299	69-81	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	29-34
31911389-0	2020	Epigenetic dysregulation of Mdr1b in the blood-testis barrier contributes to dyszoospermia in mice exposed to cadmium.	Cadmium	110-117	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	28-33
31911389-3	2020	However, whether Mdr1b dysregulation is involved in Cd-mediated dyszoospermia and the underlying mechanism remain unknown.	Cadmium	52-54	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	17-22
31911389-7	2020	Hypermethylation and decreased nuclear factor Ya (Nfya) recruitment to the Mdr1b promoter were correlated with low sperm motility in response to Cd.	Cadmium	145-147	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	75-80
31911389-8	2020	In conclusion, these findings provide in vivo evidence that epigenetic dysregulation of Mdr1b in the BTB is a potential cause of dyszoospermia upon Cd exposure.	Cadmium	148-150	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	88-93
32148406-0	2020	Ginsenoside Rg5 overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter: in vitro and in vivo study.	Ginsenosides	0-11	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	76-81
32148406-2	2020	Here we investigated whether and how ginsenoside Rg5 overcomes the MDR mediated by ABCB1 transporter in vitro and in vivo.	Ginsenosides	37-48	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	83-88
32148406-7	2020	Moreover, Rg5 activated ABCB1 ATPase and reduced verapamil-stimulated ATPase activity, suggesting a high affinity of Rg5 to ABCB1 binding site which was further demonstrated by molecular docking analysis.	Verapamil	49-58	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	124-129
32072346-5	2020	RESULTS: The folate conjugated dual drug formulations (FCGNPs) gave better results in suppressing the pgy-1 gene and also showed higher cellular uptake, cytotoxicity, apoptosis, and cell cycle arrest.	Folic Acid	13-19	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	102-107
31985119-5	2020	Mechanistically, RA inhibited NSCLC cell growth, arrested cell cycle, and induced apoptosis by activating MAPK and inhibiting the expression of P-gp and MDR1, which correspondingly enhanced p21 and p53 expression.	rosmarinic acid	17-19	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	153-157
31985119-7	2020	We demonstrate that RA is a potentially effective MDR reversal agent for NSCLC, based on downregulation of MDR1 mRNA expression and P-gp.	rosmarinic acid	20-22	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	107-111
32159961-2	2020	This work presents a combination strategy of pretreatment of MDA-MB-231/MDR1 cells with quercetin (QU) followed by doxorubicin (DOX) to overcome MDR, which can be delivered by mixed micelles composed of the reduction-sensitive hyaluronic acid-based conjugate and d-alpha-tocopheryl poly(ethylene glycol) 1000 succinate.	Quercetin	88-97	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	72-75
32159961-4	2020	The probable MDR reversal mechanisms are that the pretreatment cells with QU-loaded mixed micelles downregulate P-glycoprotein expression to decrease DOX efflux as well as initiate mitochondria-dependent apoptotic pathways to accelerate DOX-induced apoptosis.	Doxorubicin	150-153	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	13-16
32159961-4	2020	The probable MDR reversal mechanisms are that the pretreatment cells with QU-loaded mixed micelles downregulate P-glycoprotein expression to decrease DOX efflux as well as initiate mitochondria-dependent apoptotic pathways to accelerate DOX-induced apoptosis.	Doxorubicin	237-240	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	13-16
32252200-7	2020	Results: The maximum analgesic percentage (MPE) of the mice in the morphine group was (85.21+-6.53)% on the 8th day, and decreased to (38.45+-5.52)% and (28.14+-4.52)% on the 10th and 12th day, respectively, which indicated the morphine tolerance of mice with lung cancer in situ.The MPE of the mice in the group treated with morphine and compound matrine injection (300 mg/kg) was (79.34+-6.50)% on the 8th day, and decreased to (62.16+-5.53)% and (40.20+-4.50)% on the 10th and 12th day, respectively.The results of RT-PCR assay showed that the relative expression levels of MDR1 mRNA in the brain tissues of mice in the morphine group, saline group, morphine combined with compound matrine injection (300 mg/kg) group and compound matrine injection (200 mg/kg) group were 2.33+-0.79, 1.04+-0.38, 1.37+-0.38, and 1.43+-0.53, respectively.	Morphine	67-75	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	577-581
32252200-14	2020	Conclusion: Compound matrine injection can significantly improve morphine tolerance and drug resistance of lung cancer through inhibiting the upregulations of MDR1 and P-gp induced by morphine.	matrine	21-28	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	159-163
32252200-14	2020	Conclusion: Compound matrine injection can significantly improve morphine tolerance and drug resistance of lung cancer through inhibiting the upregulations of MDR1 and P-gp induced by morphine.	Morphine	184-192	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	159-163
31175939-0	2019	Brain accumulation of osimertinib and its active metabolite AZ5104 is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein).	osimertinib	22-33	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	84-89
31640252-14	2019	In summary, RES529, the first dual TORC1/TORC2 dissociative inhibitor, lacking affinity for ABCB1/ABCG2 and having good brain penetration, was active in GBM preclinical/murine models giving credence to its use in clinical trial for patients with GBM treated in association with anti-angiogenetic compounds.	resorcinarene	12-18	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	92-97
31790256-6	2020	PET data in transporter knockout mice revealed that both ABCB1 and ABCG2 mediated biliary excretion of [11C]tariquidar.	Carbon-11	104-107	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	57-62
31759109-0	2020	P-glycoprotein (ABCB1/MDR1) limits brain accumulation and Cytochrome P450-3A (CYP3A) restricts oral availability of the novel FGFR4 inhibitor fisogatinib (BLU-554).	BLU-554	142-153	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	16-21
31759109-8	2020	In summary, in mice, fisogatinib brain accumulation is substantially limited by ABCB1 P-glycoprotein in the blood-brain barrier, and oral availability of fisogatinib is markedly restricted by CYP3A activity.	BLU-554	21-32	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	80-85
31709896-2	2020	The present study ascertained whether the natural product botryllamide G is viable for in vivo inhibition of ABCG2 using lapatinib as a probe for ABCB1 and ABCG2-mediated efflux from the brain.	botryllamide G	58-72	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	146-151
31709896-7	2020	Conclusions: In summary, the ABCG2 inhibitor, botryllamide G, increases brain exposure to lapatinib in mice lacking Abcb1, although the combination of botryllamide G and tariquidar increases brain exposure in wild-type mice only briefly (1 h).	botryllamide G	46-60	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	116-121
31472126-6	2019	Intracellular accumulation of oleandrin (2.5-10 muM) was reduced in MDCKII-MDR1 than in parental cells.	oleandrin	30-39	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	75-79
31472126-7	2019	MDR1 overexpression decreased the cell sensitivity to oleandrin toxicity.	oleandrin	54-63	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	0-4
31472126-8	2019	The net flux ratio (MDCKII-MDR1 versus parental cells) was 2.9 for oleandrin.	oleandrin	67-76	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	27-31
31344512-7	2019	After entering cells, IND would be released faster than chemotherapeutic drug encapsulated in core to efficiently inhibit the expression of multidrug resistance protein 1 to reverse MDR of tumor cells before chemotherapeutic drug releasing.	Indomethacin	22-25	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	140-170
31572128-0	2019	Deactivation of ATP-Binding Cassette Transporters ABCB1 and ABCC1 Does Not Influence Post-ischemic Neurological Deficits, Secondary Neurodegeneration and Neurogenesis, but Induces Subtle Microglial Morphological Changes.	Adenosine Triphosphate	16-19	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	50-55
31132609-5	2019	Monolayer cultured cells (2D) and multicellular spheroids (3D) experiments proved that PDTC could reverse multidrug resistance (MDR), improve intracellular drugs accumulation and enhance tumor penetration by down-regulating the expression of P-gp, then resulting in higher DOX-induced cytotoxicity and apoptosis in MCF-7 and MCF-7/ADR cells.	pyrrolidine dithiocarbamic acid	87-91	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	128-131
31299237-7	2019	sEng also increased conversion of cholesterol into bile acids (BA) via upregulation of Cyp7a1 and increased Mdr1 expression.	seng	0-4	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	108-112
31398786-6	2019	As related classical 1,4-dihydropyridines are known as inhibitors of the transmembrane efflux pump ABCB1 in cancer cells, we wondered whether a use of our compounds may be of favour to enhance the antituberculotic drug efficacy of the second-line antituberculotic drug clofazimine, which is a known substrate of ABCB1 by a suggested inhibition of a corresponding efflux pump in Mycobacterium tuberculosis (Mtb).	1,4-dihydropyridine	21-41	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	99-104
31398786-6	2019	As related classical 1,4-dihydropyridines are known as inhibitors of the transmembrane efflux pump ABCB1 in cancer cells, we wondered whether a use of our compounds may be of favour to enhance the antituberculotic drug efficacy of the second-line antituberculotic drug clofazimine, which is a known substrate of ABCB1 by a suggested inhibition of a corresponding efflux pump in Mycobacterium tuberculosis (Mtb).	1,4-dihydropyridine	21-41	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	312-317
31398786-6	2019	As related classical 1,4-dihydropyridines are known as inhibitors of the transmembrane efflux pump ABCB1 in cancer cells, we wondered whether a use of our compounds may be of favour to enhance the antituberculotic drug efficacy of the second-line antituberculotic drug clofazimine, which is a known substrate of ABCB1 by a suggested inhibition of a corresponding efflux pump in Mycobacterium tuberculosis (Mtb).	Clofazimine	269-280	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	99-104
31175939-0	2019	Brain accumulation of osimertinib and its active metabolite AZ5104 is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein).	Ro 21-5104	60-66	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	84-89
30586228-0	2019	Pharmacophoric features for a very potent 5-spirofluorenehydantoin inhibitor of cancer efflux pump ABCB1, based on X-ray analysis.	5-spirofluorenehydantoin	42-66	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	99-104
30206768-8	2019	HHT increased intracellular oridonin concentration by modulating the expressions of MRP1 and MDR1, thus enhancing the effects of oridonin.	oridonin	28-36	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	93-97
30897286-3	2019	In the present study, we tested the in vivo effects of two HDAC inhibitors, valproic acid (VPA; 400 mg/kg) and apicidin (5 mg/kg), on Mdr1 and Bcrp transporter expression in brain regions of adult male mice injected intraperitoneally daily for 7 days.	Valproic Acid	76-89	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	134-138
30897286-3	2019	In the present study, we tested the in vivo effects of two HDAC inhibitors, valproic acid (VPA; 400 mg/kg) and apicidin (5 mg/kg), on Mdr1 and Bcrp transporter expression in brain regions of adult male mice injected intraperitoneally daily for 7 days.	Valproic Acid	91-94	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	134-138
30897286-3	2019	In the present study, we tested the in vivo effects of two HDAC inhibitors, valproic acid (VPA; 400 mg/kg) and apicidin (5 mg/kg), on Mdr1 and Bcrp transporter expression in brain regions of adult male mice injected intraperitoneally daily for 7 days.	apicidin	111-119	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	134-138
30897286-4	2019	VPA increased Mdr1 protein expression in the striatum (70%) and Bcrp protein in the midbrain (30%).	Valproic Acid	0-3	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	14-18
30659321-5	2019	Analysis of fluorescent substrates export (flow cytometry) revealed that CRYO did not affect the efflux of fluorescein (MRP3, MRP4 and MRP5) but inhibited that of rhodamine 123 (MDR1) and calcein (MRP1 and MRP2).	Rhodamine 123	163-176	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	178-182
30694684-0	2019	Inhibition of ABCB1 and ABCG2 at the Mouse Blood-Brain Barrier with Marketed Drugs To Improve Brain Delivery of the Model ABCB1/ABCG2 Substrate [11C]erlotinib.	Carbon-11	145-148	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	14-19
30694684-0	2019	Inhibition of ABCB1 and ABCG2 at the Mouse Blood-Brain Barrier with Marketed Drugs To Improve Brain Delivery of the Model ABCB1/ABCG2 Substrate [11C]erlotinib.	Carbon-11	145-148	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	122-127
30694684-0	2019	Inhibition of ABCB1 and ABCG2 at the Mouse Blood-Brain Barrier with Marketed Drugs To Improve Brain Delivery of the Model ABCB1/ABCG2 Substrate [11C]erlotinib.	Erlotinib Hydrochloride	149-158	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	14-19
30694684-0	2019	Inhibition of ABCB1 and ABCG2 at the Mouse Blood-Brain Barrier with Marketed Drugs To Improve Brain Delivery of the Model ABCB1/ABCG2 Substrate [11C]erlotinib.	Erlotinib Hydrochloride	149-158	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	122-127
30659321-9	2019	They induced strong (diclofenac on MRPs), modest (verapamil on MDR1) or null (fumitremorgin C on BCRP) effect on sorafenib efflux and cytotoxicity.	Verapamil	50-59	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	63-67
30221549-2	2019	One of the most widely used drugs, doxorubicin (Dox) is a substrate of three different ATP-binding cassette (ABC) transporters, namely, ABCB1, ABCG2 and ABCC1, predominantly contributing to MDR phenotype in cancer.	Doxorubicin	35-46	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	136-141
30660696-2	2019	We previously found that the efflux transporter P-glycoprotein (MDR1/ABCB1) restricts lorlatinib brain accumulation and that the drug-metabolizing enzyme cytochrome P450-3A (CYP3A) limits its oral availability.	lorlatinib	86-96	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	64-68
30660696-2	2019	We previously found that the efflux transporter P-glycoprotein (MDR1/ABCB1) restricts lorlatinib brain accumulation and that the drug-metabolizing enzyme cytochrome P450-3A (CYP3A) limits its oral availability.	lorlatinib	86-96	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	69-74
30221549-2	2019	One of the most widely used drugs, doxorubicin (Dox) is a substrate of three different ATP-binding cassette (ABC) transporters, namely, ABCB1, ABCG2 and ABCC1, predominantly contributing to MDR phenotype in cancer.	Doxorubicin	48-51	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	136-141
30622172-5	2019	The purpose of this study was to perform a quantitative assessment and evaluation of the influence of efflux mechanisms at the blood-brain barrier (BBB), in particular, Abcb1/P-glycoprotein (P-gp) and Abcg2/breast cancer resistance protein (Bcrp), on the brain distribution of three panRAF inhibitors: CCT196969 [1-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)-3-(2-fluoro-4-((3-oxo-3,4-dihydropyrido[2,3-b]pyrazin-8-yl)oxy)phenyl)urea], LY3009120 1-(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido(2,3-d)pyrimidin-6-yl)phenyl)urea, and MLN2480 [4-pyrimidinecarboxamide, 6-amino-5-chloro-N-[(1R)-1-[5-[[[5-chloro-4-(trifluoromethyl)-2-pyridinyl]amino]carbonyl]-2-thiazolyl]ethyl]-].	Urea	427-431	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	169-174
30622172-5	2019	The purpose of this study was to perform a quantitative assessment and evaluation of the influence of efflux mechanisms at the blood-brain barrier (BBB), in particular, Abcb1/P-glycoprotein (P-gp) and Abcg2/breast cancer resistance protein (Bcrp), on the brain distribution of three panRAF inhibitors: CCT196969 [1-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)-3-(2-fluoro-4-((3-oxo-3,4-dihydropyrido[2,3-b]pyrazin-8-yl)oxy)phenyl)urea], LY3009120 1-(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido(2,3-d)pyrimidin-6-yl)phenyl)urea, and MLN2480 [4-pyrimidinecarboxamide, 6-amino-5-chloro-N-[(1R)-1-[5-[[[5-chloro-4-(trifluoromethyl)-2-pyridinyl]amino]carbonyl]-2-thiazolyl]ethyl]-].	Urea	549-553	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	169-174
30765569-3	2019	A second structure of inhibited, human-mouse chimeric ABCB1 revealed two molecules of zosuquidar occupying the same drug-binding pocket.	Zosuquidar	86-96	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	54-59
30553002-0	2019	P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) limit brain accumulation of the FLT3 inhibitor quizartinib in mice.	quizartinib	125-136	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	16-20
31165698-9	2019	More importantly, PNLS combined with PTX (Paclitaxel) showed antitumor effects and high MDR1 gene silencing efficiency in the tumor-bearing nude mice.	Paclitaxel	37-40	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	88-92
31165698-9	2019	More importantly, PNLS combined with PTX (Paclitaxel) showed antitumor effects and high MDR1 gene silencing efficiency in the tumor-bearing nude mice.	Paclitaxel	42-52	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	88-92
30222077-0	2019	ABCB1 (P-glycoprotein) regulates vitamin D absorption and contributes to its transintestinal efflux.	Vitamin D	33-42	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	0-5
30222077-2	2019	Thus, we investigated the involvement of ATP binding cassette subfamily B member 1 (ABCB1) in vitamin D intestinal efflux.	Vitamin D	94-103	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	41-82
30222077-2	2019	Thus, we investigated the involvement of ATP binding cassette subfamily B member 1 (ABCB1) in vitamin D intestinal efflux.	Vitamin D	94-103	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	84-89
30669343-3	2019	A checkerboard microplate method was applied to study the drug interactions of Se-compounds and clinically relevant chemotherapeutic drugs against the multidrug-resistant (MDR) subtype of mouse t-lymphoma cells overexpressing the ABCB1 transporter.	se-compounds	79-91	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	230-235
30476727-0	2019	abcb1ab p-glycoprotein is involved in the uptake of the novel antidepressant vortioxetine into the brain of mice.	Vortioxetine	77-89	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	0-5
30460040-15	2018	Combined oral ethinyl estradiol and progesterone significantly lowered both MDR-1 mRNA and protein.	Ethinyl Estradiol	14-31	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	76-81
30553002-0	2019	P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) limit brain accumulation of the FLT3 inhibitor quizartinib in mice.	quizartinib	125-136	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	21-26
30553002-3	2019	Quizartinib was transported by human ABCB1 in vitro, and by mouse (m)Abcb1 and mAbcg2 in vivo.	quizartinib	0-11	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	69-74
30553002-4	2019	Upon oral administration, the brain accumulation of quizartinib was 6-fold decreased by mAbcb1 and 2-fold by mAbcg2 (together: 12-fold).	quizartinib	52-63	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	88-94
30553002-5	2019	Unexpectedly, the absence of mAbcb1 resulted in a ~2-fold lower plasma exposure in Abcb1a/1b-/- and Abcb1a/1b;Abcg2-/- mice, suggesting that loss of mAbcb1 causes compensatory alterations in alternative quizartinib elimination or uptake systems.	quizartinib	203-214	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	29-35
30611276-5	2019	Here, we found a significant increase of mRNA expression levels of phospholipid, bile salt and cholesterol/sterol transporters Abcb1b, Abcb11, Abcg1, Abcg5 and Abcg8.	Phospholipids	67-79	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	127-133
30611276-5	2019	Here, we found a significant increase of mRNA expression levels of phospholipid, bile salt and cholesterol/sterol transporters Abcb1b, Abcb11, Abcg1, Abcg5 and Abcg8.	Bile Acids and Salts	81-90	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	127-133
30415015-2	2018	Inhibition of ABCB1 and ABCG2 at the mouse BBB improved the BBB permeation of erlotinib but could not be achieved in humans.	Erlotinib Hydrochloride	78-87	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	14-19
30460040-15	2018	Combined oral ethinyl estradiol and progesterone significantly lowered both MDR-1 mRNA and protein.	Progesterone	36-48	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	76-81
30252484-0	2018	ABCB1 Attenuates the Brain Penetration of the PARP Inhibitor AZD2461.	AZD2461	61-68	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	0-5
30532537-3	2018	Our previous study found that BU can effectively reverse P-glycoprotein (P-gp)-mediated MDR in colon cancer.	bufalin	30-32	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	88-91
30532537-13	2018	Subsequently, in vivo studies confirmed an enhanced therapeutic efficiency and reduced side effects associated with BU@VeC/T-RGD MM compared with free BU, owing to the enhanced permeation and retention effect, improved pharmacokinetic behavior, and tumor targeting, which lead to MDR-inhibiting effect in LoVo/ADR-bearing nude mice.	bufalin	116-118	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	280-283
30247919-0	2018	P-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Bruton"s Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability.	ibrutinib	98-107	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	16-20
30396935-4	2018	Modulation of ABCB1 activity was measured by rhodamine 123 accumulation assay using flow cytometry.	Rhodamine 123	45-58	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	14-19
30247919-0	2018	P-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Bruton"s Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability.	ibrutinib	98-107	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	21-26
30247919-3	2018	Using in vitro transport assays and genetically modified mouse models, we investigated whether the multidrug efflux transporters ABCB1 and ABCG2 and the multidrug-metabolizing CYP3A enzyme family can affect the oral bioavailability and tissue disposition of ibrutinib and ibrutinib-DiOH.	ibrutinib	258-267	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	129-134
30247919-3	2018	Using in vitro transport assays and genetically modified mouse models, we investigated whether the multidrug efflux transporters ABCB1 and ABCG2 and the multidrug-metabolizing CYP3A enzyme family can affect the oral bioavailability and tissue disposition of ibrutinib and ibrutinib-DiOH.	ibrutinib	272-281	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	129-134
30247919-3	2018	Using in vitro transport assays and genetically modified mouse models, we investigated whether the multidrug efflux transporters ABCB1 and ABCG2 and the multidrug-metabolizing CYP3A enzyme family can affect the oral bioavailability and tissue disposition of ibrutinib and ibrutinib-DiOH.	dioh	282-286	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	129-134
30247919-5	2018	In mice, Abcb1 markedly restricted the brain penetration of ibrutinib and ibrutinib-DiOH, either alone or in combination with Abcg2, resulting in 4.5- and 5.9-fold increases in ibrutinib brain-to-plasma ratios in Abcb1a/1b-/- and Abcb1a/1b;Abcg2-/- mice relative to wild-type mice.	ibrutinib	60-69	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	9-14
30247919-5	2018	In mice, Abcb1 markedly restricted the brain penetration of ibrutinib and ibrutinib-DiOH, either alone or in combination with Abcg2, resulting in 4.5- and 5.9-fold increases in ibrutinib brain-to-plasma ratios in Abcb1a/1b-/- and Abcb1a/1b;Abcg2-/- mice relative to wild-type mice.	ibrutinib	74-83	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	9-14
30247919-5	2018	In mice, Abcb1 markedly restricted the brain penetration of ibrutinib and ibrutinib-DiOH, either alone or in combination with Abcg2, resulting in 4.5- and 5.9-fold increases in ibrutinib brain-to-plasma ratios in Abcb1a/1b-/- and Abcb1a/1b;Abcg2-/- mice relative to wild-type mice.	dioh	84-88	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	9-14
30247919-5	2018	In mice, Abcb1 markedly restricted the brain penetration of ibrutinib and ibrutinib-DiOH, either alone or in combination with Abcg2, resulting in 4.5- and 5.9-fold increases in ibrutinib brain-to-plasma ratios in Abcb1a/1b-/- and Abcb1a/1b;Abcg2-/- mice relative to wild-type mice.	ibrutinib	74-83	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	9-14
30396935-7	2018	The activity of the complexes proved to be up to 29- and 5-fold higher than that of the ligands and the ABCB1 inhibitor verapamil as positive control, respectively.	Verapamil	120-129	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	104-109
30139557-4	2018	Abcb1 mRNA levels were significantly reduced in AD mice compared to control mice, and it could be restored by ibuprofen treatment.	Ibuprofen	110-119	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	0-5
30253203-11	2018	ABCB1 and ABCG2 thus limit brain accumulation, toxicity, and systemic exposure of brigatinib, whereas CYP3 A also markedly restricts its oral availability.	brigatinib	82-92	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	0-5
29744867-0	2018	P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450-3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib.	lorlatinib	145-155	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	16-20
29744867-0	2018	P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450-3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib.	lorlatinib	145-155	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	21-26
29744867-3	2018	We investigated the roles of the multidrug efflux transporters ABCB1 and ABCG2, and the multispecific drug-metabolizing enzyme CYP3A in plasma pharmacokinetics and tissue distribution of lorlatinib using genetically modified mouse strains.	lorlatinib	187-197	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	63-68
29744867-7	2018	Oral coadministration of the ABCB1/ABCG2 inhibitor elacridar increased the brain accumulation of lorlatinib in wild-type mice fourfold, that is, to the same level as in Abcb1a/1b;Abcg2-/- mice, without altering plasma exposure.	lorlatinib	97-107	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	29-34
29744867-10	2018	Our data indicate that lorlatinib brain accumulation is substantially limited by P-glycoprotein/ABCB1 in the blood-brain barrier, but this can be effectively reversed by elacridar coadministration.	lorlatinib	23-33	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	96-101
30199257-2	2018	Aiming at obtaining compounds with improved multidrug-resistance (MDR) reversal activity, compound 8, an ent-abietane diterpene, was derivatized by introducing nitrogen-containing and aromatic moieties, yielding compounds 9-14.	ent-abietane	105-117	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	66-69
30199257-2	2018	Aiming at obtaining compounds with improved multidrug-resistance (MDR) reversal activity, compound 8, an ent-abietane diterpene, was derivatized by introducing nitrogen-containing and aromatic moieties, yielding compounds 9-14.	Diterpenes	118-127	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	66-69
30199257-2	2018	Aiming at obtaining compounds with improved multidrug-resistance (MDR) reversal activity, compound 8, an ent-abietane diterpene, was derivatized by introducing nitrogen-containing and aromatic moieties, yielding compounds 9-14.	Nitrogen	160-168	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	66-69
30199257-6	2018	While spiropedroxodiol (1) was found to be a very strong MDR reversal agent in both L5178Y-MDR and Colo320 cells, the chemical modifications of helioscopinolide E (8) at C-3 positively contributed to increase the MDR reversal activity of compounds 10, 12, and 13.	spiropedroxodiol	6-22	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	57-60
30304236-3	2018	ABCB1 is an efflux pump expressed in both cancer and normal cells, modulating the gradient of various metabolites, including hydrocortisone.	Hydrocortisone	125-139	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	0-5
30344740-0	2018	A 20(S)-protopanaxadiol derivative PPD12 reverses ABCB1-mediated multidrug resistance with oral bioavailability and low toxicity.	protopanaxadiol	4-23	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	50-55
30344740-2	2018	To inhibit ABCB1 activity in MDR cancer cells, the authors previously designed and synthesized a derivative from 20(S)-protopanaxadiol (PPD) PPD12 and verified its efficacy in ABCB1-overexpressing cancer cells.	protopanaxadiol	115-134	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	11-16
30344740-2	2018	To inhibit ABCB1 activity in MDR cancer cells, the authors previously designed and synthesized a derivative from 20(S)-protopanaxadiol (PPD) PPD12 and verified its efficacy in ABCB1-overexpressing cancer cells.	protopanaxadiol	115-134	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	29-32
30344740-2	2018	To inhibit ABCB1 activity in MDR cancer cells, the authors previously designed and synthesized a derivative from 20(S)-protopanaxadiol (PPD) PPD12 and verified its efficacy in ABCB1-overexpressing cancer cells.	protopanaxadiol	115-134	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	176-181
29779087-0	2018	Down-regulation of MDR1 by Ad-DKK3 via Akt/NFkappaB pathways augments the anti-tumor effect of temozolomide in glioblastoma cells and a murine xenograft model.	Temozolomide	95-107	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	19-23
29970523-3	2018	MATERIALS AND METHODS: A series of novel imidazo[4,5-b]pyridine derivatives were synthesized and their biological activities were evaluated in vitro using parental (PAR) and multidrug resistant (MDR; ABCB1-overexpressing) mouse T-lymphoma cells.	imidazo(4,5-b)pyridine	41-63	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	200-205
30304236-4	2018	Our goal was to evaluate the effect of this glucocorticoid on murine B cell differentiation and whether sensitivity to hydrocortisone could be related to ABCB1 activity in vivo.	Hydrocortisone	119-133	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	154-159
30304236-7	2018	ABCB1 activity was evaluated via the rhodamine-123 transport and inhibited by cyclosporin A in hydrocortisone-treated and control mice.	Rhodamine 123	37-50	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	0-5
30304236-7	2018	ABCB1 activity was evaluated via the rhodamine-123 transport and inhibited by cyclosporin A in hydrocortisone-treated and control mice.	Cyclosporine	78-91	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	0-5
30304236-7	2018	ABCB1 activity was evaluated via the rhodamine-123 transport and inhibited by cyclosporin A in hydrocortisone-treated and control mice.	Hydrocortisone	95-109	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	0-5
29155017-0	2018	P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) affect brain accumulation and intestinal disposition of encorafenib in mice.	encorafenib	134-145	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	16-20
29852323-0	2018	Improved Brain Penetration and Antitumor Efficacy of Temozolomide by Inhibition of ABCB1 and ABCG2.	Temozolomide	53-65	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	83-88
29147815-4	2018	Methods We have here conducted a comprehensive set of in vitro and in vivo experiments to determine to what extent two dominant efflux transporters in the BBB, P-gp (ABCB1) and BCRP (ABCG2), exhibit affinity towards AZD1775 and PD0166285 and restrict their brain penetration.	adavosertib	216-223	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	166-171
29147815-4	2018	Methods We have here conducted a comprehensive set of in vitro and in vivo experiments to determine to what extent two dominant efflux transporters in the BBB, P-gp (ABCB1) and BCRP (ABCG2), exhibit affinity towards AZD1775 and PD0166285 and restrict their brain penetration.	PD 0166285	228-237	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	166-171
29175983-14	2018	Conclusion: When Abcb1 and Abcg2 were disrupted in mice, brain uptake of 11C-erlotinib increased both at a tracer dose and at a pharmacologic dose.	Erlotinib Hydrochloride	73-86	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	17-22
29462422-7	2018	The lack of MDR1 did not affect female ovarian function and fertility; however, its deficiency significantly exacerbated the DOX-induced ovarian toxicity in both in vivo and in vitro models.	Doxorubicin	125-128	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	12-16
29462422-10	2018	In conclusion, our study demonstrates that the lack of MDR1 promotes DOX-induced ovarian toxicity, suggesting the critical role of MDR1 in protecting female ovarian functions during chemotherapy.	Doxorubicin	69-72	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	55-59
29462422-10	2018	In conclusion, our study demonstrates that the lack of MDR1 promotes DOX-induced ovarian toxicity, suggesting the critical role of MDR1 in protecting female ovarian functions during chemotherapy.	Doxorubicin	69-72	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	131-135
29765522-9	2018	Gene expression analysis of the ATP-binding cassette transporters revealed that ATP binding cassette subfamily B member1 (ABCB1) was conspicuously expressed in A99, and ABCB1 and ATP binding cassette subfamily C member2 (ABCC2) were deficient in TYUC-1, which might explain a part of different CDDP susceptibilities between cell lines.	tyuc	246-250	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	80-120
29765522-9	2018	Gene expression analysis of the ATP-binding cassette transporters revealed that ATP binding cassette subfamily B member1 (ABCB1) was conspicuously expressed in A99, and ABCB1 and ATP binding cassette subfamily C member2 (ABCC2) were deficient in TYUC-1, which might explain a part of different CDDP susceptibilities between cell lines.	tyuc	246-250	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	122-127
29765522-9	2018	Gene expression analysis of the ATP-binding cassette transporters revealed that ATP binding cassette subfamily B member1 (ABCB1) was conspicuously expressed in A99, and ABCB1 and ATP binding cassette subfamily C member2 (ABCC2) were deficient in TYUC-1, which might explain a part of different CDDP susceptibilities between cell lines.	tyuc	246-250	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	169-174
29765522-9	2018	Gene expression analysis of the ATP-binding cassette transporters revealed that ATP binding cassette subfamily B member1 (ABCB1) was conspicuously expressed in A99, and ABCB1 and ATP binding cassette subfamily C member2 (ABCC2) were deficient in TYUC-1, which might explain a part of different CDDP susceptibilities between cell lines.	cddp	294-298	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	80-120
29765522-9	2018	Gene expression analysis of the ATP-binding cassette transporters revealed that ATP binding cassette subfamily B member1 (ABCB1) was conspicuously expressed in A99, and ABCB1 and ATP binding cassette subfamily C member2 (ABCC2) were deficient in TYUC-1, which might explain a part of different CDDP susceptibilities between cell lines.	cddp	294-298	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	122-127
29765522-9	2018	Gene expression analysis of the ATP-binding cassette transporters revealed that ATP binding cassette subfamily B member1 (ABCB1) was conspicuously expressed in A99, and ABCB1 and ATP binding cassette subfamily C member2 (ABCC2) were deficient in TYUC-1, which might explain a part of different CDDP susceptibilities between cell lines.	cddp	294-298	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	169-174
28681913-3	2018	DMY enhanced cytotoxicity of adriamycin (ADR) by downregulating MDR1 mRNA and P-gp expression through MAPK/ERK pathway and also inhibiting the function of P-gp significantly.	dihydromyricetin	0-3	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	64-68
28681913-3	2018	DMY enhanced cytotoxicity of adriamycin (ADR) by downregulating MDR1 mRNA and P-gp expression through MAPK/ERK pathway and also inhibiting the function of P-gp significantly.	Doxorubicin	29-39	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	64-68
29541206-2	2018	It was reported that 20(S)-ginsenoside Rg3 (hereafter Rg3) was able to regulate MDR in mouse leukemia cells.	Ginsenoside Rh2	21-38	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	80-83
29091294-9	2018	Treatment with rapamycin restored bile acid excretion, attenuated hepatocyte damage, and extended the life span of abcb11b mutant zebrafish, correlating with the recovery of canalicular multidrug resistance protein 1 localization.	Sirolimus	15-24	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	186-216
29155017-0	2018	P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) affect brain accumulation and intestinal disposition of encorafenib in mice.	encorafenib	134-145	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	21-26
28472378-4	2017	Induction of Mdr1 (Abcb1) and Mrp1 (Abcc1), 2 multidrug resistance transporters and exporters of As+3, was associated with the reversal of As+3-induced double strand breaks and DNA damage.	as+3	97-101	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	13-17
29340044-0	2017	Cepharanthine hydrochloride reverses the mdr1 (P-glycoprotein)-mediated esophageal squamous cell carcinoma cell cisplatin resistance through JNK and p53 signals.	cepharanthine hydrochloride	0-27	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	41-45
29340044-0	2017	Cepharanthine hydrochloride reverses the mdr1 (P-glycoprotein)-mediated esophageal squamous cell carcinoma cell cisplatin resistance through JNK and p53 signals.	Cisplatin	112-121	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	41-45
29340044-10	2017	To our knowledge, we demonstrate for the first time that CEH is a potentially effective MDR reversal agent for ESCC, based on downregulation of the mRNA expression of MDR1 and P-gp.	CEH	57-60	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	167-171
28587984-4	2017	The aim of the present study was to characterize roles of ABCB1 and ABCG2 in the transmembrane transport of Huperzine A and identify a rate limiting step in its brain distribution.	huperzine A	108-119	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	58-63
28587984-6	2017	ABCB1 inhibitors significantly inhibited ABCB1 mediated efflux of Huperzine A.	huperzine A	66-77	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	0-5
28587984-6	2017	ABCB1 inhibitors significantly inhibited ABCB1 mediated efflux of Huperzine A.	huperzine A	66-77	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	41-46
28587984-8	2017	Taken together, the present study demonstrated that ABCB1 but not ABCG2 played a predominant role in the efflux of Huperzine A across BBB.	huperzine A	115-126	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	52-57
28587984-9	2017	The current finding is clinically relevant as changes in ABCB1 activity in the presence of ABCB1 inhibitors or genetic polymorphism may affect efficacy and safety of Huperzine A.	huperzine A	166-177	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	57-62
28587984-9	2017	The current finding is clinically relevant as changes in ABCB1 activity in the presence of ABCB1 inhibitors or genetic polymorphism may affect efficacy and safety of Huperzine A.	huperzine A	166-177	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	91-96
28921565-3	2018	The BBB is equipped with a range of ATP-dependent efflux transport proteins, of which P-gp (ABCB1) and BCRP (ABCG2) are the two most dominant for drug efflux from the brain.	Adenosine Triphosphate	36-39	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	92-97
29064386-1	2017	Lopinavir (LPV), an antiretroviral protease inhibitor frequently prescribed in HIV-positive pregnancies, is a substrate of Abcb1 and Abcc2.	Lopinavir	0-9	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	123-128
29064386-1	2017	Lopinavir (LPV), an antiretroviral protease inhibitor frequently prescribed in HIV-positive pregnancies, is a substrate of Abcb1 and Abcc2.	Lopinavir	11-14	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	123-128
28880088-0	2017	Brain Accumulation of Ponatinib and Its Active Metabolite, N-Desmethyl Ponatinib, Is Limited by P-Glycoprotein (P-GP/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2).	ponatinib	22-31	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	117-122
28880088-0	2017	Brain Accumulation of Ponatinib and Its Active Metabolite, N-Desmethyl Ponatinib, Is Limited by P-Glycoprotein (P-GP/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2).	UNII-5EMP4AZ4U5	59-80	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	117-122
28880088-4	2017	In mice, both Abcb1 and Abcg2 markedly restricted brain accumulation of ponatinib and DMP, but not ponatinib oral availability.	ponatinib	72-81	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	14-19
28796259-8	2017	Moreover, co-administration of the inhibitors of MUC1-EGFR-ABCB1 with paclitaxel significantly blocked not only tumor growth but also relapse in xenograft mouse model.	Paclitaxel	70-80	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	59-64
28671633-0	2017	L1210 Cells Overexpressing ABCB1 Drug Transporters Are Resistant to Inhibitors of the N- and O-glycosylation of Proteins.	Nitrogen	86-87	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	27-32
28472378-4	2017	Induction of Mdr1 (Abcb1) and Mrp1 (Abcc1), 2 multidrug resistance transporters and exporters of As+3, was associated with the reversal of As+3-induced double strand breaks and DNA damage.	as+3	97-101	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	19-24
28472378-4	2017	Induction of Mdr1 (Abcb1) and Mrp1 (Abcc1), 2 multidrug resistance transporters and exporters of As+3, was associated with the reversal of As+3-induced double strand breaks and DNA damage.	as+3	139-143	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	13-17
28472378-4	2017	Induction of Mdr1 (Abcb1) and Mrp1 (Abcc1), 2 multidrug resistance transporters and exporters of As+3, was associated with the reversal of As+3-induced double strand breaks and DNA damage.	as+3	139-143	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	19-24
28472378-8	2017	Knockdown study of As+3 exporters in the DN thymic cell line, D1 using siRNA, demonstrated that Mdr1 and Mrp1 regulate intracellular As+3 accumulation and genotoxicity.	as+3	19-23	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	96-100
28302530-0	2017	Regorafenib overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter in colorectal cancer: In vitro and in vivo study.	regorafenib	0-11	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	72-77
28302530-4	2017	We investigated whether and how regorafenib overcame MDR mediated by ABCB1.	regorafenib	32-43	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	53-56
28302530-4	2017	We investigated whether and how regorafenib overcame MDR mediated by ABCB1.	regorafenib	32-43	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	69-74
28302530-5	2017	The results showed that regorafenib reversed the ABCB1-mediated MDR and increased the accumulation of [3H]-paclitaxel in ABCB1-overexpressing cells by suppressing efflux activity of ABCB1, but not altering expression level and localization of ABCB1.	regorafenib	24-35	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	49-54
28302530-5	2017	The results showed that regorafenib reversed the ABCB1-mediated MDR and increased the accumulation of [3H]-paclitaxel in ABCB1-overexpressing cells by suppressing efflux activity of ABCB1, but not altering expression level and localization of ABCB1.	regorafenib	24-35	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	64-67
28302530-5	2017	The results showed that regorafenib reversed the ABCB1-mediated MDR and increased the accumulation of [3H]-paclitaxel in ABCB1-overexpressing cells by suppressing efflux activity of ABCB1, but not altering expression level and localization of ABCB1.	regorafenib	24-35	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	121-126
28302530-5	2017	The results showed that regorafenib reversed the ABCB1-mediated MDR and increased the accumulation of [3H]-paclitaxel in ABCB1-overexpressing cells by suppressing efflux activity of ABCB1, but not altering expression level and localization of ABCB1.	regorafenib	24-35	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	121-126
28302530-5	2017	The results showed that regorafenib reversed the ABCB1-mediated MDR and increased the accumulation of [3H]-paclitaxel in ABCB1-overexpressing cells by suppressing efflux activity of ABCB1, but not altering expression level and localization of ABCB1.	regorafenib	24-35	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	121-126
28302530-5	2017	The results showed that regorafenib reversed the ABCB1-mediated MDR and increased the accumulation of [3H]-paclitaxel in ABCB1-overexpressing cells by suppressing efflux activity of ABCB1, but not altering expression level and localization of ABCB1.	Tritium	103-105	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	121-126
28302530-5	2017	The results showed that regorafenib reversed the ABCB1-mediated MDR and increased the accumulation of [3H]-paclitaxel in ABCB1-overexpressing cells by suppressing efflux activity of ABCB1, but not altering expression level and localization of ABCB1.	Tritium	103-105	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	121-126
28302530-5	2017	The results showed that regorafenib reversed the ABCB1-mediated MDR and increased the accumulation of [3H]-paclitaxel in ABCB1-overexpressing cells by suppressing efflux activity of ABCB1, but not altering expression level and localization of ABCB1.	Tritium	103-105	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	121-126
28302530-5	2017	The results showed that regorafenib reversed the ABCB1-mediated MDR and increased the accumulation of [3H]-paclitaxel in ABCB1-overexpressing cells by suppressing efflux activity of ABCB1, but not altering expression level and localization of ABCB1.	Paclitaxel	107-117	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	121-126
28302530-5	2017	The results showed that regorafenib reversed the ABCB1-mediated MDR and increased the accumulation of [3H]-paclitaxel in ABCB1-overexpressing cells by suppressing efflux activity of ABCB1, but not altering expression level and localization of ABCB1.	Paclitaxel	107-117	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	121-126
28302530-5	2017	The results showed that regorafenib reversed the ABCB1-mediated MDR and increased the accumulation of [3H]-paclitaxel in ABCB1-overexpressing cells by suppressing efflux activity of ABCB1, but not altering expression level and localization of ABCB1.	Paclitaxel	107-117	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	121-126
28302530-6	2017	Regorafenib inhibited ATPase activity of ABCB1.	regorafenib	0-11	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	41-46
28540728-6	2017	Compared with that in wild-type Friend Virus B (FVB) mice, plasma exposure of acacetin-7-sulfate decreased significantly in multidrug resistance protein 1 knockout (Mrp1-/-) mice vut increased clearly in breast cancer resistance protein knockout (Bcrp-/-) mice.	acacetin-7-sulfate	78-96	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	124-154
28495533-4	2017	MicroRNA miR-27a was reported to be reduced in the brain of R6/2 HD mouse model and modulate multidrug resistance protein-1 (MDR-1).	mir-27a	9-16	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	93-123
28495533-4	2017	MicroRNA miR-27a was reported to be reduced in the brain of R6/2 HD mouse model and modulate multidrug resistance protein-1 (MDR-1).	mir-27a	9-16	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	125-130
28495533-10	2017	In addition, MDR-1, which can transport mHtt, protein level was increased by miR-27a transfection.	mhtt	40-44	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	13-18
28495533-12	2017	Our results indicate that miR-27a could reduce mHtt level of the HD cell by augmenting MDR-1 function.	mhtt	47-51	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	87-92
28624193-6	2017	Furthermore, miR-375 dramatically inhibited drug resistance of DOX by reducing the expression of multidrug resistance gene 1 (MDR1).	Doxorubicin	63-66	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	97-124
28624193-6	2017	Furthermore, miR-375 dramatically inhibited drug resistance of DOX by reducing the expression of multidrug resistance gene 1 (MDR1).	Doxorubicin	63-66	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	126-130
28629814-4	2017	Additionally, in the presence of LY335979, an ABCB1/Abcb1a specific inhibitor, the observed ER for seliciclib in the LLC-PK1-mMdr1a cells decreased to 1.05+-0.25.	zosuquidar trihydrochloride	33-41	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	46-51
27706944-10	2017	INNOVATION: These are the first reported results to show that berry extracts can inhibit MRP-1 function that causes apoptotic tumor cell death by accumulation of GSSG in the nucleus of EOMA cells where NADPH oxidase is hyperactive and causes pathological angiogenesis.	Glutathione Disulfide	162-166	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	89-94
28265007-3	2017	The ATP-binding cassette subfamily B member 1 (ABCB1/P-glycoprotein) and subfamily C member 10 (ABCC10/MRP7) are the major membrane protein transporters responsible for the efflux of paclitaxel, constituting one of the most important mechanisms of paclitaxel resistance.	Paclitaxel	248-258	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	4-45
28265007-0	2017	The BTK Inhibitor Ibrutinib (PCI-32765) Overcomes Paclitaxel Resistance in ABCB1- and ABCC10-Overexpressing Cells and Tumors.	ibrutinib	18-27	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	75-80
28265007-0	2017	The BTK Inhibitor Ibrutinib (PCI-32765) Overcomes Paclitaxel Resistance in ABCB1- and ABCC10-Overexpressing Cells and Tumors.	Paclitaxel	50-60	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	75-80
28265007-3	2017	The ATP-binding cassette subfamily B member 1 (ABCB1/P-glycoprotein) and subfamily C member 10 (ABCC10/MRP7) are the major membrane protein transporters responsible for the efflux of paclitaxel, constituting one of the most important mechanisms of paclitaxel resistance.	Paclitaxel	183-193	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	4-45
28265007-3	2017	The ATP-binding cassette subfamily B member 1 (ABCB1/P-glycoprotein) and subfamily C member 10 (ABCC10/MRP7) are the major membrane protein transporters responsible for the efflux of paclitaxel, constituting one of the most important mechanisms of paclitaxel resistance.	Paclitaxel	183-193	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	47-52
28288939-0	2017	Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation.	Afatinib	88-96	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	71-76
28265007-3	2017	The ATP-binding cassette subfamily B member 1 (ABCB1/P-glycoprotein) and subfamily C member 10 (ABCC10/MRP7) are the major membrane protein transporters responsible for the efflux of paclitaxel, constituting one of the most important mechanisms of paclitaxel resistance.	Paclitaxel	248-258	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	47-52
28265007-4	2017	Here, we demonstrated that the Bruton tyrosine kinase inhibitor, ibrutinib, significantly enhanced the antitumor activity of paclitaxel by antagonizing the efflux function of ABCB1 and ABCC10 in cells overexpressing these transporters.	ibrutinib	65-74	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	175-180
28265007-4	2017	Here, we demonstrated that the Bruton tyrosine kinase inhibitor, ibrutinib, significantly enhanced the antitumor activity of paclitaxel by antagonizing the efflux function of ABCB1 and ABCC10 in cells overexpressing these transporters.	Paclitaxel	125-135	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	175-180
28265007-6	2017	However, the ATPase activity of ABCB1 was significantly stimulated by treatment with ibrutinib.	ibrutinib	85-94	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	32-37
28265007-7	2017	Molecular docking analysis suggested the binding conformation of ibrutinib within the large cavity of the transmembrane region of ABCB1.	ibrutinib	65-74	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	130-135
28265007-8	2017	Importantly, ibrutinib could effectively enhance paclitaxel-induced inhibition on the growth of ABCB1- and ABCC10-overexpressing tumors in nude athymic mice.	ibrutinib	13-22	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	96-101
28265007-8	2017	Importantly, ibrutinib could effectively enhance paclitaxel-induced inhibition on the growth of ABCB1- and ABCC10-overexpressing tumors in nude athymic mice.	Paclitaxel	49-59	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	96-101
28265007-9	2017	These results demonstrate that the combination of ibrutinib and paclitaxel can effectively antagonize ABCB1- or ABCC10-mediated paclitaxel resistance that could be of great clinical interest.	ibrutinib	50-59	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	102-107
28265007-9	2017	These results demonstrate that the combination of ibrutinib and paclitaxel can effectively antagonize ABCB1- or ABCC10-mediated paclitaxel resistance that could be of great clinical interest.	Paclitaxel	64-74	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	102-107
28265007-9	2017	These results demonstrate that the combination of ibrutinib and paclitaxel can effectively antagonize ABCB1- or ABCC10-mediated paclitaxel resistance that could be of great clinical interest.	Paclitaxel	128-138	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	102-107
28503421-0	2017	Differential expression of breast cancer-resistance protein, lung resistance protein, and multidrug resistance protein 1 in retinas of streptozotocin-induced diabetic mice.	Streptozocin	135-149	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	90-120
27193034-3	2017	Here, we define a role for peroxisome proliferator-activated receptor alpha in regulating the expression of three ATP-driven drug efflux transporters at the rat and mouse blood-brain barriers: P-glycoprotein (Abcb1), breast cancer resistance protein (Bcrp/Abcg2), and multidrug resistance-associated protein 2 (Mrp2/Abcc2).	Adenosine Triphosphate	114-117	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	209-214
28216407-3	2017	Previously we identified MDR-dependent cytoprotection from cyclophosphamide in mouse and human oocytes by use of MDR inhibitors.	Cyclophosphamide	59-75	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	25-28
28216407-3	2017	Previously we identified MDR-dependent cytoprotection from cyclophosphamide in mouse and human oocytes by use of MDR inhibitors.	Cyclophosphamide	59-75	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	113-116
28216407-4	2017	Here we use genetic deletions in MDR1a/b/BCRP of mice to test MDR function in ovarian somatic cells and find that mdr1a/b/bcrp-/- mice had significantly increased sensitivity to cyclophosphamide.	Cyclophosphamide	178-194	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	33-36
27760838-6	2017	Pgp expression associated with the resistance of the doxorubicin-resistant Brca1-/-;p53-/- spontaneous mouse mammary carcinoma cells could be eliminated by a single treatment with NSC57969, suggesting that MDR-selective compounds can effectively revert the MDR phenotype of cells expressing Pgp at clinically relevant levels.	Doxorubicin	53-64	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	206-209
28111265-0	2017	P-gp/ABCB1 exerts differential impacts on brain and fetal exposure to norbuprenorphine.	norbuprenorphine	70-86	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	5-10
28289287-3	2017	Here we used double electron-electron resonance and molecular dynamics simulations to describe the ATP- and substrate-coupled conformational cycle of the mouse ABC efflux transporter P-glycoprotein (Pgp; also known as ABCB1), which has a central role in the clearance of xenobiotics and in cancer resistance to chemotherapy.	Adenosine Triphosphate	99-102	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	218-223
28295025-6	2017	PDT resistance to soluble glycol porphyrins was mediated mainly by increased drug efflux through ABCB1 (P-glycoprotein) as we demonstrated by specific ABCB1 knockdown experiments, which in turn rescued the sensitivity of resistant cells to PDT.	glycol porphyrins	26-43	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	97-102
28295025-6	2017	PDT resistance to soluble glycol porphyrins was mediated mainly by increased drug efflux through ABCB1 (P-glycoprotein) as we demonstrated by specific ABCB1 knockdown experiments, which in turn rescued the sensitivity of resistant cells to PDT.	glycol porphyrins	26-43	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	151-156
28181548-0	2017	Thiazole-valine peptidomimetic (TTT-28) antagonizes multidrug resistance in vitro and in vivo by selectively inhibiting the efflux activity of ABCB1.	Thiazoles	0-8	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	143-148
28181548-4	2017	TTT-28 reversed the ABCB1-mediated MDR and increased the accumulation of [3H]-paclitaxel in ABCB1 overexpressing cells by selectively blocking the efflux function of ABCB1, but not interfering with the expression level and localization of ABCB1.	Tritium	74-76	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	92-97
28181548-4	2017	TTT-28 reversed the ABCB1-mediated MDR and increased the accumulation of [3H]-paclitaxel in ABCB1 overexpressing cells by selectively blocking the efflux function of ABCB1, but not interfering with the expression level and localization of ABCB1.	Tritium	74-76	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	92-97
28181548-4	2017	TTT-28 reversed the ABCB1-mediated MDR and increased the accumulation of [3H]-paclitaxel in ABCB1 overexpressing cells by selectively blocking the efflux function of ABCB1, but not interfering with the expression level and localization of ABCB1.	Tritium	74-76	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	92-97
28181548-4	2017	TTT-28 reversed the ABCB1-mediated MDR and increased the accumulation of [3H]-paclitaxel in ABCB1 overexpressing cells by selectively blocking the efflux function of ABCB1, but not interfering with the expression level and localization of ABCB1.	Paclitaxel	78-88	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	92-97
28181548-4	2017	TTT-28 reversed the ABCB1-mediated MDR and increased the accumulation of [3H]-paclitaxel in ABCB1 overexpressing cells by selectively blocking the efflux function of ABCB1, but not interfering with the expression level and localization of ABCB1.	Paclitaxel	78-88	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	92-97
28181548-4	2017	TTT-28 reversed the ABCB1-mediated MDR and increased the accumulation of [3H]-paclitaxel in ABCB1 overexpressing cells by selectively blocking the efflux function of ABCB1, but not interfering with the expression level and localization of ABCB1.	Paclitaxel	78-88	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	92-97
28181548-8	2017	The identification and characterization of this new thiazole-valine peptidomimetic will facilitate design and synthesis of a new generation of ABCB1 inhibitors, leading to further research on multidrug resistance and combination chemotherapy.	Thiazoles	52-60	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	143-148
28181548-9	2017	Furthermore, the strategy that co-administer MDR-ABCB1 inhibitor to overcome the resistance of one FDA approved, widely used chemotherapeutic paclitaxel, may be promising direction for the field of adjuvant chemotherapy.	Paclitaxel	142-152	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	49-54
28325287-2	2017	Here, we studied the carrier-free biodistribution and biological activity of a nuclease-resistant anti-MDR1 cholesterol-siRNA conjugate in healthy and tumor-bearing severe combined immune deficiency (SCID) mice.	Cholesterol	108-119	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	103-107
27553832-5	2017	The efficacy of PI3K-mTOR inhibition was established using orthotopic allograft and genetically engineered spontaneous glioblastoma mouse models.Results: The mTOR inhibitors rapamycin and AZD8055 are substrates of ABCB1, whereas the dual PI3K/mTOR inhibitor NVP-BEZ235 and the PI3K inhibitor ZSTK474 are not.	Sirolimus	174-183	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	214-219
27553832-5	2017	The efficacy of PI3K-mTOR inhibition was established using orthotopic allograft and genetically engineered spontaneous glioblastoma mouse models.Results: The mTOR inhibitors rapamycin and AZD8055 are substrates of ABCB1, whereas the dual PI3K/mTOR inhibitor NVP-BEZ235 and the PI3K inhibitor ZSTK474 are not.	(5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol	188-195	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	214-219
27553832-5	2017	The efficacy of PI3K-mTOR inhibition was established using orthotopic allograft and genetically engineered spontaneous glioblastoma mouse models.Results: The mTOR inhibitors rapamycin and AZD8055 are substrates of ABCB1, whereas the dual PI3K/mTOR inhibitor NVP-BEZ235 and the PI3K inhibitor ZSTK474 are not.	dactolisib	262-268	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	214-219
27553832-5	2017	The efficacy of PI3K-mTOR inhibition was established using orthotopic allograft and genetically engineered spontaneous glioblastoma mouse models.Results: The mTOR inhibitors rapamycin and AZD8055 are substrates of ABCB1, whereas the dual PI3K/mTOR inhibitor NVP-BEZ235 and the PI3K inhibitor ZSTK474 are not.	ZSTK474	292-299	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	214-219
28025333-0	2017	Modulation of bilirubin neurotoxicity by the Abcb1 transporter in the Ugt1-/- lethal mouse model of neonatal hyperbilirubinemia.	Bilirubin	14-23	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	45-50
28025333-5	2017	The Abcb1 and Abcc1 members of the ABC family of transporters have been suggested to have an active role in exporting unconjugated bilirubin from the central nervous system into plasma.	Bilirubin	131-140	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	4-9
28025333-8	2017	Interestingly, Abcc1 role appeared to be less important.In the cerebellum of Ugt1-/- mice, hyperbilirubinemia induced the expression of Car and Pxr nuclear receptors, known regulators of genes involved in the genotoxic response.We demonstrated a critical role of Abcb1 in protecting the cerebellum from bilirubin toxicity during neonatal development, the most clinically relevant phase for human babies, providing further understanding of the mechanisms regulating bilirubin neurotoxicity in vivo.	Bilirubin	96-105	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	263-268
27760838-6	2017	Pgp expression associated with the resistance of the doxorubicin-resistant Brca1-/-;p53-/- spontaneous mouse mammary carcinoma cells could be eliminated by a single treatment with NSC57969, suggesting that MDR-selective compounds can effectively revert the MDR phenotype of cells expressing Pgp at clinically relevant levels.	Doxorubicin	53-64	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	257-260
27760838-7	2017	The discovery of new MDR-selective compounds shows the potential of this emerging technology and highlights the 8-hydroxyquinoline scaffold as a promising starting point for the development of compounds targeting the Achilles heel of drug-resistant cancer.	Oxyquinoline	112-130	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	21-24
27777271-3	2017	Although doxorubicin is a known substrate for efflux transporters such as P-glycoprotein (P-gp; MDR1, ABCB1), significantly less is known regarding its interactions with drug uptake transporters.	Doxorubicin	9-20	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	96-100
27777271-3	2017	Although doxorubicin is a known substrate for efflux transporters such as P-glycoprotein (P-gp; MDR1, ABCB1), significantly less is known regarding its interactions with drug uptake transporters.	Doxorubicin	9-20	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	102-107
26850595-7	2016	ABCB1 overexpression reduced sensitivities of ovarian cancer lines OVCAR3 and A2780 to cisplatin and paclitaxel, which can be reversed by miR-873 mimic transfection (P &lt; 0.05).	Cisplatin	87-96	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	0-5
27495788-1	2016	PURPOSE: Pharmacokinetic interaction of sunitinib with diclofenac, paracetamol, mefenamic acid and ibuprofen was evaluated due to their P450 mediated metabolism and OATP1B1, OATP1B3, ABCB1, ABCG2 transporters overlapping features.	Sunitinib	40-49	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	183-188
27495788-1	2016	PURPOSE: Pharmacokinetic interaction of sunitinib with diclofenac, paracetamol, mefenamic acid and ibuprofen was evaluated due to their P450 mediated metabolism and OATP1B1, OATP1B3, ABCB1, ABCG2 transporters overlapping features.	Ibuprofen	99-108	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	183-188
27698692-5	2016	In addition, GBEE effectively inhibited the expression of MDR-1 mRNA and multidrug resistance-associated protein-1 mRNA in S180 MDR cells of ascites tumor in mice and improved the expression levels of cytokines, including interleukin (IL)-3, IL-18 and interferon-gamma in the blood serum of S180 MDR tumor-bearing mice.	gbee	13-17	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	58-63
26850595-8	2016	In summary, we demonstrated that overexpression of miR-873 increased the sensitivity of ovarian cancer cells to cisplatin and paclitaxel by targeting MDR1 expression.	Paclitaxel	126-136	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	150-154
28116130-0	2016	Glycosphingolipid storage in Fabry mice extends beyond globotriaosylceramide and is affected by ABCB1 depletion.	Glycosphingolipids	0-17	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	96-101
28116130-6	2016	Depletion of ABCB1 had a complex effect on glycosphingolipid storage.	Glycosphingolipids	43-60	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	13-18
26850595-7	2016	ABCB1 overexpression reduced sensitivities of ovarian cancer lines OVCAR3 and A2780 to cisplatin and paclitaxel, which can be reversed by miR-873 mimic transfection (P &lt; 0.05).	Paclitaxel	101-111	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	0-5
26850595-8	2016	In summary, we demonstrated that overexpression of miR-873 increased the sensitivity of ovarian cancer cells to cisplatin and paclitaxel by targeting MDR1 expression.	Cisplatin	112-121	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	150-154
26883271-0	2016	ABCG2 and ABCB1 Limit the Efficacy of Dasatinib in a PDGF-B-Driven Brainstem Glioma Model.	Dasatinib	38-47	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	10-15
27156771-2	2016	Herein, the selenoanhydride and selected selenoesters were evaluated for their ability to reverse the cancer multidrug resistance (MDR) using the ABCB1 efflux pump inhibition assay in mouse MDR T-lymphoma cells.	selenoanhydride	12-27	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	131-134
27156771-2	2016	Herein, the selenoanhydride and selected selenoesters were evaluated for their ability to reverse the cancer multidrug resistance (MDR) using the ABCB1 efflux pump inhibition assay in mouse MDR T-lymphoma cells.	selenoanhydride	12-27	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	146-151
27156771-2	2016	Herein, the selenoanhydride and selected selenoesters were evaluated for their ability to reverse the cancer multidrug resistance (MDR) using the ABCB1 efflux pump inhibition assay in mouse MDR T-lymphoma cells.	selenoanhydride	12-27	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	190-193
27156771-2	2016	Herein, the selenoanhydride and selected selenoesters were evaluated for their ability to reverse the cancer multidrug resistance (MDR) using the ABCB1 efflux pump inhibition assay in mouse MDR T-lymphoma cells.	selenoesters	41-53	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	131-134
27156771-2	2016	Herein, the selenoanhydride and selected selenoesters were evaluated for their ability to reverse the cancer multidrug resistance (MDR) using the ABCB1 efflux pump inhibition assay in mouse MDR T-lymphoma cells.	selenoesters	41-53	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	146-151
27156771-2	2016	Herein, the selenoanhydride and selected selenoesters were evaluated for their ability to reverse the cancer multidrug resistance (MDR) using the ABCB1 efflux pump inhibition assay in mouse MDR T-lymphoma cells.	selenoesters	41-53	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	190-193
27160056-0	2016	The 5-aromatic hydantoin-3-acetate derivatives as inhibitors of the tumour multidrug resistance efflux pump P-glycoprotein (ABCB1): Synthesis, crystallographic and biological studies.	5-aromatic hydantoin-3-acetate	4-34	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	124-129
27272776-0	2016	siRNA Targeting of MDR1 Reverses Multidrug Resistance in a Nude Mouse Model of Doxorubicin-resistant Human Hepatocellular Carcinoma.	Doxorubicin	79-90	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	19-23
26883271-2	2016	We investigated whether the ABC efflux transporters ABCG2 and ABCB1 expressed in the blood-brain barrier (BBB), are limiting the efficacy of dasatinib in the treatment of glioma using genetic and pharmacologic approaches.	Dasatinib	141-150	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	62-67
26824187-8	2016	PPD12 also enhanced the efficacy of adriamycin against ABCB1-overexpressing KB/VCR xenografts in nude mice.	Doxorubicin	36-46	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	55-60
27236077-2	2016	Here we reported the potential role of peroxisome proliferator-activated receptor-gamma coactivator 1alpha (PGC-1alpha) and multidrug resistance protein 1 (MRP1) in lead acetate-induced mitochondrial toxicity in mouse testicular Sertoli cells TM4 line.	Acetates	170-177	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	124-154
27236077-2	2016	Here we reported the potential role of peroxisome proliferator-activated receptor-gamma coactivator 1alpha (PGC-1alpha) and multidrug resistance protein 1 (MRP1) in lead acetate-induced mitochondrial toxicity in mouse testicular Sertoli cells TM4 line.	Acetates	170-177	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	156-160
27236077-3	2016	We found that lead acetate treatment significantly reduced the expression level of PGC-1alpha, but increased the level of MRP1 in mitochondria of TM4 cells.	Acetates	19-26	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	122-126
26264927-2	2015	In this study we developed a PET-CT imaging method for non-invasive, quantitative analysis of the effect of ABCB1 and ABCG2 on brain penetration of the anti-cancer drug gefitinib, and demonstrated the applicability of this method for identification and quantification of potential modulators of ABCB1 and ABCB2 using the dual inhibitor elacridar.	Gefitinib	169-178	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	108-113
26780497-5	2016	ELISA analysis of brain homogenates for Abeta showed rivastigmine treatment to significantly decrease Abeta brain load in APP(+)/mdr1(+/+) by 25% and in APP(+)/mdr1(+/-) mice by 21% compared to their vehicle treated littermates, but not in APP(+)/mdr1(-/-) mice.	Rivastigmine	53-65	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	129-133
26780497-5	2016	ELISA analysis of brain homogenates for Abeta showed rivastigmine treatment to significantly decrease Abeta brain load in APP(+)/mdr1(+/+) by 25% and in APP(+)/mdr1(+/-) mice by 21% compared to their vehicle treated littermates, but not in APP(+)/mdr1(-/-) mice.	Rivastigmine	53-65	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	160-164
26780497-5	2016	ELISA analysis of brain homogenates for Abeta showed rivastigmine treatment to significantly decrease Abeta brain load in APP(+)/mdr1(+/+) by 25% and in APP(+)/mdr1(+/-) mice by 21% compared to their vehicle treated littermates, but not in APP(+)/mdr1(-/-) mice.	Rivastigmine	53-65	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	160-164
26780497-6	2016	In addition, rivastigmine reduced GFAP immunostaining of astrocytes by 50% and IL-1beta brain level by 43% in APP(+)/mdr1(+/+) mice, however its effect was less pronounced in P-gp knockout mice.	Rivastigmine	13-25	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	117-121
26780497-7	2016	Moreover, rivastigmine demonstrated a P-gp expression dependent neuroprotective effect that was highest in APP(+)/mdr1(+/+)>APP(+)/mdr1(+/-)>APP(+)/mdr1(-/-) as determined by expression of synaptic markers PSD-95 and SNAP-25 using Western blot analysis.	Rivastigmine	10-22	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	114-118
26780497-7	2016	Moreover, rivastigmine demonstrated a P-gp expression dependent neuroprotective effect that was highest in APP(+)/mdr1(+/+)>APP(+)/mdr1(+/-)>APP(+)/mdr1(-/-) as determined by expression of synaptic markers PSD-95 and SNAP-25 using Western blot analysis.	Rivastigmine	10-22	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	131-135
26780497-7	2016	Moreover, rivastigmine demonstrated a P-gp expression dependent neuroprotective effect that was highest in APP(+)/mdr1(+/+)>APP(+)/mdr1(+/-)>APP(+)/mdr1(-/-) as determined by expression of synaptic markers PSD-95 and SNAP-25 using Western blot analysis.	Rivastigmine	10-22	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	131-135
26651614-6	2015	RESULTS: Efficient chemoprotection of CDD and MDR1 transduced hematopoietic 32D as well as primary lin(-) cells was proven in the context of Ara-C and anthracycline application.	Cytarabine	141-146	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	46-50
26651614-6	2015	RESULTS: Efficient chemoprotection of CDD and MDR1 transduced hematopoietic 32D as well as primary lin(-) cells was proven in the context of Ara-C and anthracycline application.	Anthracyclines	151-164	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	46-50
26633878-0	2015	Fentanyl Enhances Hepatotoxicity of Paclitaxel via Inhibition of CYP3A4 and ABCB1 Transport Activity in Mice.	Fentanyl	0-8	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	76-81
26633878-0	2015	Fentanyl Enhances Hepatotoxicity of Paclitaxel via Inhibition of CYP3A4 and ABCB1 Transport Activity in Mice.	Paclitaxel	36-46	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	76-81
26633878-10	2015	Furthermore, fentanyl enhanced the cytotoxicity of anti-carcinogens that are ABCB1 substrates and increased the accumulation of doxorubicin and rhodamine 123.	Fentanyl	13-21	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	77-82
26633878-11	2015	Additionally, fentanyl stimulated ABCB1 ATPase activity and inhibited CYP3A4 activity in the liver microsomes of mice.	Fentanyl	14-22	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	34-39
26359257-9	2015	CONCLUSION: ABCG2, ABCB1, and possibly other transporters influence in vivo disposition of (11)C-erlotinib and thereby affect its distribution to normal and potentially also tumor tissue.	Erlotinib Hydrochloride	91-106	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	19-24
26359257-11	2015	The inhibition of ABCB1 and ABCG2 is a promising approach to enhance brain distribution of erlotinib to increase its efficacy in the treatment of brain tumors.	Erlotinib Hydrochloride	91-100	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	18-23
26910071-6	2016	The use of ABCB1-transfected mouse T-lymphoma cell line to study the uptake/efflux of fluorescent probes like ethidium bromide (EB), rhodamine 123 (Rh-123), and carbocyanine dye DiOC2, in the presence and absence of potential inhibitors, is currently used in our laboratories to evaluate the ability of a drug to inhibit ABCB1-mediated drug accumulation and efflux.	Ethidium	110-126	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	11-16
26910071-6	2016	The use of ABCB1-transfected mouse T-lymphoma cell line to study the uptake/efflux of fluorescent probes like ethidium bromide (EB), rhodamine 123 (Rh-123), and carbocyanine dye DiOC2, in the presence and absence of potential inhibitors, is currently used in our laboratories to evaluate the ability of a drug to inhibit ABCB1-mediated drug accumulation and efflux.	Ethidium	128-130	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	11-16
26910071-6	2016	The use of ABCB1-transfected mouse T-lymphoma cell line to study the uptake/efflux of fluorescent probes like ethidium bromide (EB), rhodamine 123 (Rh-123), and carbocyanine dye DiOC2, in the presence and absence of potential inhibitors, is currently used in our laboratories to evaluate the ability of a drug to inhibit ABCB1-mediated drug accumulation and efflux.	Rhodamine 123	133-146	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	11-16
26910071-6	2016	The use of ABCB1-transfected mouse T-lymphoma cell line to study the uptake/efflux of fluorescent probes like ethidium bromide (EB), rhodamine 123 (Rh-123), and carbocyanine dye DiOC2, in the presence and absence of potential inhibitors, is currently used in our laboratories to evaluate the ability of a drug to inhibit ABCB1-mediated drug accumulation and efflux.	Rhodamine 123	148-154	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	11-16
26910071-6	2016	The use of ABCB1-transfected mouse T-lymphoma cell line to study the uptake/efflux of fluorescent probes like ethidium bromide (EB), rhodamine 123 (Rh-123), and carbocyanine dye DiOC2, in the presence and absence of potential inhibitors, is currently used in our laboratories to evaluate the ability of a drug to inhibit ABCB1-mediated drug accumulation and efflux.	Carbocyanines	161-173	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	11-16
26910071-6	2016	The use of ABCB1-transfected mouse T-lymphoma cell line to study the uptake/efflux of fluorescent probes like ethidium bromide (EB), rhodamine 123 (Rh-123), and carbocyanine dye DiOC2, in the presence and absence of potential inhibitors, is currently used in our laboratories to evaluate the ability of a drug to inhibit ABCB1-mediated drug accumulation and efflux.	3,3'-diethyloxacarbocyanine	178-183	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	11-16
26910071-7	2016	Here we describe and compare three in vitro methods, which evaluate the permeability, transport kinetics of fluorescent substrates, and inhibition of the ABCB1 efflux pump by drugs of chemical synthesis or extracted from natural sources, using model cancer cell lines overexpressing this transporter, namely (1) real-time fluorimetry that assesses the accumulation of ethidium bromide, (2) flow cytometry, and (3) fluorescent microscopy using rhodamine 123 and DiOC2.	Ethidium	368-384	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	154-159
26910071-7	2016	Here we describe and compare three in vitro methods, which evaluate the permeability, transport kinetics of fluorescent substrates, and inhibition of the ABCB1 efflux pump by drugs of chemical synthesis or extracted from natural sources, using model cancer cell lines overexpressing this transporter, namely (1) real-time fluorimetry that assesses the accumulation of ethidium bromide, (2) flow cytometry, and (3) fluorescent microscopy using rhodamine 123 and DiOC2.	Rhodamine 123	443-456	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	154-159
26910071-7	2016	Here we describe and compare three in vitro methods, which evaluate the permeability, transport kinetics of fluorescent substrates, and inhibition of the ABCB1 efflux pump by drugs of chemical synthesis or extracted from natural sources, using model cancer cell lines overexpressing this transporter, namely (1) real-time fluorimetry that assesses the accumulation of ethidium bromide, (2) flow cytometry, and (3) fluorescent microscopy using rhodamine 123 and DiOC2.	3,3'-diethyloxacarbocyanine	461-466	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	154-159
26319048-7	2016	In simvastatin-treated murine xenografts, ABCB1 was also reduced in the liver and rhabdomyosarcoma but did not reach significance in neuroblastoma.	Simvastatin	3-14	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	42-47
26361725-0	2015	Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2).	ceritinib	45-54	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	93-98
26361725-1	2015	We aimed to clarify the roles of the multidrug transporters ABCB1 and ABCG2 in oral availability and brain accumulation of ceritinib, an oral anaplastic lymphoma kinase (ALK) inhibitor used to treat metastatic non-small cell lung cancer (NSCLC) after progression on crizotinib.	ceritinib	123-132	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	60-65
26361725-1	2015	We aimed to clarify the roles of the multidrug transporters ABCB1 and ABCG2 in oral availability and brain accumulation of ceritinib, an oral anaplastic lymphoma kinase (ALK) inhibitor used to treat metastatic non-small cell lung cancer (NSCLC) after progression on crizotinib.	Crizotinib	266-276	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	60-65
26361725-5	2015	Ceritinib was very efficiently transported by hABCB1, and efficiently by hABCG2 and mAbcg2 in vitro, and transport was specifically inhibited by the ABCB1 inhibitor zosuquidar and ABCG2 inhibitor Ko143, respectively.	ceritinib	0-9	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	47-52
26361725-9	2015	Our data suggest that coadministration of ceritinib with a dual ABCB1 and ABCG2 inhibitor may improve treatment of brain (micro) metastases positioned behind a functionally intact blood-brain barrier, and possibly also of tumors resistant to ceritinib due to ABCB1 or ABCG2 overexpression.	ceritinib	42-51	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	64-69
26361725-9	2015	Our data suggest that coadministration of ceritinib with a dual ABCB1 and ABCG2 inhibitor may improve treatment of brain (micro) metastases positioned behind a functionally intact blood-brain barrier, and possibly also of tumors resistant to ceritinib due to ABCB1 or ABCG2 overexpression.	ceritinib	42-51	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	259-264
26586297-3	2015	The results of the present study demonstrated that mHtt aggregation in the nucleus was altered by the activity of multidrug resistance protein 1 (MDR1), which was experimentally modulated by verapamil, siRNA and an expression vector.	Verapamil	191-200	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	114-144
26586297-3	2015	The results of the present study demonstrated that mHtt aggregation in the nucleus was altered by the activity of multidrug resistance protein 1 (MDR1), which was experimentally modulated by verapamil, siRNA and an expression vector.	Verapamil	191-200	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	146-150
26586297-7	2015	When MDR1 activity in cells was decreased by verapamil or siRNA, mHtt aggregation in the nuclei increased, whereas the induction of MDR1 resulted in a decrease in mHtt aggregation.	Verapamil	45-54	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	5-9
26504015-0	2015	Fluorinated beta-Diketo Phosphorus Ylides Are Novel Inhibitors of the ABCB1 Efflux Pump of Cancer Cells.	beta-diketo phosphorus ylides	12-41	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	70-75
26504015-4	2015	These compounds, with low cytotoxicity against mouse T-lymphoma cells, exhibited more potency than the positive control ABCB1 inhibitor verapamil.	Verapamil	136-145	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	120-125
26281846-7	2015	Basal expression was detectable in the brain, and treatment with activators of the constitutive androstane, pregnane X, and glucocorticoid receptors induced brain and spinal MDR1-luc transcription.	androstane	96-106	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	174-178
26281846-7	2015	Basal expression was detectable in the brain, and treatment with activators of the constitutive androstane, pregnane X, and glucocorticoid receptors induced brain and spinal MDR1-luc transcription.	pregnane x	108-118	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	174-178
26281846-9	2015	The brain and spine MDR1-luc signal intensity was increased by elacridar treatment, suggesting enhanced D-luciferin brain bioavailability.	D-luciferin	104-115	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	20-24
25868794-8	2015	Moreover, the oral bioavailability of GSK126 is only 0.2% in WT mice, which increases to 14.4% in Abcb1;Abcg2 knockout mice.	GSK-2816126	38-44	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	98-103
26317243-1	2015	We aimed to clarify the roles of the multidrug-detoxifying proteins ABCB1, ABCG2, ABCC2, and CYP3A in oral availability and brain accumulation of cabazitaxel, a taxane developed for improved therapy of docetaxel-resistant prostate cancer.	Docetaxel	202-211	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	68-73
26317243-1	2015	We aimed to clarify the roles of the multidrug-detoxifying proteins ABCB1, ABCG2, ABCC2, and CYP3A in oral availability and brain accumulation of cabazitaxel, a taxane developed for improved therapy of docetaxel-resistant prostate cancer.	cabazitaxel	146-157	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	68-73
26317243-1	2015	We aimed to clarify the roles of the multidrug-detoxifying proteins ABCB1, ABCG2, ABCC2, and CYP3A in oral availability and brain accumulation of cabazitaxel, a taxane developed for improved therapy of docetaxel-resistant prostate cancer.	taxane	161-167	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	68-73
26317243-11	2015	In summary, ABCB1 limits cabazitaxel brain accumulation and therefore potentially therapeutic efficacy against (micro)metastases or primary tumors positioned wholly or partly behind a functional blood-brain barrier.	cabazitaxel	25-36	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	12-17
25563977-0	2015	Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1).	regorafenib	33-44	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	133-138
26264927-2	2015	In this study we developed a PET-CT imaging method for non-invasive, quantitative analysis of the effect of ABCB1 and ABCG2 on brain penetration of the anti-cancer drug gefitinib, and demonstrated the applicability of this method for identification and quantification of potential modulators of ABCB1 and ABCB2 using the dual inhibitor elacridar.	Gefitinib	169-178	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	295-300
26264927-3	2015	METHODS: In vitro cellular accumulation studies with [(14)C]-gefitinib were conducted in LLC-PK1, MDCKII, and the corresponding ABCB1/Abcb1a and ABCG2/Abcg2 overexpressing cell lines.	Gefitinib	61-70	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	128-133
26264927-9	2015	Furthermore, enhanced brain accumulation of [(18)F]-gefitinib after administration of the ABCB1 and ABCG2 inhibitor elacridar (10 mg/kg) could be quantified with PET-CT imaging.	[(18)f]-gefitinib	44-61	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	90-95
26264927-10	2015	CONCLUSIONS: PET-CT imaging with [(18)F]-gefitinib is a powerful tool to non-invasively assess potential ABCB1- and ABCG2-mediated drug-drug interactions (DDIs) in vivo.	Gefitinib	41-50	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	105-110
26194248-0	2015	Effect of Knockout of Mdr1a and Mdr1b ABCB1 Genes on the Systemic Exposure of a Doxorubicin-Conjugated Block Copolymer in Mice.	Doxorubicin	80-91	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	32-37
26194248-0	2015	Effect of Knockout of Mdr1a and Mdr1b ABCB1 Genes on the Systemic Exposure of a Doxorubicin-Conjugated Block Copolymer in Mice.	Doxorubicin	80-91	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	38-43
26194248-0	2015	Effect of Knockout of Mdr1a and Mdr1b ABCB1 Genes on the Systemic Exposure of a Doxorubicin-Conjugated Block Copolymer in Mice.	copolymer	109-118	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	32-37
26194248-0	2015	Effect of Knockout of Mdr1a and Mdr1b ABCB1 Genes on the Systemic Exposure of a Doxorubicin-Conjugated Block Copolymer in Mice.	copolymer	109-118	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	38-43
26194248-2	2015	Here, we investigated the role of ABCB1 in the in vivo behavior of a doxorubicin-conjugated polymer in Mdr1a/1b(-/-) mice.	Doxorubicin	69-80	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	34-39
26194248-2	2015	Here, we investigated the role of ABCB1 in the in vivo behavior of a doxorubicin-conjugated polymer in Mdr1a/1b(-/-) mice.	Polymers	92-99	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	34-39
26194248-8	2015	These results show that knockout of ABCB1 prolonged systemic exposure of the doxorubicin-conjugated polymer in mice.	Doxorubicin	77-88	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	36-41
26194248-9	2015	Our results suggest that ABCB1 mediated the excretion of doxorubicin-conjugated polymer in urine and feces.	Doxorubicin	57-68	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	25-30
26202880-5	2015	We performed in vitro transport experiments with [(3)H]verapamil and [(3)H]-N-desmethyl-loperamide in ABCB1 and Abcb1a overexpressing cell lines.	[(3)h]verapamil	49-64	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	102-107
26202880-5	2015	We performed in vitro transport experiments with [(3)H]verapamil and [(3)H]-N-desmethyl-loperamide in ABCB1 and Abcb1a overexpressing cell lines.	[(3)h]-n-desmethyl-loperamide	69-98	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	102-107
26202880-14	2015	Isoflurane anesthesia altered [(11)C]-N-desmethyl-loperamide but not (R)-[(11)C]verapamil metabolism, and this had a direct effect on the magnitude of the increase in brain distribution following ABCB1 inhibition.	Isoflurane	0-10	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	196-201
26516354-1	2015	BACKGROUND: Active efflux of irinotecan by ATP-binding cassette (ABC)-transporters, in particular ABCB1 and ABCG2, is a well-established drug resistance mechanism in vitro and in pre-clinical mouse models, but its relevance in colorectal cancer (CRC) patients is unknown.	Irinotecan	29-39	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	98-103
25915534-0	2015	Trametinib modulates cancer multidrug resistance by targeting ABCB1 transporter.	trametinib	0-10	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	62-67
25915534-4	2015	Trametinib significantly potentiated the effects of two ABCB1 substrates vincristine and doxorubicin on inhibition of growth, arrest of cell cycle and induction of apoptosis in cancer cells overexpressed ABCB1, but not ABCC1 and ABCG2.	trametinib	0-10	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	56-61
25915534-4	2015	Trametinib significantly potentiated the effects of two ABCB1 substrates vincristine and doxorubicin on inhibition of growth, arrest of cell cycle and induction of apoptosis in cancer cells overexpressed ABCB1, but not ABCC1 and ABCG2.	trametinib	0-10	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	204-209
25915534-4	2015	Trametinib significantly potentiated the effects of two ABCB1 substrates vincristine and doxorubicin on inhibition of growth, arrest of cell cycle and induction of apoptosis in cancer cells overexpressed ABCB1, but not ABCC1 and ABCG2.	Vincristine	73-84	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	56-61
25915534-4	2015	Trametinib significantly potentiated the effects of two ABCB1 substrates vincristine and doxorubicin on inhibition of growth, arrest of cell cycle and induction of apoptosis in cancer cells overexpressed ABCB1, but not ABCC1 and ABCG2.	Vincristine	73-84	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	204-209
25915534-4	2015	Trametinib significantly potentiated the effects of two ABCB1 substrates vincristine and doxorubicin on inhibition of growth, arrest of cell cycle and induction of apoptosis in cancer cells overexpressed ABCB1, but not ABCC1 and ABCG2.	Doxorubicin	89-100	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	204-209
25915534-6	2015	Mechanistically, trametinib potently blocked the drug-efflux activity of ABCB1 to increase the intracellular accumulation of rhodamine 123 and doxorubicin and stimulates the ATPase of ABCB1 without alteration of the expression of ABCB1.	trametinib	17-27	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	73-78
25915534-6	2015	Mechanistically, trametinib potently blocked the drug-efflux activity of ABCB1 to increase the intracellular accumulation of rhodamine 123 and doxorubicin and stimulates the ATPase of ABCB1 without alteration of the expression of ABCB1.	trametinib	17-27	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	184-189
25915534-6	2015	Mechanistically, trametinib potently blocked the drug-efflux activity of ABCB1 to increase the intracellular accumulation of rhodamine 123 and doxorubicin and stimulates the ATPase of ABCB1 without alteration of the expression of ABCB1.	trametinib	17-27	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	184-189
25915534-6	2015	Mechanistically, trametinib potently blocked the drug-efflux activity of ABCB1 to increase the intracellular accumulation of rhodamine 123 and doxorubicin and stimulates the ATPase of ABCB1 without alteration of the expression of ABCB1.	Rhodamine 123	125-138	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	73-78
25915534-6	2015	Mechanistically, trametinib potently blocked the drug-efflux activity of ABCB1 to increase the intracellular accumulation of rhodamine 123 and doxorubicin and stimulates the ATPase of ABCB1 without alteration of the expression of ABCB1.	Doxorubicin	143-154	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	73-78
25915534-7	2015	Importantly, trametinib remarkably enhanced the effect of vincristine against the xenografts of ABCB1-overexpressing cancer cells in nude mice.	trametinib	13-23	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	96-101
25915534-7	2015	Importantly, trametinib remarkably enhanced the effect of vincristine against the xenografts of ABCB1-overexpressing cancer cells in nude mice.	Vincristine	58-69	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	96-101
25915534-8	2015	The predicted binding mode showed the hydrophobic interactions of trametinib within the large drug binding cavity of ABCB1.	trametinib	66-76	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	117-122
25865432-2	2015	In this study the interactions of three key avermectins, abamectin, emamectin and ivermectin, with human and mouse homologues of MDR1 (ABCB1/Abcb1a) and MRP (ABCC/Abcc), transporters endogenously expressed by human SH-SY5Y and mouse N2a neuroblastoma cells were investigated.	avermectin	44-55	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	129-133
25865432-2	2015	In this study the interactions of three key avermectins, abamectin, emamectin and ivermectin, with human and mouse homologues of MDR1 (ABCB1/Abcb1a) and MRP (ABCC/Abcc), transporters endogenously expressed by human SH-SY5Y and mouse N2a neuroblastoma cells were investigated.	avermectin	44-55	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	135-140
25867020-12	2015	These results suggested that the Asp-DOX modified drug may provide a new treatment strategy for tumors that overexpress LAT1 and MDR1.	asp-dox	33-40	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	129-133
26011058-1	2015	Tyrosine kinase inhibitor sunitinib (used in GIST, advanced RCC, and pancreatic neuroendocrine tumors) undergoes CYP3A4 metabolism and is an ABCB1B and ABCG2 efflux transporters substrate.	Sunitinib	26-35	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	141-147
26177448-8	2015	In this model, co-treatment with BAR502 increases survival, attenuates serum alkaline phosphatase levels and robustly modulates the liver expression of canonical FXR target genes including OSTalpha, BSEP, SHP and MDR1, without inducing pruritus.	BAR502	33-39	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	213-217
25823393-1	2015	INTRODUCTION: Transport of 2-[(18)F]fluoro-2-deoxy-d-glucose ([(18)F]FDG) by the multidrug efflux transporters P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) at the blood-brain barrier (BBB) may confound the interpretation of [(18)F]FDG brain PET data.	Fluorine	33-35	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	127-132
25823393-1	2015	INTRODUCTION: Transport of 2-[(18)F]fluoro-2-deoxy-d-glucose ([(18)F]FDG) by the multidrug efflux transporters P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) at the blood-brain barrier (BBB) may confound the interpretation of [(18)F]FDG brain PET data.	fluoro-2-deoxy-d-glucose	36-60	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	127-132
25677062-8	2015	RESULTS: Paclitaxel treated cells eventually developed MDR with overexpression of Pgp and MDR1, and with high activity of Pgp, while paclitaxel-NSC23925 co-treated cells remained sensitive to chemotherapeutic agents in both in vitro and in vivo models.	Paclitaxel	9-19	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	55-58
25701040-2	2015	To circumvent this limitation, we fabricated a camptothecin (CPT)-loaded poly(lactic-co-glycolic acid) nanoparticle (NP) with dual-surface functionalization-Pluronic F127 and chitosan-for inhibiting multi-drug resistant gene 1 (MDR1) expression and enhancing tumor uptake.	Camptothecin	47-59	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	199-226
25701040-2	2015	To circumvent this limitation, we fabricated a camptothecin (CPT)-loaded poly(lactic-co-glycolic acid) nanoparticle (NP) with dual-surface functionalization-Pluronic F127 and chitosan-for inhibiting multi-drug resistant gene 1 (MDR1) expression and enhancing tumor uptake.	Camptothecin	47-59	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	228-232
25701040-2	2015	To circumvent this limitation, we fabricated a camptothecin (CPT)-loaded poly(lactic-co-glycolic acid) nanoparticle (NP) with dual-surface functionalization-Pluronic F127 and chitosan-for inhibiting multi-drug resistant gene 1 (MDR1) expression and enhancing tumor uptake.	Polylactic Acid-Polyglycolic Acid Copolymer	73-102	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	199-226
25701040-2	2015	To circumvent this limitation, we fabricated a camptothecin (CPT)-loaded poly(lactic-co-glycolic acid) nanoparticle (NP) with dual-surface functionalization-Pluronic F127 and chitosan-for inhibiting multi-drug resistant gene 1 (MDR1) expression and enhancing tumor uptake.	Polylactic Acid-Polyglycolic Acid Copolymer	73-102	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	228-232
25515492-2	2015	Here we designed and characterized a hyaluronic acid (HA) based self-assembling nanoparticles that can target CD44 receptors overexpressed on multidrug resistance (MDR) ovarian cancer.	Hyaluronic Acid	37-52	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	164-167
25515492-2	2015	Here we designed and characterized a hyaluronic acid (HA) based self-assembling nanoparticles that can target CD44 receptors overexpressed on multidrug resistance (MDR) ovarian cancer.	Hyaluronic Acid	54-56	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	164-167
25515492-3	2015	The nanoparticle system is composed of HA-poly(ethyleneimine)/HA-poly(ethylene glycol) (HA-PEI/HA-PEG) designed to deliver MDR1 siRNA for the treatment of MDR in an ovarian cancer model.	ha-poly(ethyleneimine)	39-61	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	123-126
25515492-3	2015	The nanoparticle system is composed of HA-poly(ethyleneimine)/HA-poly(ethylene glycol) (HA-PEI/HA-PEG) designed to deliver MDR1 siRNA for the treatment of MDR in an ovarian cancer model.	ha-poly(ethylene glycol)	62-86	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	123-126
25515492-3	2015	The nanoparticle system is composed of HA-poly(ethyleneimine)/HA-poly(ethylene glycol) (HA-PEI/HA-PEG) designed to deliver MDR1 siRNA for the treatment of MDR in an ovarian cancer model.	ha-pei	88-94	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	123-126
25515492-3	2015	The nanoparticle system is composed of HA-poly(ethyleneimine)/HA-poly(ethylene glycol) (HA-PEI/HA-PEG) designed to deliver MDR1 siRNA for the treatment of MDR in an ovarian cancer model.	Hyaluronic Acid	39-41	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	123-126
25515492-3	2015	The nanoparticle system is composed of HA-poly(ethyleneimine)/HA-poly(ethylene glycol) (HA-PEI/HA-PEG) designed to deliver MDR1 siRNA for the treatment of MDR in an ovarian cancer model.	Polyethylene Glycols	98-101	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	123-126
25567291-1	2015	Multi-drug resistance (MDR)-ATP binding cassette (ABC) transporters, ABCB1, ABCC1, and ABCG2 participate in the efflux of steroid hormones, estrogens, and androgens, which regulate prostate development and differentiation.	Steroids	122-138	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	69-74
25716150-5	2015	In vitro, the time course of (18)F-FDG uptake in MDR1 cells was influenced by the presence of valspodar in the absence of D-glucose but not in the presence of high D-glucose concentration.	Glucose	122-131	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	49-53
25695368-4	2015	Four compounds from this series were discovered as potent chemosensitizers for MDR1-G185 NIH-3T3 murine cells (3, 4, 6, and 7), showing higher efficacies than the classical P-glycoprotein inhibitor verapamil, a first-generation chemosensitizer, when reversing resistance to daunomycin and vinblastine at the lowest concentration tested of 1 muM.	Verapamil	198-207	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	79-83
25695368-4	2015	Four compounds from this series were discovered as potent chemosensitizers for MDR1-G185 NIH-3T3 murine cells (3, 4, 6, and 7), showing higher efficacies than the classical P-glycoprotein inhibitor verapamil, a first-generation chemosensitizer, when reversing resistance to daunomycin and vinblastine at the lowest concentration tested of 1 muM.	Daunorubicin	274-284	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	79-83
25695368-4	2015	Four compounds from this series were discovered as potent chemosensitizers for MDR1-G185 NIH-3T3 murine cells (3, 4, 6, and 7), showing higher efficacies than the classical P-glycoprotein inhibitor verapamil, a first-generation chemosensitizer, when reversing resistance to daunomycin and vinblastine at the lowest concentration tested of 1 muM.	Vinblastine	289-300	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	79-83
25802484-13	2015	RESULTS: Verapamil, an ABCB1 inhibitor, significantly (p&lt;0.001) increased fluorescent calcein retention in the cytoplasm of the TM and RAW 264.7 cells compared to the PBS control.	Verapamil	9-18	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	23-28
25692026-6	2015	The chemo-preventive synthetic dithiolethione oltipraz was reidentified with our assay as an already known inducer of Mdr1 gene expression.	dithiolethione	31-45	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	118-122
25692026-6	2015	The chemo-preventive synthetic dithiolethione oltipraz was reidentified with our assay as an already known inducer of Mdr1 gene expression.	oltipraz	46-54	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	118-122
25378644-6	2014	We furthermore show that standard intravenous administration of a third-generation MDR1 inhibitor, HM30181, failed to rescue drug accumulation; however, the same MDR1 inhibitor encapsulated within a nanoparticle delivery system reversed the multidrug-resistant phenotype and potentiated the eribulin effect in vitro and in vivo in mice.	4-oxo-4H-chromene-2-carboxylic acid (2-(2-(4-(2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-ethyl)-phenyl)-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl)amide	99-106	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	83-87
25268938-4	2015	In this study, the P-gp interaction of propiconazole and its hydroxylated metabolites were evaluated using MDR1-expressing membrane vesicles and NIH-3T3/MDR1 cells.	propiconazole	39-52	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	107-111
25268938-6	2015	P-gp mediated transport of propiconazole in MDR1-expressed vesicles was not detected indicating propiconazole interacts with P-gp as an inhibitor rather than a substrate.	propiconazole	27-40	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	44-48
25268938-7	2015	In NIH-3T3/MDR1 cells, propiconazole (1 and 10muM) led to decreased cellular resistance (chemosensitization) to paclitaxel, a chemotherapeutic drug and known MDR1 substrate.	propiconazole	23-36	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	11-15
25268938-7	2015	In NIH-3T3/MDR1 cells, propiconazole (1 and 10muM) led to decreased cellular resistance (chemosensitization) to paclitaxel, a chemotherapeutic drug and known MDR1 substrate.	propiconazole	23-36	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	158-162
25268938-7	2015	In NIH-3T3/MDR1 cells, propiconazole (1 and 10muM) led to decreased cellular resistance (chemosensitization) to paclitaxel, a chemotherapeutic drug and known MDR1 substrate.	Paclitaxel	112-122	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	158-162
26075272-0	2015	Ecdysteroids sensitize MDR and non-MDR cancer cell lines to doxorubicin, paclitaxel, and vincristine but tend to protect them from cisplatin.	Ecdysteroids	0-12	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	23-26
26075272-0	2015	Ecdysteroids sensitize MDR and non-MDR cancer cell lines to doxorubicin, paclitaxel, and vincristine but tend to protect them from cisplatin.	Ecdysteroids	0-12	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	35-38
26075272-0	2015	Ecdysteroids sensitize MDR and non-MDR cancer cell lines to doxorubicin, paclitaxel, and vincristine but tend to protect them from cisplatin.	Doxorubicin	60-71	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	23-26
26075272-0	2015	Ecdysteroids sensitize MDR and non-MDR cancer cell lines to doxorubicin, paclitaxel, and vincristine but tend to protect them from cisplatin.	Paclitaxel	73-83	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	23-26
26075272-0	2015	Ecdysteroids sensitize MDR and non-MDR cancer cell lines to doxorubicin, paclitaxel, and vincristine but tend to protect them from cisplatin.	Vincristine	89-100	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	23-26
26075272-2	2015	Previously, we reported that less-polar ecdysteroids can modulate the doxorubicin resistance of a multidrug resistant (MDR) mouse lymphoma cell line expressing the human ABCB1 transporter.	Doxorubicin	70-81	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	119-122
26075272-3	2015	Here, we describe the ability of 20-hydroxyecdysone (1) and its mono- (2) and diacetonide (3) derivatives to sensitize various MDR and non-MDR cancer cell lines towards doxorubicin, paclitaxel, vincristine, or cisplatin.	Ecdysterone	33-51	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	127-130
26075272-3	2015	Here, we describe the ability of 20-hydroxyecdysone (1) and its mono- (2) and diacetonide (3) derivatives to sensitize various MDR and non-MDR cancer cell lines towards doxorubicin, paclitaxel, vincristine, or cisplatin.	Ecdysterone	33-51	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	139-142
26075272-3	2015	Here, we describe the ability of 20-hydroxyecdysone (1) and its mono- (2) and diacetonide (3) derivatives to sensitize various MDR and non-MDR cancer cell lines towards doxorubicin, paclitaxel, vincristine, or cisplatin.	Mono-S	64-69	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	127-130
26075272-3	2015	Here, we describe the ability of 20-hydroxyecdysone (1) and its mono- (2) and diacetonide (3) derivatives to sensitize various MDR and non-MDR cancer cell lines towards doxorubicin, paclitaxel, vincristine, or cisplatin.	Mono-S	64-69	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	139-142
26075272-3	2015	Here, we describe the ability of 20-hydroxyecdysone (1) and its mono- (2) and diacetonide (3) derivatives to sensitize various MDR and non-MDR cancer cell lines towards doxorubicin, paclitaxel, vincristine, or cisplatin.	3-azido-2,7-naphthalene disulfonate	56-59	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	127-130
26075272-3	2015	Here, we describe the ability of 20-hydroxyecdysone (1) and its mono- (2) and diacetonide (3) derivatives to sensitize various MDR and non-MDR cancer cell lines towards doxorubicin, paclitaxel, vincristine, or cisplatin.	3-azido-2,7-naphthalene disulfonate	56-59	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	139-142
26075272-3	2015	Here, we describe the ability of 20-hydroxyecdysone (1) and its mono- (2) and diacetonide (3) derivatives to sensitize various MDR and non-MDR cancer cell lines towards doxorubicin, paclitaxel, vincristine, or cisplatin.	diacetonide	78-89	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	127-130
26075272-3	2015	Here, we describe the ability of 20-hydroxyecdysone (1) and its mono- (2) and diacetonide (3) derivatives to sensitize various MDR and non-MDR cancer cell lines towards doxorubicin, paclitaxel, vincristine, or cisplatin.	Doxorubicin	169-180	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	127-130
25385827-5	2015	Furthermore, the cells efficiently sequestered the substrates of Abcc1 and Abcb1, fluo-4 and doxorubicin, in subcellular compartments.	Fluo 4	82-88	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	75-80
25385827-8	2015	A combined treatment with the inhibitors of Abcb1 and Abcc1, zosuquidar and MK571, respectively, reversed the compartmentalization of doxorubicin and rendered the cells sensitive to doxorubicin-induced apoptosis.	Doxorubicin	134-145	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	44-49
25385827-8	2015	A combined treatment with the inhibitors of Abcb1 and Abcc1, zosuquidar and MK571, respectively, reversed the compartmentalization of doxorubicin and rendered the cells sensitive to doxorubicin-induced apoptosis.	Doxorubicin	182-193	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	44-49
24962512-3	2015	PURPOSE: We aimed to establish whether the multidrug efflux transporters ABCG2 (BCRP) and ABCB1 (P-gp, MDR1) affect the oral availability and brain penetration of rucaparib in mice.	rucaparib	163-172	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	90-95
24962512-3	2015	PURPOSE: We aimed to establish whether the multidrug efflux transporters ABCG2 (BCRP) and ABCB1 (P-gp, MDR1) affect the oral availability and brain penetration of rucaparib in mice.	rucaparib	163-172	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	103-107
25078948-0	2014	"Effect of the drug transporters ABCB1, ABCC2, and ABCG2 on the disposition and brain accumulation of the taxane analog BMS-275,183".	taxane	106-112	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	33-38
25393253-5	2014	Finally, co-culture experiments of K562 CML cells with CXCL12 expressing mesenchymal cells (OP9 cells or human CXCL12 transfected 3T3 cells) revealed enhanced mRNA levels for MDR1 in a CXCL12 rich environment.These results suggest that imatinib treatment restores the bone marrow microenvironment in CML with the presence of CXCL12 expressing reticular cells but in turn induces the overexpression of MDR1 in haematopoietic cells due to up-regulated expression of CXCL12.	Imatinib Mesylate	236-244	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	175-179
25066113-4	2014	To investigate the effects of indirubins on the DNA binding of NF-Y, a major MDR1 gene transcription factor that recognizes an inverted CCAAT element in the promoter, gel mobility shift assay was performed using the element as a probe with nuclear extracts from NG108-15, MCF7, HepG2, C2C12, and SK-N-SH cells.	indirubin	30-40	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	77-81
25173796-7	2014	Here, we set out to explore whether sertraline (Zoloft ), a molecule belonging to the SSRI family, can be used as an MDR modulator.	Sertraline	36-46	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	117-120
25173796-7	2014	Here, we set out to explore whether sertraline (Zoloft ), a molecule belonging to the SSRI family, can be used as an MDR modulator.	Sertraline	48-54	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	117-120
25173796-9	2014	Our findings reveal that sertraline acts as a pump modulator in cellular models of MDR.	Sertraline	25-35	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	83-86
25173796-11	2014	Taken together, our results show that sertraline could act as a clinically relevant cancer MDR inhibitor.	Sertraline	38-48	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	91-94
25053824-0	2014	Temozolomide induces the production of epidermal growth factor to regulate MDR1 expression in glioblastoma cells.	Temozolomide	0-12	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	75-79
25053824-3	2014	This study investigated the mechanisms underlying MDR1-mediated resistance by GBM to temozolomide.	Temozolomide	85-97	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	50-54
25053824-9	2014	At the later phase, gene transcription of MDR1 was induced by temozolomide-mediated production of EGF.	Temozolomide	62-74	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	42-46
25053824-13	2014	Temozolomide resistance occurred through a biphasic response; first, by a conformational change in P-gp into the active form and, second, by releasing EGF, which caused autocrine stimulation of GBM cells to induce MDR1.	Temozolomide	0-12	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	214-218
25015657-5	2014	In RPTEC cells, reduction of MDR1 activity using the antagonist PSC833 or siRNA transfection increased the cellular accumulation of paraquat by 50%.	Paraquat	132-140	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	29-33